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Abstract 
The vast majority of protein/peptide drugs are not available orally.  Their oral 
delivery is hindered by intestinal instability and limited permeability.  The aim of 
this project was to gain an understanding of the stability of a large protein, 
lactase, a small protein, insulin, and a newly discovered peptide throughout the 
intestinal tract.  This was used for the rational design of their oral formulations. 
Lactase was completely denatured at gastric pH within 10 minutes but was 
stable with intestinal enzymes.  Encapsulation in enteric Eudragit L100 
microparticles using a method previously used to encapsulate low molecular 
weight drugs produced small particles with a high yield and encapsulation 
efficiency, >90%.  They restricted lactase release in acid but did not protect it 
from denaturation.  Porosity and particle morphology investigations using an 
SEM with a new type of detector revealed surface structures which disappeared 
upon dispersal in acid and an inner porous structure which may allow acid entry 
and lactase denaturation.  Co-encapsulation of an antacid preserved almost 
10% of lactase activity in acid, superior to existing oral lactase supplements. 
Insulin was not hydrolysed at gastric pH but was immediately and completely 
digested by gastrointestinal enzymes.  To protect it from pepsin insulin was 
encapsulated in Eudragit L100 microparticles.  The particles produced were 
<100µm with a yield and encapsulation efficiency of >70%.  After incubation 
with pepsin they protected 80% of encapsulated insulin.   
A small peptide, peptide 1 was gradually degraded in the intestinal fluids.  To 
provide protection and increase its permeability peptide 1 was encapsulated in 
PLGA nanoparticles but 15% of the encapsulated peptide was immediately 
released in vitro.  Encapsulation of the nanoparticles in Eudragit L100 
microparticles successfully prevented any burst release in acid.  This should 
minimise gastric digestion of peptide 1 and concentrate nanoparticle release in 
the small intestine providing a higher probability of permeation. 
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1.1 Protein and peptide drugs 
Protein and peptides are biological molecules consisting of amino acids.  
Typically peptides consist of 50 amino acids or less and proteins have more 
than 50 amino acids.  The primary structure of proteins is the linear sequence of 
amino acids, held together by peptide bonds, and any disulphide bonds 
between them.  Secondary structures are regular local substructures of either 
alpha helix or beta sheets held together by hydrogen bonds.  Tertiary structure 
is the three dimensional structure of the folded protein and is held together by 
hydrogen bonds, hydrophobic interactions, ionic interactions, van der Waals 
forces and disulphide bonds.  The three dimensional structure of a multisubunit 
protein, held together by non-covalent interactions and disulphide bonds, is 
defined as quaternary structure.  Proteins and peptides are used as 
pharmaceuticals due to their specific and vital therapeutic activities. 
A review of the British National Formulary (BNF) reveals numerous protein and 
peptide drugs are currently available for a wide variety of therapeutic 
applications.  Most of these fall into the following categories; enzymes, 
hormones, cytokines or monoclonal antibodies, table 1.1.  Productivity in 
research and development by large pharmaceutical companies has declined 
and with it focus has shifted from small molecule therapeutics to biologicals 
such as proteins and peptides (IMAP, 2011).  Patent applications by leading 
pharmaceutical companies for biologicals now exceeds that of small molecules 
and this gap is widening.  Reflecting this the top selling pharmaceutical drugs of 
2012 are set to be protein drugs, more specifically antibodies; Humira 
(Adalimumab) (Abbot) and Remicade (Infliximab) (Janssen Biotech, Shering-
plough, Mitsubishi Tanabe Pharma) (Genetic Engineering & Biotechnology 
News, 2013).  This shift away from smaller molecules towards larger biologicals 
presents new challenges to formulators. 
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Table 1.1 Examples of protein and peptide drugs in the BNF, their size and indications 
Protein/peptide drugs Size (kDa) Amino 
acids 
Indications 
Enzymes (eg lysosomal enzymes, 
pancreatic enzymes) 
29-320 260-2928 Cardiac disorders, lysosomal storage disorders, leukaemia 
treatment, digestion aids 
Hormones: (eg gonadotrophins, 
vasopressin analogs, oxytocin analogs, 
calcitonin, insulin) 
0.4-37 3-244 Infertility treatment, hormonal cancer treatment, antidiuretic, 
osteoporosis, blood glucose maintenance, growth 
stimulation/inhibition, endometriosis  
Cytokines: (interleukins, interferons) 15-19  132-165 Tumour shrinkage, rheumatoid arthritis, hepatitis B/C, multiple 
sclerosis, lymphomas 
Growth factors (eg palifermin) 16-25 109-140 Ulcer treatment, oral mucositis 
Antibiotics (eg vancomycin) 1-2 9-10 Cancer, bacterial infections, tuberculosis 
Vaccines (antigens, toxins) 12-150  Immunisation 
Monoclonal antibodies (eg infliximab, 
abciximab) 
48-150  Coronary disease, Crohn’s disease, psoriasis, rheumatoid 
arthritis, leukaemia, organ rejection, cancer treatment, irritable 
bowel disease, multiple sclerosis 
Immunoglobulins (eg hepatitis B 
immunoglobulin) 
150  Rheumatoid arthritis, psoriasis, prophylaxis against infection 
Miscellaneous: cyclosporine A 1.2 11 Organ transplant, ulcerative colitis, rheumatoid arthritis, psoriasis 
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Peptide therapeutics is a dynamic and growing part of the pharmaceutical 
industry.  Biotechnological advances have enabled their production on a 
commercial scale and new peptide chemical entities have increased from 9.7 
per year in the 1990s to 16.8 per year from 2000-08 (Peptide Therapeutics 
Foundation, 2010).  The therapeutic peptide market is predicted to grow from 
€5.3 billion in 2003 to €11.5 billion in 2013 (Pichereau and Allary, 2005).  
However this represents less than 2% of the global pharmaceutical market, 
estimated to reach €770 billion in 2012. 
Despite the importance and growth of the protein and peptide therapeutic area, 
of more then 100 protein and peptide drugs listed in the BNF only four are 
available orally.  The vast majority are only available by injection despite oral 
preparations being the most desirous dosage form from both the patient and 
pharmaceutical manufacturer’s view.  The first pure protein therapeutic 
molecule, insulin, was discovered 90 years ago and yet there is still no oral 
formulation available.  Despite almost 100 years of research and development 
by academic groups and the pharmaceutical industry there are still very few 
protein and peptide drugs orally available.  This introduction will explore the 
reasons for this, review the academic and industrial strategies that have been 
attempted for oral protein and peptide drug delivery and assess the probability 
of oral protein and peptide drugs becoming widely available. 
1.2 Orally delivered protein and peptide drugs 
The four orally available protein and peptide drugs listed in the BNF are listed in 
table 1.2.  Oral delivery for these specific drugs, rather than for the majority, is 
due to unique characteristics of the drug or their delivery requirements.   
 
 
 
 
 
 
30 
 
Table 1.2 Orally delivered protein and peptide drugs in the BNF 
Protein/peptide 
drug 
Size 
(kDa) 
Amino 
acids 
Action and indications 
Pancreatin: amylase, 
lipase, chymotrypsin 
26-55  244-
969  
Compensates for reduced intestinal 
secretion, improves digestion 
Desmopressin  1.1 10 Antidiuretic 
Cyclosporine A 1.2 11 Immunosuppressant, organ 
transplants, ulcerative colitis, 
rheumatoid arthritis, psoriasis 
Vancomycin 1.4  10  Gram positive infections, oral for 
colonic Clostridium difficile infection 
 
Pancreatin and vancomycin are orally delivered as their site of therapeutic 
action is in the gastrointestinal (GI) tract.  Pancreatin is delivered to the small 
intestine to replace a lack of pancreatic enzymes and vancomycin is delivered 
to the colon to treat Clostridium difficile infection.  Pancreatin is generally 
enterically coated to protect the enzymes from denaturation while travelling 
through the stomach.  Vancomycin is formulated in Macrogol 6000 
(polyethylene glycol) filled capsules which may provide some stabilisation 
during GI tract transit.  The glycosylated, tricyclic structure of vancomycin may 
also provide protection from enzymatic digestion, figure 1.1. 
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Figure 1.1 Structure of vancomycin 
Desmopressin and cyclosporine A are orally delivered peptide drugs absorbed 
from the GI tract into the systemic circulation to elicit their therapeutic action.  
Cyclosporine A possess’ some unique characteristics amongst peptides that 
make it suitable for oral delivery.  It has an oral bioavailability of approximately 
30%, most peptides are less than 5% orally available.  Unlike most proteins and 
peptides it is highly lipophilic (logP 3) which may enable its partition across the 
lipid membranes of intestinal cells into the systemic circulation.  Its 
bioavailability is actually limited by this high lipid solubility as its aqueous 
solubility is low.  Formulations of cyclosporine A are pre-concentrates of oil and 
surfactant that upon contact with GI fluid form emulsions or microemulsions.  
Cyclosporine A also has a cyclic structure which may provide protection from 
digestive enzymes, figure 1.2. 
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Figure 1.2 Structure of cyclosporine A 
Desmopressin does not possess the lipophilicity of cyclosporine A, logP -1.95 
(Ito et al., 2011), and is only part cyclised, figure 1.3, so may have less 
enzymatic protection, yet it is orally delivered.  Its oral bioavailability is less than 
1% but as only a very low dose is required to elicit its therapeutic effect only a 
very low oral bioavailability is required.  Its wide therapeutic window also 
minimises any problems encountered by variations in oral absorption. 
 
Figure 1.3 Structure of desmopressin 
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1.3 Advantages of oral delivery 
Oral delivery of protein and peptide drugs is preferable to injections for patients 
as it eliminates any pain, discomfort or fear associated with needles.  A survey 
of breast cancer patients found that 63% would prefer daily tablets to monthly 
intramuscular injections (Fallowfield et al., 2006).  The reasons given for this 
were dislike of needles and greater convenience.  There may also be greater 
compliance as taking an oral dosage form is generally considered less daunting 
than having an injection.  Oral delivery is also preferable from a pharmaceutical 
manufacturer’s point of view as costs of producing injectables under sterile 
conditions are higher than for oral dosages. 
1.4 Oral and intestinal bioavailabilities of protein and peptide drugs 
Currently the vast majority of protein and peptide drugs are not delivered orally 
due to their low oral bioavailability.  Table 1.3 lists the bioavailabilities of protein 
and peptide drugs when administered orally or directly to various intestinal 
segments of humans and animals.  With the exception of cyclosporine A, due to 
the reasons discussed above, all of the proteins and peptides listed have 
bioavailabilities of less than 5% in conscious animals, relative to intravenous or 
subcutaneous delivery, regardless of their size and location of administration.  
The reason why so few protein and peptide drugs are available as oral dosage 
forms is that sufficient drug would not be able to reach its therapeutic target and 
elicit an effect by this route. 
The low bioavailabilities displayed in table 1.3 reveal that even if protein/peptide 
delivery is targeted to a specific part of the GI tract it will still experience huge 
obstacles to its stability and absorption into the bloodstream.  Relatively higher 
oral bioavailabilities of thyrotropin releasing hormone (TRH), vancomycin and 
octreotide may be due to their small size, providing less opportunity for 
digestion, stabilising effects of glycosylation and a tricyclic structure of 
vancomycin, and the cyclic structure of octreotide.  
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Table 1.3 Bioavailabilities of protein/peptide drugs when administered orally or to intestinal segments in humans/animals 
Protein/peptide 
(amino acids, size) 
Site of administration-bioavailability relative to intravenous/subcutaneous dose (%) 
Oral Stomach Duodenum Jejunum Ileum Colon 
TRH–rat  (3, 0.4kDa) 1.6%1      
Vancomycin-rat  
(7, 1.4kDa) 
1.7%2      
Octreotide-human (8,1kDa)  0.2% sc3 0.1% sc3 0.2% sc3 0.06% sc3  
Octreotide-rat (8, 1kDa) 4.3%4   0.3%-3.1%5-6    
Leuprolide-rat (9, 1.2kDa) 0.02-0.3%   
1.2% sc7-9 
 0.08%7 1.3*% 10 0.6-5.6*% 10 0.4-9.6*%10 
Buserelin-rat (9,1.3kDa)   0.1-0.8%11-12    
Vasopressin analogs-rat 
(9/10, 1.1kDa) 
<0.1%13   0.9%5   
Desmopressin-human  
(10, 1.1kDa) 
 0.2%14 0.09-0.2%14-15 0.2%14 0.03%14 0.04%14 
Cyclosporine A-human  
(11, 1.2kDa) 
20-50%16      
Calcitonin-rat  
(32, 3.4kDa) 
0-0.2%17-20  0.02-0.15%17, 21, 22 0.2-3.3%22, 23 0.06%17 0.02-0.9%17, 20, 23, 24 
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Calcitonin-human       0.22%25 
Calcitonin-dog    0.04%26  0.06%26 0.02%26 
Exenatide-rat (39, 4.2kDa) 0%27  0.005%28    
Insulin-rat (51, 5.8kDa) 0.7%, <1%19, 29      
Parathyroid hormone-
rat/monkey (84, 9.4kDa) 
0%30, 31    0%30  
Erythropoietin-rat  
(106, 18kDa) 
   0.6%32   
Interferon α-rat/rabbit  
(165, 19kDa) 
 0%33 <1% 33  
GCSF-rat (175, 19kDa)   0%34    
* In anesthetized rats, thyrotropin releasing hormone (TRH), granulocyte colony stimulating factor (GCSF).  Bioavailabilities are relative to 
an intravenous dose, unless specified as relative to a subcutaneous dose (sc).   
1 (Sasaki et al., 1997), 2 (Anderson et al., 2001), 3 (Kohler et al., 1987), 4 (Fricker et al., 1991), 5 (Michael et al., 2000), 6 (Thanou et al., 
2000b), 7 (Adjei et al., 1993), 8 (Iqbal et al., 2011), 9 (Iqbal et al., 2012), 10 (Zheng et al., 1999b), 11 (Luessen et al., 1996), 12 (Thanou et al., 
2000a), 13 (Lundin et al., 1994), 14 (d'Agay-Abensour et al., 1993), 15 (Fjellestad-Paulsen et al., 1996), 16 (Jaiswal et al., 2004), 17 (Hee Lee 
et al., 2000), 18 (Ogiso et al., 2001), 19 (Tozaki et al., 2001), 20 (Fetih et al., 2006), 21 (Sinko et al., 1995), 22 (Tozaki et al., 1998), 23 (du 
Plessis et al., 2010), 24 (Hastewell et al., 1992), 25 (Hastewell et al., 1995), 26 (Sinko et al., 1999), 27 (Jin et al., 2009), 28 (Gedulin et al., 
2008), 29 (Takeuchi et al., 1996), 30 (Guo et al., 2011), 31 (Leone-Bay et al., 2001), 32 (Venkatesan et al., 2006a), 33 (Bayley et al., 1995), 34 
(Jensen-Pippo et al., 1996)
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Of the intestinal segments the jejunum appears to be the most favourable for 
successful absorption.  Possibly the enzyme concentration is lower here than in 
other segments, there is greater surface area for absorption or it is more 
permeable to protein and peptide drugs.  Despite the lack of secretion of 
intestinal enzymes in the colon bioavailabilities of drugs administered here were 
less than 1% in conscious animals.  This suggests they are vulnerable to 
microbial mediated fermentation and enzymes.  The smaller surface area for 
absorption and the tighter intercellular channels, compared to the small 
intestine, may also have restricted bioavailability. 
All the proteins and peptides listed in table 1.3 are hormones, with the exception 
of interferon α, cyclosporine A and vancomycin, and therefore not completely 
representative of all therapeutic protein and peptide drugs.  Research may have 
focused on these due to their relatively small size and they may be easier to 
obtain than some of the larger and more expensive proteins such as 
monoclonal antibodies.  Most of the studies have not been conducted in 
humans so they may not represent what would happen upon oral administration 
to humans.  However, the results show that generally, regardless of size, 
structure, site of administration and subject, protein and peptide drugs have 
very low oral bioavailabilities, <5%, and therefore cannot be administered in 
standard oral tablet or capsule formulations. 
1.5 Barriers to oral protein/peptide drug delivery- instability 
The major barriers to oral protein/peptide drug delivery are illustrated in figure 
1.4.  The GI tract is designed to digest proteins and peptides and thus it plays a 
major role in the bioavailability of orally delivered protein and peptide drugs.  
Protein and peptide digestion is initiated by acid and pepsin in the stomach and 
continued throughout the small intestine by a multitude of proteases and 
peptidases in its lumen and along the intestinal wall.  Should any proteins or 
peptides enter the large intestine intact they may be digested or fermented by 
its large population of bacteria.  These processes necessary for protein 
digestion work antagonistically to the oral delivery of intact protein/peptide 
drugs. 
37 
 
 
Figure 1.4 The stability and permeability barriers to oral protein and peptide 
drug delivery, adapted from www.encognitive.com 
1.5.1 Gastric instability 
The first major barrier faced by an orally delivered protein or peptide drug is the 
stomach.  The pH of a human fasting stomach has been measured as pH 1-2.5 
by a pH sensitive radiotelemetry capsule (Evans et al., 1988).  Exposure to this 
low pH can alter the ionisation of amino acids which can affect the bonds that 
hold together the secondary and tertiary structure of larger peptides and 
proteins.  Disruption of these bonds may cause a loss of specific structure and 
function.   
Acid can also break peptide bonds between amino acids.  Acid hydrolysis is 
used to determine the amino acid constituents of proteins and peptides (Berg, 
2002).  Peptides/proteins are placed in acid and heated to 100-110°C for 24 
hours to break all peptide bonds.  Due to the necessity of a high temperature 
and prolonged exposure peptide bonds are unlikely to be completely disrupted 
in the stomach.  Therefore small peptides with no secondary or tertiary structure 
may not lose their structure at gastric pH.   
As well as the acidic pH there is an enzymatic obstacle present in the stomach.  
Pepsin is secreted here and cleaves peptide bonds within a peptide chain 
(endopeptidase) between hydrophobic, preferably aromatic amino acids. 
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Table 1.4 indicates that the gastric stability of peptides and proteins is at least 
partly dependent on their size.  The smaller peptides, vasopressin, oxytocin and 
TRH analogues appear to be completely stable in simulated, human and animal 
gastric fluids and mucosa.  This may be due to their lack of higher structure 
which could be disrupted by the low pH.  They also appear to be stable in the 
presence of pepsin which may mean they lack specific pepsin cleavage motifs 
or are partially protected by disulphide bridges as in oxytocin and vasopressin.  
The larger peptides and proteins such as the digestive enzymes, insulin and 
teriparatide appear to be susceptible to gastric denaturation of their secondary 
and tertiary structures. 
These results suggest for successful oral delivery gastric protection is 
necessary for larger peptides and proteins and those containing pepsin 
cleavage sites.  However, protection in the stomach is not needed for all 
proteins and peptides.  Assessment of gastric stability is beneficial to not only 
discover where protection is needed for orally administered protein/peptide 
drugs but also to assess where protection is not required as this will reduce 
manufacturing costs and make oral delivery more achievable. 
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Table 1.4 Protein/peptide recovery after incubation in simulated gastric fluid (SGF), human/animal gastric fluid and mucosa 
Protein/peptide  
(amino acids, size) 
Proportion intact/active after incubation in simulated/human/animal gastric media 
SGF no pepsin SGF pepsin Gastric fluid Gastric mucosa 
TRH (3, 0.4kDa)  100% 2hours1-2 100%-2 hours rat1-2  
Oxytocin analogs (9, 1kDa)   100% human3 100% human3 
Vasopressin analogs  
(9/10, 1.1kDa) 
  100% human3 100% human3 
LHRH (10, 1.2kDa)  60%, 6 hours4   
Teriparatide (34, 4.1kDa)  0% 5 mins5   
Insulin (51, 5.8kDa)  3%-10% 2 hours6-7 0% 3 mins- pig8  
Lysozyme (128, 14.3kDa) 0% 30 mins9    
β-lactoglobulin A/B  
(162, 18.4kDa) 
17.2-34.3% 60 mins9 0% 2 mins9   
Ovomucoid (28kDa)  0% immediate9   
Digestive enzymes: amylase, 
lipase, trypsin  
(244-969, 26-55kDa) 
 0-8% 30 mins10-11   
Chicken egg yolk 
immunoglobulin (150kDa) 
 0% 1 hour12   
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Luteinising hormone releasing hormone (LHRH) 
1 (Sasaki et al., 1997), 2 (Khomane et al., 2011), 3 (Fjellestad-Paulsen et al., 1995), 4 (Kafka et al., 2011), 5 (Werle et al., 2006),                  
6 (Han et al., 2012), 7(Jain et al., 2012), 8 (Werle et al., 2008), 9 (Zheng et al., 2010), 10 (Scocca et al., 2007), 11 (Massicotte et al., 2008),  
12 (Li et al., 2009)
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1.5.2 Small intestinal instability 
The small intestine is the major site of protein and peptide digestion and 
represents a barrier to oral protein and peptide drug delivery.  The pH of the 
gastrointestinal tract rises to pH 6.6 in the proximal small intestine and rises to 
pH 7.5 in the terminal ileum (Evans et al., 1988).  The small intestine contains 
luminally secreted proteases and membrane bound peptidases which can 
digest protein and peptide drugs.  They may also be subject to degradation by 
thiol-disulfide exchange reactions if they contain cysteine residues
The major enzymes secreted into the small intestine are the endopeptidases 
trypsin, chymotrypsin and elastase and the exopeptidases aminopeptidase and 
carboxypeptidase.  These cleave within or from the ends of peptide chains 
according to their cleavage specificities.  Identification of a cleavage motif within 
a peptide chain may not definitely indicate digestion by a specific enzyme.  
Cleavage is not just dependent on the presence of a vulnerable peptide bond 
but the size and position of other amino acids in the peptide sequence. 
Investigations of protein and peptide stability in simulated intestinal fluid and 
enzyme solutions are summarised in table 1.5.  With the exception of TRH there 
is a general trend that proteins are more stable than peptides in these 
conditions.  This may be because proteins do not have as easily accessible 
cleavable peptide bonds as their peptide chains are involved in complex 
secondary and tertiary structures.  However, if orally delivered these structures 
may be unfolded in the stomach and so would be more vulnerable to enzymatic 
digestion. 
Trypsin and chymotrypsin appear to be the most degradative towards peptides 
and proteins and so for successful oral delivery these enzymes should be 
specifically inhibited.  A reduction of pH to pH 6 reduced the degradation of 
desmopressin by chymotrypsin so this may be used to inhibit intestinal enzymes 
(Fredholt et al., 1999). 
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Table 1.5 Protein/peptide recovery and half lives (HL) in simulated intestinal fluid (SIF) with pancreatin and enzyme solutions 
Protein/peptide drug    
(amino acids, size) 
Proportion remaining after incubation and half lives in SIF/enzyme solutions 
SIF  Trypsin Chymotrypsin Elastase Aminopeptidase 
TRH (3, 0.4kDa) 100%, 3hrs1     
Desmopressin  
(10, 1.1kDa) 
  pH 7.4-20.2min HL pH 
6- 105.6min HL2 
  
LHRH (10, 1.2kDa) 0%, 
immediate3 
850 min HL, 100% 
2hr4-5 
2-2.7 min HL4-5 70-114 min HL4-5  
Calcitonin (32, 3.4kDa) 0%, 1hr6 1.5-8.6 min HL 
0% 15min7-9 
12.8-22.4 min HL7, 10 
0% 30 min8-9 
21 min HL7,10, 0% 
40 min8-9 
4.8 hr HL10 
Teriparatide (34, 4.1kDa)  0% 5 min11 0% 5 min11 85% 3 hr11 20% 6hr11 
GLP-1 analogs (39, 4.2kDa)  0.6-1.9 min HL12    
Insulin (51, 5.8kDa) 10% 2hr13 2% 30 min14  0% 
1hr15 
0% 15 min15, 8%       
40 min16, 4% 6hr14 
35% 3hr15  
Lysozyme (128, 14.3kDa) 22.8%, 1 hr17     
GCSF (175, 19kDa)  50%18 100%18   
Ovomucoid (28kDa) 23.4%, 1 hr17     
BSA (583, 66.5kDa) 17.7%, 1 hr17     
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Glucagon like peptide 1 (GLP-1), bovine serum albumin (BSA) 
1 (Khomane et al., 2011), 2 (Fredholt et al., 1999), 3 (Kafka et al., 2011), 4 (Wen et al., 2002c), 5 (Walker et al., 2001), 6 (Lee et al., 2010),   
7 (Lu et al., 1999), 8 (Ryan et al., 2011), 9 (Shah and Khan, 2004), 10 (Youn et al., 2006), 11 (Werle et al., 2006), 12 (Jin et al., 2009),           
13 (Jain et al., 2012), 14 (Agarwal et al., 2001), 15 (Werle et al., 2008), 16 (Schilling and Mitra, 1991), 17 (Zheng et al., 2010),                         
18 (Jensen-Pippo et al., 1996)
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Glutathione, which is part of the antioxidant defence system of the GI tract, may 
also contribute to intestinal instability.  Reduced glutathione plays a role in thiol-
disulphide reactions so may metabolise proteins/peptides with disulphide 
bonds.  Table 1.6 shows the vulnerability of some peptides with disulphide 
bridges to degradation in the presence of glutathione.  There was no 
degradation of octreotide, possibly due to the presence of aromatic amino acids 
in the vicinity of its disulphide bridge.   
Table 1.6 Stability of disulphide bridge containing peptides with glutathione 
 
Investigations into the stability of peptides in animal and human small intestinal 
fluids, table 1.7, revealed that the smaller peptides TRH and hexarelin were 
more stable than the larger peptides tested.  As they have fewer amino acids 
they have a lower probability of containing one of the specific cleavage sites of 
the small intestinal enzymes so may be more stable.  Tests with small intestinal 
enzyme solutions suggested proteins may be more stable in this environment 
but as no proteins >6kDa were tested it cannot be determined if this stability 
would persist in actual small intestinal fluids.  Lowering the pH of human small 
intestinal fluids reduced vasopressin degradation possibly by inactivating the 
enzymes present (Fjellestad-Paulsen et al., 1995).   
 
Peptide Media Proportion intact after 
incubation 
Desmopressin Glutathione pH 3/pH 5.5 100%/50% (Schmitz et al., 2006) 
Oxytocin Glutathione pH 3 20% 3 hrs (Huck et al., 2006) 
Oxytocin Human ileal 
mucosa/+glutathione  
~100%/60% 3 hrs  
(Fjellestad-Paulsen et al., 1995) 
Octreotide Glutathione pH 3 100% 3hrs (Huck et al., 2006) 
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Table 1.7 Protein/peptide recovery and half lives (HL) after incubation in human/animal small intestinal fluid and mucosa  
Protein/peptide          
(amino acids, size) 
Proportion remaining and half lives after incubation in human/animal small intestinal fluid/mucosa 
Small intestinal fluid Small intestinal mucosa 
TRH (3, 0.4kDa)  Rat-100%1 Rat-100%1 Rabbit-94% 65 min2 
Hexarelin (6, 0.9kDa) Rat jejuna/ileal- 80%/60% 1hr3  
Octreotide (8, 1kDa)  Rat-100%4 
Oxytocin analogs (9, 1kDa) Human ileal-0% 60mins5 Human jejunal/ileal 100%5 
Vasopressin analogs   
(9/10, 1.1kDa) 
Human 0-50% 35 mins (at pH 4 100%)5 
Rat-0.2-58.3% 30 mins6 
Pig 0% 5 mins7 
Human jejunal-30% 3hrs, 
ileal 100% 3 hrs5 
 
Gonadotrophin releasing 
hormone analogs         
(9/10, 1.2-1.3kDa) 
Brushtail possum- 22 min HL8 Rabbit-1.1% 1hr 
Rat-24.8% 5 hr9, 90 min HL10 
Calcitonin (32, 3.4kDa) Rabbit- 20 min HL11 
Rat-jejunal 0% 5min, 0.4 min HL12 
Rabbit- 239 min HL11 
Rat- 0% 25 min13, 4.1-10.6 min HL12, 14 
Teriparatide (34, 4.1kDa)  Rat- 50% 3 hr15 
GLP-1 analogs (39, 4.2kDa) Rat-0.51-1.76 min HL16-17 Rat- 0.79 min HL17 
Insulin (51, 5.8kDa) Pig-0% 3 min18  
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 1 (Sasaki et al., 1997), 2 (Thwaites et al., 1993), 3 (Fagerholm et al., 1998), 4  (Fricker et al., 1991), 5 (Fjellestad-Paulsen et al., 1995),        
6 (Lundin et al., 1994), 7 (Lundin et al., 1989), 8 (Wen et al., 2002c), 9 (Guo et al., 2004), 10 (Zheng et al., 1999a), 11 (Lu et al., 1999),          
12 (Ogiso et al., 2001), 13 (Tozaki et al., 1998), 14 (Youn et al., 2006), 15 (Werle et al., 2006), 16 (Jin et al., 2009), 17 (Youn et al., 2008),       
18 (Werle et al., 2008)
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Degradation of peptides was generally reduced in the intestinal mucosal 
homogenates (Fjellestad-Paulsen et al., 1995) and proteolytic activity was found 
to be reduced here compared to the lumen (Wen et al., 2002c).  There may be 
fewer enzymes here capable of digesting larger peptide chains as usually when 
they arrive at the mucosal membranes they have been digested to tri and 
dipeptides.  Protein and peptide drugs could be targeted to the intestinal 
mucosa for release as here they will encounter less digestion. 
Different regions of the intestinal tract have been found to have differing 
proteolytic activities.  The luminal and mucosal extracts from the jejunum of the 
rat and brushtail possum were found to have greater proteolytic activity than 
those from the ileum (Wen et al., 2002c, Tozaki et al., 1998).  LHRH was most 
degraded in brushtail possum luminal and mucosal extracts from the jejunum 
than the ileum or duodenum (Wen et al., 2002a, Wen et al., 2002b).  Despite 
this, bioavailability of protein and peptide drugs tended to be greater when 
administered to the jejunum than from the duodenum or ileum, table 1.3.  
Possibly the opportunity for absorption into the systemic circulation is far greater 
from the jejunum than the other intestinal segments and so overcomes the 
greater proteolytic activity. 
1.5.3 Large intestinal instability 
Proteolytic activity in the large intestinal fluids and mucosa has been found to 
be lower than in the small intestine of brushtail possums (Wen et al., 2002c) 
and rats (Tozaki et al., 1998).  LHRH degradation was least in the colonic 
contents of a brushtail possum intestine (Wen et al., 2002a, Wen et al., 2002b).  
Glatiramer acetate degradation was also lower in rat colonic mucosa compared 
to the other intestinal segments (Haupt et al., 2002).  Desmopressin 
degradation was lowest in the colonic contents from a rat compared to extracts 
from small intestinal segments, however vasopressin was degraded mainly in 
the colonic contents (Ungell et al., 1992).  This reduced proteolytic activity may 
make the large intestine a more attractive target for oral protein and peptide 
drug delivery than the small intestine. 
Table 1.8 shows that despite reduced proteolytic activity in the large intestine 
protein/peptide degradation still occurs and would need to be minimised for oral 
delivery strategies targeted here.   
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The colon is home to a large population of microbes which may secrete their 
own proteases.  Proteins and peptides may also be fermented by microbes in 
the large intestine metabolising them to volatile fatty acids.  The contribution of 
microbial mediated degradation of orally delivered TRH was demonstrated by 
an increase in oral bioavailability from 1.6% to 3.1% when administered with 
antibiotics (Sasaki et al., 1997). 
Table 1.8 Protein/peptide recovery and half lives (HL) after incubation in 
human/animal large intestinal, faecal fluid and mucosa 
Protein/peptide 
(amino acids, 
size) 
Proportion remaining and half lives (HL) in large 
intestinal and faecal fluids/mucosa 
Caecal Colonic Faecal 
TRH 
(3, 0.4kDa) 
Rat-degraded1 Rat-degraded1 Rat/human/dog 
degraded1 
Hexarelin 
 (6, 0.9kDa) 
Rat fluid- 100% 
1hr2 
Rat fluid- 100% 1hr2  
Vasopressin 
 (9, 1.1kDa) 
 Human mucosal-  
40% 30min3 
 
Calcitonin  
(32, 3.4kDa) 
Rat-2.5 min HL4-5 Rat-19.23 min 
Rabbit-128 min HL6-7 
Human-2-132 
min HL7-8  
Insulin  
(51, 5.8kDa) 
Rat-34 min HL4-5   
1 (Sasaki et al., 1997), 2 (Fagerholm et al., 1998), 3 (Fjellestad-Paulsen et al., 
1995), 4 (Tozaki et al., 1997), 5 (Tozaki et al., 1995), 6 (Tozaki et al., 1998),         
7 (Lu et al., 1999), 8 (Hastewell et al., 1995) 
1.5.4 Systemic instability 
Short circulation half life is an issue for peptide and protein drugs delivered by 
injection and many strategies such as pegylation and sustained release depot 
formulations have sought to overcome this.  Opsonins can bind to 
proteins/peptides in the blood stream enabling them to be cleared by 
macrophages reducing their systemic half life.  Should orally delivered 
protein/peptide drugs be absorbed intact into the systemic circulation they may 
also require strategies to prolong their systemic half life. 
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1.6 Barriers to oral protein/peptide drug delivery-permeability 
The very low oral bioavailabilities of protein and peptide drugs are not just the 
result of their instability but also poor permeability.  The routes for 
protein/peptide drug absorption from the intestinal lumen into the systemic 
circulation are between cells, paracellular, through cells, transcellular, by 
endocytosis/pinocytosis or by carrier mediated transport.  The relatively small 
peptide TRH appeared to be absorbed by carrier mediated transport 
(Yokohama et al., 1984).  However carrier mediated transport for larger 
peptides and proteins is likely to be limited as peptide carriers in the intestinal 
membrane are present for the uptake of di/tri peptides produced by digestion. 
The relatively large size of protein and peptide drugs hampers their absorption 
as it has been shown to be size dependent and decreases rapidly when 
molecular weight is greater than 700Da (Humphrey and Ringrose, 1986, 
McMartin et al., 1987, Donovan et al., 1990).  The paracellular route is 
particularly limited by the tight junctions between cells and restricted to 
molecules less than 200Da (Humphrey and Ringrose, 1986, McMartin et al., 
1987, Donovan et al., 1990).  As even the smaller peptides are larger than 
700Da their intestinal absorption is likely to be very limited. 
The majority of protein and peptide drugs are hydrophilic and therefore not 
compatible with passive transcellular absorption across the lipid bilayer 
membranes of intestinal cells.  The lipophilic nature of cyclosporine A is thought 
to account for its higher oral bioavailability as it can be absorbed by the 
transcellular pathway.  However a study found no correlation between the 
lipophilicity of peptides and their uptake across the Caco-2 in vitro intestinal cell 
model (Conradi et al., 1991).  Instead they found a correlation between the 
number of hydrogen bonds a peptide could make with water and its 
permeability.  The more H-bonds it could form the less permeable it was, 
possibly due to the greater amount of energy required to break these bonds 
before absorption.   
The paracellular route may be more compatible for absorption of hydrophilic 
protein and peptide drugs.  However paracellular spaces contribute less than 
1% of the total mucosal surface area and their small diameter, less than 10Å, 
(Jung et al., 2000) limits the passage of these large molecules. 
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Human colon carcinoma (Caco-2) cells are used to mimic the intestinal 
absorptive epithelium for studying transepithelial drug transport.  Caco-2 cell 
uptake studies revealed more than 90% of TRH remained on the donor side 
and salmon calcitonin uptake was negligible (Yoo and Park, 2004).  The low 
uptake of even the very small peptide TRH shows the inherent lack of 
permeability of intact peptide and protein drugs. 
Most absorption takes place in the small intestine due to its large absorptive 
surface area and leakier paracellular channels than those in the large intestine.   
Vasopressin absorption in a rat was found to be greater from the small intestine 
than the large intestine or stomach (Ritschel, 1991).  Absorption of calcitonin in 
rats and dogs (Tozaki et al., 1998, Hee Lee et al., 2000, Sinko et al., 1999) and 
desmopressin in humans (d'Agay-Abensour et al., 1993) was greater from the 
small intestine than the colon. 
Table 1.3 indicated bioavailabilities were greater after administration to the 
jejunum, however the results were gathered from many different studies which 
may have used different parameters possibly making comparisons inaccurate.  
Studies conducted to compare the absorption of various protein and peptide 
drugs from small intestinal segments in rats, beagle dogs and rabbits found that 
calcitonin (Tozaki et al., 1998, Hee Lee et al., 2000, Sinko et al., 1999), insulin 
(Han et al., 2012), oxytocin, carbetocin (Lundin et al., 1991), desmopressin, 
vasopressin (Pantzar et al., 1995, Lundin et al., 1991) and leuprolide (Zheng et 
al., 1999b) were all more absorbed from the distal than proximal small intestine.  
This may be due to lower proteolytic activity of the ileum than the jejunum.  The 
M cells of gut associated lymphoid tissue are known to sample macromolecules 
from the ileum and represent a potential portal for oral protein/peptide 
absorption.  Increased absorption from this segment may be due to these cells. 
In human studies, however, desmopressin (d'Agay-Abensour et al., 1993) and 
octreotide (Kohler et al., 1987) absorption was greater from the proximal small 
intestine than the ileum.  This disparity with animal absorption studies could be 
due to their higher percentage of M cells in Peyer’s patches, 10-50%, in 
rodents, and 46% in rabbits (Gebert et al., 2004) compared to humans, 5%.   
Absorption of leuprolide from small intestinal and colonic segments was greater 
in anesthetized rats than conscious rats (Zheng et al., 1999b), table 1.3.         
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This may have been due to reduced GI motility and enzyme secretion.  The 
absorption of desmopressin was increased by pretreatment with loperamide, 
which decreased intestinal motility, in human volunteers (Callreus et al., 1999).  
This increased desmopressin residence time and therefore its absorption.  It 
may also have inhibited pancreatic secretions increasing its bioavailability by 
reducing its enzymatic digestion.  An increased intestinal residence time may be 
used to increase the oral bioavailability of protein and peptide drugs. 
1.7 Oral protein/peptide drug delivery strategies 
To overcome the stability and permeability barriers to oral protein and peptide 
delivery many different strategies have been attempted, illustrated in figure 1.5 
and described below.  The main challenge for the oral delivery system is to 
increase oral bioavailability from less than 5% to at least 30-50% (Shaji and 
Patole, 2008).  In addition to this the formulation preparation process must not 
denature fragile protein/peptide drugs. 
The vast majority of oral delivery research has been conducted with calcitonin 
and insulin, possibly due to the frequency of their administration and clinical 
importance.  Some research has also focused on improving the oral delivery of 
cyclosporine A, desmopressin and pancreatin.  There has also been research 
conducted with the peptide hormones leuprolide, oxytocin and octreotide 
possibly due to their smaller size making them more compatible for oral 
delivery.  There has been very little investigation into the oral delivery of larger 
proteins.  This could be because of the inherent difficulties of maintaining their 
complex structure during GI transit and the greater difficulty of absorption of 
such large molecules into the bloodstream.  Recently the oral delivery of GLP-1 
and its analogues exenatide and liraglutide has been explored possibly due to 
their importance in the treatment of type 2 diabetes (Rekha and Sharma, 2013). 
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Figure 1.5 Strategies to overcome the stability and permeability barriers to oral 
protein and peptide drug delivery, adapted from www.encognitive.com 
1.8 Overcoming the gastric barrier  
Strategies to overcome gastric degradation of orally delivered proteins and 
peptides include excipients to raise gastric pH and encapsulation within enteric 
carriers, table 1.9.  Reduction of stomach acid enabled the oral delivery of 
active pancreatic enzymes (Regan et al., 1977) and a murine monoclonal 
antibody (Ilan et al., 2010) in human volunteers.  Local buffering provided by a 
carboxylated high amylase starch tablet in simulated gastric conditions enabled 
a 70% retention of pancreatic enzyme activity (Massicotte et al., 2008).  
However a prolonged and chronic raising of stomach pH may compromise this 
acidic barrier to ingested toxins and its role in digestion.  Raising the pH may 
only partially or temporarily inhibit pepsin. 
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Table 1.9 Oral protein/peptide drug delivery strategies to increase stability in gastric conditions 
Protein/ 
peptide drug 
pH modulation Enteric micro/nanoparticles pH sensitive hydrogels 
Oxytocin   Hydrogel of succinic derivatives of inulin1 
Cyclosporine A  Eudragit L100, L100-55, S100 
nanoparticles2-3 * 
 
Bleomycin   P(MAA-g-EG) nanospheres4-5 
Calcitonin  Eudragit L100 nanoparticles6* 
Eudragit P-1435F micropsheres7 
P(MAA-g-EG)/ P(MAA-co-NVP) 
micro/nanospheres8-10,  
Insulin  Eudragit L100/S100/L100-5511-17 *, 
Eudragit L30D coated PLGA18 *, 
PLGA/HP5519 *, HPMCP cross-linked 
chitosan20 *, hyaluronic acid21* 
micro/nanoparticles 
P(MAA-g-EG) microspheres 8, 22 * 
Poly N-vinyl caprolactam-co-methacrylic 
acid23 * 
 
Interferon β   P(MAA-g-EG) microspheres8 * 
Human growth 
hormone 
  P(MAA-co-NVP) microparticles10 
Pancreatic enzymes Cimetidine –H2 receptor 
antagonist24 
Eudragit L10026 *,S100-Alginate27, 
HPMCP26 * micro/nanoparticles  
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Pancreatic enzymes Carboxylated high amylase 
starch tablet-local buffering 25 
  
Murine monoclonal 
antibody, OKT3 
Omeprazole –proton pump 
inhibitor28 
  
Egg yolk 
immunoglobulin 
 Chitosan alginate microcapsules29 *  
Poly(methacrylic acid-g-ethylene glycol) : P(MAA-g-EG), poly(methacrylic acid-co-N-vinyl pyrrolidone): P(MAA-co-NVP)    
* Enteric strategy enabled retention of at least 75% encapsulated drug in vitro in acid 
1 (Mandracchia et al., 2010), 2 (Dai et al., 2004a), 3 (Dai et al., 2004b), 4 (Blanchette and Peppas, 2005a),                                                     
5 (Blanchette and Peppas, 2005b), 6 (Cetin et al., 2012), 7 (Lamprecht et al., 2004), 8 (Kamei et al., 2009), 9 (Torres-Lugo et al., 2002),     
10 (Carr et al., 2010), 11 (Agarwal et al., 2001), 12 (Zhang et al., 2012b), 13 (Mundargi et al., 2011a), 14 (Jain et al., 2005),                             
15 (Jain et al., 2006), 16 (Jelvehgari et al., 2010), 17 (Morishita et al., 1993), 18 (Naha et al., 2008), 19 (Wu et al., 2012a),                                
20 (Makhlof et al., 2011b), 21 (Han et al., 2012), 22 (Torres-Lugo et al., 2002), 23 (Mundargi et al., 2011b), 24 (Regan et al., 1977),                
25 (Massicotte et al., 2008), 26 (Naikwade et al., 2009), 27(Scocca et al., 2007), 28 (Ilan et al., 2010), 29 (Li et al., 2007)
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Enteric formulations can prevent the release of orally delivered protein and 
peptide drugs in the stomach protecting them from acid and/or pepsin 
degradation, and can target their release to favourable regions of the intestinal 
tract for their absorption.  Pancreatin is currently available as enteric coated 
tablets, granules and microspheres to prevent its gastric denaturation.  Enteric 
micro and nanoparticles offer advantages over enteric tablets or capsules in 
terms of a faster drug release at small intestinal pH (Naikwade et al., 2009) and 
better in vivo control of symptoms (Littlewood et al., 1988). 
Enteric micro/nanoparticles and most of the pH sensitive hydrogels, which swell 
in response to pH, were able to restrict the release of encapsulated 
protein/peptide drugs in vitro in acid, table 1.9, however some of the hydrogel 
particles prematurely released their loaded drug.  Almost 40% of calcitonin and 
bleomycin were released from P(MAA-g-EG) hydrogels at pH 1.2 possibly due 
to their small size (Kamei et al., 2009, Blanchette and Peppas, 2005a, 
Blanchette and Peppas, 2005b). 
While enteric particles prevented release of a high proportion of encapsulated 
protein/peptide drug in acid the proportion retaining activity after pepsin 
incubation was much lower, 26-60% (Scocca et al., 2007, Li et al., 2009, 
Makhlof et al., 2011b, Han et al., 2012).  This disparity suggests they may not 
be able to prevent premature drug release, degradation of drugs exposed at the 
particle surface and/or influx of acid and pepsin which can degrade the 
encapsulated protein/peptide.   
Encapsulation of pancreatin (Naikwade et al., 2009), calcitonin (Cetin et al., 
2012) and insulin (Mundargi et al., 2011a, Jain et al., 2005, Naha et al., 2008, 
Han et al., 2012) in enteric particles increased their oral efficacy up to four times 
that of a drug solution in rabbits and rats. Pharmacological availabilities of 
insulin encapsulated in enteric micro/nanoparticulates, ranged from 0.8 to 
11.4% relative to subcutaneous insulin (Zhang et al., 2012b, Morishita et al., 
1993, Wu et al., 2012a, Makhlof et al., 2011b).  An insulin solution produced 
negligible availability.  Encapsulation of cyclosporine A in enteric nanoparticles 
increased its oral bioavailability in rats by 32.5% compared to the currently 
available microemulsion formulation Neoral (Novartis) (Dai et al., 2004a, Dai et 
al., 2004b).   
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Loading in pH sensitive hydrogels increased absorption of calcitonin and 
interferon β from rat ileum (Kamei et al., 2009).  Insulin loaded hydrogels 
decreased blood glucose levels by 50% when orally administered to rats 
(Mundargi et al., 2011b).   
Oral bioavailabilities of protein and peptide drugs, except cyclosporine A, solely 
encapsulated in enteric polymers were less than 5% (Han et al., 2012, Cetin et 
al., 2012, Lamprecht et al., 2004, Morishita et al., 1993).  The vulnerability of the 
released protein/peptide to enzymatic degradation in the small intestine and 
poor permeability may restrict its bioavailability.  Combining a pH sensitive 
polymer with a sustained release polymer, PLGA, increased insulin oral 
bioavailability to 11.4% (Wu et al., 2012a).  Enteric polymers may need to be 
combined with other, sustained release polymers, enzyme inhibitors and 
permeation enhancers to form a successful oral delivery strategy. 
1.9 Overcoming intestinal instability 
1.9.1 Enzyme protection 
To inhibit the enzymatic degradation of orally delivered protein and peptide 
drugs specific enzyme inhibitors and organic acids to lower the pH of the 
intestine, inactivating enzymes, have been used.  These strategies inhibited 
degradation in vitro in enzyme solutions and in human, rat and brushtail possum 
intestinal fluids and mucosa, table 1.10.  However, they may disrupt the normal 
digestion of proteins making them unsuitable for prolonged use.  The 
attachment of polyethylene glycol (PEG) has also been used to stabilise 
proteins/peptides by shielding them from enzymes.  Pegylation has been used 
to lengthen the circulatory half life and bioavailability of interferons (Pegasys, 
PegIntron) and GCSF (Neulasta) reducing the frequency of their injection.   
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Table 1.10 Oral protein/peptide drug delivery strategies to overcome intestinal enzymatic degradation 
3,4 dichloroisocoumarin (DCI), ethylenediaminetetraacetic acid (EDTA).  * Inhibited enzyme degradation in vitro in enzyme solutions and 
in human, rat and brushtail possum intestinal fluids and mucosa 
1 (Zheng et al., 1999a),2 (Fjellestad-Paulsen et al., 1995), 3 (Fjellestad-Paulsen et al., 1996), 4 (Ungell et al., 1992), 5 (Fredholt et al., 
1999), 6 (Wen et al., 2002a), 7 (Wen et al., 2002b),  8 (Tozaki et al., 1997), 9 (Shah and Khan, 2004), 10 (Tozaki et al., 1998), 11(Guggi and 
Bernkop-Schnurch, 2003), 12 (Ogiso et al., 2001), 13 (Lee et al., 2000), 14 (Lee et al., 1999), 15 (Wu et al., 2010), 16 (Tozaki et al., 2001),   
17 (Kraeling and Ritschel, 1992), 18 (Agarwal et al., 2001), 19 (Bai et al., 1996), 20 (Ushirogawa et al., 1992)
Protein/ 
peptide drug 
Protease inhibitors pH 
reduction 
Colonic formulation 
Leuprolide Antipain, DCI 1 *   
Desmopressin Aprotinin2-4 *, chymostatin2 *, bestatin4 *,cyclodextrins5 *   
LHRH Soybean trypsin inhibitor, bestatin, bacitracin, sodium deoxycholate, 
carbopol, EDTA 6-7 * 
  
Calcitonin Aprotinin8-10 *, camostat 8, 10 *, soybean trypsin inhibitor8, 10 *, chicken, duck, 
turkey ovomucoids9 *, bacitracin10, Bowman Birk inhibitor11 *, elastatinal11 *, 
sodium glycocholate8 *, sodium taurocholate12 *, carbopol12 * 
Citric acid 
13-15 
Azopolymer coated 
pellets16 
Insulin Aprotinin8 *, 17, camostat 8 *, soybean trypsin inhibitor 8 *, sodium 
glycocholate8 *, chicken, duck ovomucoids18 *, carbopol19 * 
 Colonic release capsules6 
Azopolymer coated 
pellets16 
GCSF  Citric acid 20  
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In vivo the trypsin/chymotrypsin inhibitor aprotinin increased the bioavailability 
of desmopressin from 0.09 to 0.46%, when administered intraduodenally in 
human volunteers (Fjellestad-Paulsen et al., 1996), and of insulin from 5.02% to 
6.15% when administered orally to dogs in a colonic formulation (Kraeling and 
Ritschel, 1992).  Aprotinin attached to liposomes with calcitonin (Werle and 
Takeuchi, 2009) and insulin (Morishita et al., 1993) increased oral hypocalcemic 
activity 11 fold, compared to plain liposomes, and oral insulin bioavailability in 
rats from 1.3% to 3.6%. 
Citric acid increased GCSF activity five fold when administered intraduodenally 
to rats, compared to a solution, (Ushirogawa et al., 1992).  It also increased the 
oral bioavailability of salmon calcitonin in dogs, when loaded in enteric 
capsules, from 0.02% to 0.86% (Lee et al., 2000, Lee et al., 1999), and 
produced an oral calcitonin bioavailability of 1.8% in rats (Wu et al., 2010).   
Pegylation increased GCSF bioavailability following intraduodenal 
administration to rats from undetectable to 1.8%, relative to intravenous GCSF  
(Jensen-Pippo et al., 1996).  When pegylated calcitonin was administered 
intestinally in rats its activity was 5.8 fold greater than unmodified calcitonin 
(Youn et al., 2006) but when orally administered it was not as active as 
unmodified calcitonin (Cheng and Lim, 2009).  Possibly PEG was detached 
from the drug before it reached the small intestine and may require additional GI 
protection.   
Oral protein/peptide drug bioavailability of pegylated drugs or those formulated 
with protease inhibitors or citric acid alone was not more than 5%, relative to the 
intravenously administered drugs.  These strategies alone may not be enough 
to enable oral protein and peptide drug delivery, however combined with other 
strategies they can increase oral bioavailabilities. 
1.9.2 Colonic delivery 
As the colon has been shown to be less proteolytically active than the small 
intestine (Tozaki et al., 1998, Wen et al., 2002c) some oral protein and peptide 
drug delivery strategies have been targeted there, table 1.10.  However drugs 
released here will be vulnerable to microbial mediated degradation and any 
permeation enhancement could result in the uptake of potentially toxic material. 
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pH sensitive colonic release capsules loaded with an insulin microemulsion 
increased its oral pharmacological availability in dogs from 2.1%, for the 
microemulsion, to 5% from the capsules (Kraeling and Ritschel, 1992).  Colon 
targeted azopolymer coated pellets loaded with eel calcitonin and insulin 
increased their oral pharmacological availabilities in rats from 0.16 to 1.04% and 
0.67 to 3.38% respectively (Tozaki et al., 2001).  The azo bonds of the polymer 
can be reduced by colonic microbiota triggering drug release.  The increased 
bioavailability is still only 5% of that of an intravenous dose and therefore to 
reach desired oral bioavailability levels additional excipients may be required. 
1.10 Overcoming the permeation barrier 
1.10.1  Mucoadhesion 
Mucoadhesive polymers such as chitosan, polyacrylic acids (carbopol, 
carbomer, carbophil) and thiomers have been used in oral protein and peptide 
drug formulations and increased in vitro mucoadhesion to cells and intestinal 
segments, table 1.11.  Lectin attachment can increase binding to cells in the 
small intestine and therefore uptake of protein and peptide drugs.  The lectin 
wheat germ agglutinin, WGA, has been most frequently used and can bind to 
intestinal cell surface receptors, table 1.11.   Mucoadhesion can increase 
intestinal residence time and concentration gradient between the delivery 
system and intestinal membrane, increasing the absorption of the associated 
drug. 
Chitosan is a natural, mucoadhesive polymer with a positive charge that allows 
it to interact with negatively charged intestinal mucosa. Chitosan coating of 
liposomes loaded with insulin increased its oral pharmacological availability five 
fold, compared to a solution, and produced a pharmacological availability of 5% 
relative to a subcutaneous dose (Takeuchi et al., 1996).  Chitosan coated 
liposomes increased the oral efficacy of calcitonin in rats up to six times that of 
uncoated liposomes (Takeuchi, 1999).  A dispersion of buserelin with chitosan 
increased its bioavailability from 0.1 to 5.1% when administered intraduodenally 
to rats (Luessen et al., 1996). 
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Table 1.11 Oral protein/peptide drug delivery strategies to increase mucoadhesion and intestinal residence duration 
 
* Increased in vitro mucoadhesion to cells and permeation 
1 (Guo et al., 2005), 2 (Iqbal et al., 2012), 3 (Luessen et al., 1996), 4 (van der Merwe et al., 2004), 5 (Ilan et al., 1996), 6 (Lehr et al., 1992), 
7 (Malaekeh-Nikouei et al., 2008), 8 (Huang et al., 2011), 9 (Takeuchi et al., 1999), 10 (Ogiso et al., 2001), 11 (Makhlof et al., 2011a),         
12 (Werle et al., 2010), 13 (Gradauer et al., 2012), 14 (Zhang et al., 2012a), 15 (Takeuchi et al., 1996), 16 (Wood et al., 2006),                      
17 (Zhang et al., 2012b)
Protein/ 
peptide drug 
Chitosan Poly (acrylic acids)  Lectins Thiomers 
Leuprolide Coated liposomes1 *   Thiolated chitosan 
attached to gels2 
Buserelin Dispersion3    
Desmopressin Coated minitablets/granules4 * Coated 
nanoemulsion5/particles6 
  
Cyclosporine A Coated PLGA microspheres7 *    
Calcitonin Coated liposomes 8-9 * Coated liposomes9 *, 
emulsion10 
WGA modified 
liposomes11-12 * 
Thiolated chitosan 
attached to 
liposomes13 * 
Insulin Coated PLGA nanoparticles14 *, 
liposomes15 * 
Coated liposomes15 * WGA attachment 
to hydrogel16 * 
Thiolated Eudragit 
L100 nanoparticles17 * 
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Carbopol coated liposomes and emulsions increased the oral efficacy of 
calcitonin in rats 2.4 fold compared to uncoated liposomes (Takeuchi, 1999) 
and  increased its oral bioavailability from 0.3 to 0.4% (Ogiso et al., 2001).  
Insulin loaded thiolated Eudragit L100 nanoparticles had an oral bioavailability 
of 7.3% in rats and a 2.8 fold greater efficacy compared to unmodified 
nanoparticles (Zhang et al., 2012b).  Thiolated chitosan attachment to leuprolide 
loaded gels increased its oral bioavailability in rats from 1.2 to 4.5% (Iqbal et al., 
2012).  Attachment of WGA to carbopol coated liposomes increased oral 
calcitonin efficacy in rats six fold compared to those with no WGA (Werle et al., 
2010). 
Gastrointestinal mucoadhesive patches (GI MAPs) produced oral and intestinal 
availabilities of GCSF (Eiamtrakarn et al., 2002), interferon α (Ito et al., 2005), 
erythropoietin (Venkatesan et al., 2006a, Venkatesan et al., 2006b) and 
surfactant coated insulin (Toorisaka et al., 2012) of 2-23%, relative to an 
intravenous dose, in rats and dogs.  In addition to a mucoadhesive layer, eg 
chitosan or polyacrylic acid, the patches had an enteric layer, citric acid to 
inhibit enzymes and permeation enhancers to aid absorption.   
Mucoadhesion alone increased oral protein/peptide drug bioavailability to about 
5% but with pH protection, protease inhibition and permeation enhancement, in 
the form of GI MAPs, oral bioavailability increased up to 23% (Eiamtrakarn et 
al., 2002).  The use of mucoadhesive polymers to enhance oral delivery is 
limited however by the natural mucus turnover which is in the range of 12-24 
hours in the human intestine (Shaji and Patole, 2008).   
1.10.2  Permeation enhancers 
To overcome the limited permeability of protein and peptide drugs excipients 
that disrupt the membranes of intestinal cells or widen the paracellular channels 
between them have been used, but they may cause the uptake of potentially 
toxic substances, limiting their prolonged use.   
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Chitosan (Luessen et al., 1997, Kotze et al., 1997a, Prego et al., 2005, Kotze et 
al., 1997b, Lin et al., 2007, Nguyen et al., 2011), polyacrylic acids (Kotze et al., 
1997a), spermine (Makhlof et al., 2011c), sodium salts of medium chain fatty 
acids (Lindmark et al., 1995), acylcarnitines (LeCluyse et al., 1991) and bile 
salts (Michael et al., 2000) were able to reduce the transepithelial resistance 
(TEER) of Caco-2 cells and open paracellular channels.  In formulations with 
protein and peptide drugs they increased their in vitro cell absorption, table 
1.12.  
Chitosan increased intraduodenal bioavailability of buserelin from 0.8% to 13%,  
(Thanou et al., 2000a), and octreotide intrajejunal bioavailability in rats from 
3.1%  to 15.9% (Thanou et al., 2000b).  Exenatide encapsulation in γ-PGA 
nanoparticles shelled with chitosan increased its oral bioavailability in rats from 
undetectable to 14% (Nguyen et al., 2011).  Spermine nanoparticles loaded with 
calcitonin were 15.2 fold more active than the free drug when orally 
administered to rats (Makhlof et al., 2011c) and acylcarnitine increased the oral 
bioavailability of salmon calcitonin in dogs from <0.5% to 1.3% (Sinko et al., 
1999). 
Bile salts increased desmopressin intrajejunal uptake in rats (Michael et al., 
2000), and octreotide intrajejunal availability from 0.26 to 20.2% (Fricker et al., 
1996).  Bile salts formulated with insulin loaded liposomes (Niu et al., 2012) and 
PLGA nanoparticles (Sun et al., 2011a) produced an oral bioavailability of 11-
12% in rats.  Bile salts also increased the oral bioavailability of salmon 
calcitonin in dogs from less than 0.5% to 1.1% (Sinko et al., 1999) and 
produced an oral octreotide bioavailability in humans of 1.26% (Fricker et al., 
1996).   
Surfactants such as sodium dodecyl sulphate (SDS) can disrupt the cell 
membrane making it more permeable to protein and peptide drugs.  SDS 
decreased the TEER of Caco-2 cells (Anderberg and Artursson, 1993).  
However exposure to SDS for two hours irreversibly altered the villi morphology, 
caused apical membrane wounds and structural separation of the tight 
junctions.  Prolonged exposure of intestinal cells to surfactants like SDS could 
cause intestinal cell damage and unwanted absorption of harmful molecules.
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Table 1.12 Oral protein/peptide drug delivery strategies to increase intestinal permeation 
Protein/ 
peptide drug 
Permeation enhancer Lipidisation Targeting ligands 
Vancomycin   Folate coupled liposomes1 
Octreotide Chitosan2 *, bile salts3-4 *, cyclodextrins5 * 
Intravail alkylsaccharides6 * 
  
Buserelin Chitosan7-9 * and carbopol 7 *   
Desmopressin Chitosan 7, 10 *, bile salts3 *, SDS11 *   
Cyclosporine A Bile salts, cyclodextrins and medium chain fatty acids12  Vitamin B12 conjugation to micelles 13 * 
LHRH   Vitamin B1214 * 
Calcitonin Chitosan coated PLGA nanospheres15, chitosan 
nanocapsules16, spermine nanoparticles17 *, cyclodextrins5 
*, acylcarnitine18 *, bile salts18 
Palmitoylation 
19 
Biotin20 
Exenatide Chitosan shelled γ-PGA nanoparticles21 
Cell penetrating peptides22 * 
 Biotin23 
GLP-1 Cell penetrating peptides22 *  Biotin 24-25 * 
Insulin Chitosan7 *, cell penetrating peptides26 *, ZOT27 *  
Bile salts with liposomes28/PLGA nanoparticles29 
 
 Vitamin B12 30 *, attached to dextran 
nanoparticles31, Folate coupled PLGA 
nanoparticles32 
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Erythropoietin   Vitamin B1233 
GCSF   Vitamin B1233 ,transferrin34 
Interferon β Cell penetrating peptides22 *   
Human growth 
hormone 
  Fusion to transferrin 35 and Fc 36 * 
Alpha-
galactosidase 
  Attachment of antibody to ICAM-1 to 
polystyrene beads 37 * 
* Increased in vitro absorption, Zonula occludens toxin (ZOT)  
1 (Anderson et al., 2001), 2 (Thanou et al., 2000b), 3 (Michael et al., 2000), 4 (Fricker et al., 1996), 5 (Haeberlin et al., 1996),                       
6 (Maggio and Grasso, 2011), 7 (Kotze et al., 1997a), 8 (Thanou et al., 2000a), 9 (Kotze et al., 1997b), 10 (Luessen et al., 1997),               
11 (Anderberg and Artursson, 1993), 12 (Sharma et al., 2005), 13 (Francis et al., 2005a), 14 (Alsenz et al., 2000),                                         
15 (Kawashima et al., 2000), 16 (Prego et al., 2005), 17 (Makhlof et al., 2011c), 18 (Sinko et al., 1999), 19 (Wang et al., 2003),                      
20 (Cetin et al., 2008), 21 (Nguyen et al., 2011), 22 (Khafagy el et al., 2009), 23 (Jin et al., 2009), 24 (Chae et al., 2008),                                
25 (Youn et al., 2008), 26 (Liang and Yang, 2005), 27 (Fasano and Uzzau, 1997), 28 (Niu et al., 2012), 29 (Sun et al., 2011a),                       
30 (Petrus et al., 2007), 31 (Chalasani et al., 2007), 32 (Jain et al., 2012), 33 (Russell-Jones et al., 1995), 34 (Bai et al., 2005),                       
35 (Amet et al., 2010), 36 (Lee et al., 2007), 37 (Ghaffarian et al., 2012)
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Aegis Therapeutics have developed Intravail, an alkylsaccharide transmucosal 
absorption enhancing agent of hydrophilic saccharides linked to hydrophobic 
alkyl, non ionic surfactants.  They transiently open tight junctions increasing 
paracellular permeability.  They increased the oral bioavailability of octreotide 
four fold compared to subcutaneous delivery (Maggio and Grasso, 2011).  This 
large increase in bioavailability may be due to limited perfusion of octreotide at 
the injection site or its retention in local tissues reducing its systemic uptake.  
Intravail has been tested preclinically with octreotide, parathyroid hormone, 
calcitonin, interferons and GLP-1 but not entered clinical trials yet.   
Permeation enhancement increased oral protein/peptide drug bioavailabilities to 
more than 10%, and up to four fold greater than a subcutaneously delivered 
dose with Intravail (Maggio and Grasso, 2011), far greater than seen with 
previously assessed strategies.  Despite the dangers of increasing intestinal 
permeability without it oral protein and peptide drug delivery may not be 
possible.   
1.10.3  Lipidisation 
As the hydrophilicity of proteins and peptides hampers their transcellular 
absorption attachment of fatty acids has been used to increase their lipophilicity 
and absorption, table 1.12.  Palmitoylation of salmon calcitonin increased its 
lipophilicity and absorption 19 fold when administered orally to rats compared to 
unmodified salmon calcitonin (Wang et al., 2003).  Modification of 
protein/peptide drugs to enhance their absorption may however alter their 
efficacy or toxicity. 
1.10.4  Targeting ligands 
Biotin, vitamin B12, folate and transferrin have been conjugated to 
protein/peptide drugs or their carriers to increase uptake by exploiting their 
intestinal receptor mediated endocytosis, table 1.12.  Vitamin B12 conjugation 
to dextran nanoparticles and folate conjugation to PLGA nanoparticles 
increased encapsulated insulin oral pharmacological availability from 10.3 to 
26.5% (Chalasani et al., 2007) and from 12.73% to 20.4% (Jain et al., 2012) 
respectively, relative to subcutaneous insulin, in rats.   
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Folate coupling of vancomycin loaded liposomes increased its oral 
bioavailability in rats from 6.7% for the uncoupled liposomes to 21.8% 
(Anderson et al., 2001).   Biotin conjugation increased intrajejunal calcitonin 
absorption three fold compared to the unmodified drug in rats (Cetin et al., 
2008) and exenatide oral bioavailability in rats from undetectable to 3.95% (Jin 
et al., 2009).  Conjugation of transferrin however caused GCSF to lose 90% of 
its activity (Bai et al., 2005).  Attachment of an antibody to a protein, ICAM-1, 
expressed on GI epithelium, to polystyrene beads with attached alpha-
galactosidase enabled its uptake in vitro by Caco-2 cells (Ghaffarian et al., 
2012).  Fusion of human growth hormone to Fc increased in vitro uptake 
compared to a control by targeting the FcRn (receptor) found in the intestine of 
human adults (Lee et al., 2007).  Neonatal FcRn mediates the transcytosis of 
intact immunoglobulins in milk in suckling rodents.   
This strategy produced oral bioavailabilities of >20% when combined with 
encapsulation of the protein/peptide drug and doesn’t involve membrane 
disruption.  However conjugation to targeting ligands is a more complex 
procedure and could increase production costs.  Conjugation may also cause a 
loss of therapeutic activity or increased toxicity (Bai et al., 2005).  Absorption 
may also be limited in vivo by competitive binding of the natural ligand to the 
transporter. 
1.11 Multiparticulates and emulsions 
Encapsulation of protein/peptide drugs within microparticles, nanoparticles, 
liposomes, micelles and emulsions can provide protection from enzymes and 
acid, by a physical polymeric, lipid or oily barrier, and enhanced permeability, 
table 1.13.  Their smaller size compared to tablets, capsules and granules can 
increase bioavailability by their rapid gastric emptying and dissolution due to 
their large surface area.  Encapsulation of additional protease inhibitors and 
permeation enhancers and coating with enteric, mucoadhesive and/or 
permeation enhancing polymers can further increase oral bioavailability. 
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Table 1.13 Oral protein/peptide multiparticulate delivery strategies 
Protein/ 
peptide drug 
Polymeric 
micro/nanoparticles 
Lipid particles Micelles Liposomes 
Octreotide    Tetraether lipid1 
Vasopressin   Polymeric micelles2  
Leuprolide Poly (ethylcyanoacrylate) 3 * 
and polyacrylic acid 
nanoparticles 4 
  Chitosan coated5 * ** 
Cyclosporine A PLGA micro/nanoparticles6-8 
 
Glyceryl 
monooleate/poloxamer 407 
nanoparticles9, lipospheres10 
and solid lipid nanoparticles11  
PEG-poly(lactide) 12-13 
polysaccharide14 ** 
Soybean 
phosphatidylcholine, 
sodium 
deoxycholate15 
Calcitonin PLGA16 * **, polyacrylic acid17 
and Eudragit RSPO18 
nanoparticles  
Trimyristin nanoparticles19   
GLP-1 PLGA microspheres20    
Insulin PLGA nanoparticles 21-28 
Polyisobutylcyanoacrylate 
nanopheres29, poly (alkyl 
cyanoacrylate) nanospheres30 * 
Solid lipid nanoparticles31-34 * Dioctadecylamine-501 
micelles35, 
phosphatidylcholine 
micelles36 
Hybrid silica37*, 
cationic liposomes38, 
chitosan coated39, 
double liposomes40 * 
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* Increased in vitro stability, ** increased in vitro permeation, Poly (lactic-co-glycolic) acid (PLGA) 
1 (Parmentier et al., 2011), 2 (Ritschel, 1991), 3 (Kafka et al., 2011), 4 (Iqbal et al., 2011), 5 (Guo et al., 2005), 6 (Ankola et al., 2010),         
7 (Italia et al., 2007), 8 (Fukata et al., 2010), 9 (Lai et al., 2010), 10 (Bekerman et al., 2004), 11 (Muller et al., 2006), 12 (Zhang et al., 2010a), 
13 (Zhang et al., 2010b), 14 (Francis et al., 2005b), 15 (Guan et al., 2011), 16 (Yoo and Park, 2004), 17 (Makhlof et al., 2011c),                     
18 (Cetin et al., 2012), 19 (Martins et al., 2009), 20 (Joseph et al., 2000), 21 (Jain et al., 2012), 22 (Zhang et al., 2012a), 23 (Lin et al., 2007), 
24 (Yang et al., 2012), 25 (Cui et al., 2006b), 26 (Sun et al., 2011b), 27 (Sharma et al., 2012), 28 (Kafka et al., 2011), 29 (Radwan, 2001),         
30 (Damge et al., 1997), 31 (Fangueiro et al., 2011), 32 (Yang et al., 2011), 33 (Sarmento et al., 2007), 34  (Battaglia et al., 2007),                 
35 (Lin et al., 2011), 36 (Wang et al., 2010), 37 (Mohanraj et al., 2010), 38 (Park et al., 2011), 39 (Wu et al., 2004), 40 (Katayama et al., 2003), 
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1.11.1  Polymeric particles 
Polymeric particles can protect encapsulated protein and peptide drugs and are 
more stable in the GI tract than liposomes or micelles.  The encapsulated drug 
can be absorbed within the particles as the use of hydrophobic polymers can 
increase transcellular uptake.  They have increased the in vitro stability and 
permeability of encapsulated protein/peptide drugs, table 1.13. 
Salmon calcitonin loaded PLGA nanoparticles produced an oral bioavailability in 
rats of 0.4%, it was only negligible for a drug solution (Yoo and Park, 2004).  
Encapsulation of cyclosporine A in PLGA nanoparticles increased its oral 
efficacy in rodents and produced a 20% greater oral bioavailability than the 
commercial microemulsion formulation Neoral (Ankola et al., 2010).  
Encapsulation of insulin in PLGA nanoparticles produced oral bioavailabilities of 
between 7.6 and 12.7% in rats, relative to subcutaneous insulin (Jain et al., 
2012, Zhang et al., 2012a, Sun et al., 2011b, Cui et al., 2006b).  With co-
encapsulated antacids to neutralise the acidic by-products of PLGA degradation 
oral insulin availability increased to 17% (Sharma et al., 2012). 
Leuprolide encapsulation in poly(ethylcyanoacrylate) nanoparticles increased its 
absorption from a brushtail possum intestine (Kafka et al., 2011).  
Encapsulation in polyacrylic acid nanoparticles increased leuprolide oral 
bioavailability in rats from 0.26 to 0.55% when enterically coated (Iqbal et al., 
2011), and calcitonin oral efficacy in rats 15 fold compared to a solution 
(Makhlof et al., 2011c).  Encapsulation of salmon calcitonin in sustained release 
Eudragit RSPO nanoparticles increased its oral efficacy in rats compared to a 
drug solution (Cetin et al., 2012). 
The intestinal absorption of polymeric particles has been shown to be restricted 
to small particles, <10µm, (Kompella and Lee, 2001).  However, smaller 
particles may have a limited drug loading capacity and leave more drug 
vulnerable to intestinal degradation at, or near the surface of particles.  
Incompatibility of hydrophilic protein/peptide drugs with hydrophobic particles 
may result in low encapsulation efficiencies and rapid, uncontrolled drug 
release.  Insulin and salmon calcitonin were complexed with fatty acids to 
increase their lipophilicity and encapsulation in PLGA nanoparticles (Yoo and 
Park, 2004, Sun et al., 2011b).   
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Production of polymeric particles often involves the use of solvents and high 
shear forces which need to be minimised to encapsulate fragile protein and 
peptide drugs. 
1.11.2  Lipid particles 
Lipid particles can provide protection and increased lipophilicity to increase 
protein/peptide drug oral bioavailabilities, table 1.13.  Encapsulation of lipophilic 
cyclosporine A produced a 78% greater oral bioavailability than Neoral in dogs 
(Lai et al., 2010), and a similar bioavailability in humans (Bekerman et al., 
2004).  Solid lipid nanoparticles produced an insulin oral pharmacological 
availability of up to 5% in rats, relative to subcutaneous insulin, but these 
particles experienced high, immediate burst release in vitro (Yang et al., 2011, 
Sarmento et al., 2007, Trotta et al., 2005).  As most proteins and peptides are 
hydrophilic they are less compatible with encapsulation within lipid particles 
reducing their encapsulation efficiency and causing uncontrolled and immediate 
burst release. 
1.11.3  Micelles 
Micelles can provide protection and enhanced permeation of loaded protein and 
peptide drugs, table 1.13.  They increased in vitro permeation (Francis et al., 
2005b) of cyclosporine A and its oral efficacy in rats (Zhang et al., 2010a, 
Zhang et al., 2010b).  They also increased the oral activity of vasopressin in rats 
(Jones et al., 2008). 
1.11.4  Liposomes 
Liposomes are vesicles composed of a phospholipid bilayer with an aqueous 
core in which hydrophilic proteins and peptide drugs can be protected from 
enzymatic digestion, table 1.13.  The lipid bilayer can fuse with the bilayer of 
cell membranes facilitating absorption of the drug into intestinal cells.  They 
increased the in vitro stability of leuprolide (Guo et al., 2005), the oral 
bioavailability of octreotide in rats, 4.6 times that of a solution (Parmentier et al., 
2011), and of cyclosporine A, 20% greater than Neoral (Guan et al., 2011).  
Oral efficacy of insulin in rodents was increased by encapsulation in chitosan 
coated liposomes (Wu et al., 2004).   
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However, liposomes have shown instability with bile acids (Anderson et al., 
2001) and lipase, which could cause premature drug release in vivo leaving 
them vulnerable to degradation.   
1.11.5  Microemulsions 
Microemulsions are dispersions of two immiscible liquids such as oil and water 
stabilised by an interfacial film of surfactant molecules.  They can improve drug 
solubilisation, provide protection from enzymes and enhance intestinal 
absorption.  Hydrophilic protein and peptide drugs in an aqueous phase are 
dispersed in a protective oil phase.  Lipophilic drugs in an oil phase are 
dispersed in an aqueous phase to increase their solubility in GI fluids. 
Microemulsions have been used to deliver cyclosporine A due to its low water 
solubility and high lipid solubility (Odeberg et al., 2003, Sarciaux et al., 1995, 
Dunn et al., 1997, Ritschel et al., 1990, Lei et al., 2012).  A microemulsion of 
cyclosporine A produced an oral bioavailability of 51.8% in rats compared to 
41.6% for Neoral, relative to an intravenous dose (Gao et al., 1998).  The 
success of oral microemulsions of cyclosporine A are due to its relatively small 
size and hydrophobicity. 
Microemulsions increased the oral efficacy of salmon calcitonin in rats (Fan et 
al., 2011) and the absorption of vasopressin from rat small intestine (Ritschel, 
1991).  Emulsion and microemulsion formulations of insulin produced an oral 
glucose reduction in rats of 25-37.5% (Sharma et al., 2010, Toorisaka et al., 
2003) and increased its pharmacological availability from undetectable to 7% 
(Elsayed et al., 2009).  Emulsions of leuprolide increased its in vitro stability 
(Zheng et al., 1999a) and bioavailability from 0.08 to 6.8%, relative to an 
intravenous dose, when administered to the duodenum of rats (Adjei et al., 
1993).  A microemulsion of parathyroid hormone produced an oral bioavailability 
of 5.4% relative to a subcutaneous dose (Guo et al., 2011). 
Incompatibility of hydrophilic protein and peptide drugs with the oil phase of an 
emulsion may have caused 60% calcitonin leakage in SGF from a 
microemulsion which would leave it vulnerable to degradation if administered 
orally (Fan et al., 2011).   
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Surfactant coating of proteins and peptides has been used to make them more 
lipophilic and compatible for loading in emulsions (Toorisaka et al., 2003). 
1.11.6  Multiparticulates- potential for oral delivery 
Encapsulation in multiparticulates alone can increase the oral bioavailability of 
protein and peptide drugs to more than 10% but bioavailabilities of more than 
20% are only achievable in conjunction with other strategies.  Attachment of 
targeting ligands to their surface, coating with mucoadhesive or pH sensitive 
polymers and the co-encapsulation of protease inhibitors and permeation 
enhancers are necessary for these greater oral bioavailabilities. 
1.12 Commercial oral delivery strategies 
In addition to academic research and development many biotechnology 
companies have also been pursuing oral protein and peptide formulations.  This 
has been met with mixed success.  Unfortunately this sector is littered with 
companies which have demonstrated promising results in preclinical or early 
stage clinical trials but have since gone into liquidation.  This means the full 
potential of some delivery strategies have not been fully determined. 
1.12.1  Discontinued/inactive oral delivery strategies 
AutoImmune with Eli Lilly and Provalis with Cortecs Ltd developed oral insulin 
formulations which showed efficacy in phase II clinical trials but they have since 
been suspended.  Oral insulin delivery strategies developed by Endorex, based 
on liposomes, by Apollo Lifesciences, based on vitamin B12 coated 
nanoparticles, and by Bow pharmaceuticals, based on encapsulation in a 
dextran matrix, have also been suspended.  Diasome developed a nanosized 
oral insulin that was stable at low pH and in the bloodstream.  This was tested 
in phase II and III clinical trials with type II diabetics in 2009 but there have been 
no further trials or information regarding this product.  Oral formulations of 
insulin, developed by Diabetology, and calcitonin, by Bone Limited, 
demonstrated efficacy in Phase I and IIa clinical trials using Axcess delivery 
technology.  This delivery technology involves encapsulation in enteric coated 
capsules with an absorption enhancer and bile acids.   
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These trials were conducted in 2004 and 2005, there have been no further trials 
but Diabetology recently announced a partnership with USV Limited to develop 
oral insulin for the Indian market.   
1.12.2  Current oral delivery strategies in clinical trials 
Despite the suspension of many projects some have completed successful 
clinical trials and are pursuing filings in the near future.  These active programs 
are outlined in table 1.14. 
Emisphere’s Eligen technology utilises delivery agents, which interact non-
covalently with protein and peptide drugs exposing their hydrophobic side 
chains, increasing their lipophilicity and absorption.  This strategy was one of 
the most promising for protein/peptide delivery increasing the oral 
bioavailabilities of parathyroid hormone (Leone-Bay et al., 2001, Leone-Bay et 
al., 1996) , human growth hormone (Milstein et al., 1998), salmon calcitonin 
(Leone-Bay et al., 1995a, Leone-Bay et al., 1995b) and interferon-α (Milstein et 
al., 1998, Leone-Bay et al., 1995b) in rats and primates.  However, a three year 
phase III clinical trial with salmon calcitonin, which ended in 2011, failed to meet 
primary and secondary endpoints in treating postmenopausal osteoporosis and 
its planned 2012 submission has been abandoned.  Its oral programs for 
parathyroid hormone, human growth hormone and insulin for type I diabetes 
have all been terminated.  Its only remaining oral peptide delivery program is 
with GLP-1 analogs and insulin for type 2 diabetes which entered phase I 
clinical trials in 2010. 
Biocon have continued the development of an oral insulin formulation, IN-105, 
initiated originally by the Nobex Corporation.  However, phase III clinical trials 
did not meet desired expectations, not thought necessarily to be due to a lack of 
efficacy but due to behavioural modifications of those taking the placebo.  The 
project is still active though and a partnership with Bristol-Myers-Squibb for 
further development appears likely.   
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Table 1.14 Currently active oral protein/peptide drug delivery programs in clinical trials 
Company Protein/peptide drug Oral delivery formulation/technology Clinical trial status 
Emisphere Insulin/GLP-1 analogs  Eligen technology-Delivery agents inducing increased 
hydrophobicity 
Phase I-2010 
Biocon  Insulin Conjugation to amphiphilic oligomers of PEG and 
alkyl groups/fatty acids (Soltero and Ekwuribe, 2001), 
with a fatty acid absorption enhancer 
Phase III-failed to meet all endpoints 
but still active 
Phase II trials planned outside India 
2013 
Tarsa 
Therapeutics  
Salmon Calcitonin 
(OSTORA) 
Enteric tablet with citric acid, acylcarnitine, oral 
bioavailability increased from <1% to 20% 
Phase III-successfully met endpoints 
2012, New Drug Application (NDA) 
planned 
Chiasma and 
Roche 
Octreotide (Octreolin) Transient permeation enhancer technology; solid, 
hydrophilic drug particles suspended in a hydrophobic 
medium with medium chain fatty acids 
Phase III began Q4 2011 
Oramed Insulin/Exenatide 
(Eldor et al., 2010b) 
Enteric coated tablet/capsule, protease inhibitor, 
omega-3 fatty acids and EDTA  
Insulin-Phase II in US commence 2013 
Exenatide- Phase Ib/IIa started Jan 
2013 
Unigene Parathyroid hormone Excipients inhibit digestion, enhance absorption, 
increase oral bioavailability <1% to 20% 
Phase II completed Nov 2011 achieved 
primary endpoints 
Merrion with 
Novo Nordisk 
Insulin, GLP1 Gastrointestinal permeation enhancement 
technology: medium chain fatty acid matrix 
Phase I for both compounds 
successfully completed 2013 
Amarillo 
Biosciences 
Interferon α Orally dissolving lozenges targeting throat receptors 
to initiate immune response 
Phase II completed 2012 
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The other oral protein/peptide delivery system that has completed phase III 
clinical trials is Tarsa Therapeutic’s OSTORA, salmon calcitonin tablet.  It 
successfully met all clinical endpoints and represents the most promising oral 
peptide strategy for future availability (Binkley et al., 2012).  However an FDA 
Advisory Committee decided in 2013 that salmon calcitonin should no longer be 
broadly marketed as the risk of it causing cancer outweighs its benefits.  This 
unfortunately may end the progress of this oral peptide which had progressed 
much farther than many others. 
Chiasma’s oral octreotide is currently undergoing phase III clinical trials and 
they are hopeful of filing an NDA in 2013.  A new partnership with Roche was 
announced in February 2013 to develop and commercialise Octreolin.  
Unigene’s oral formulation of parathyroid hormone, Amarillo Bioscience’s oral 
formulation of interferon α and Oramed’s oral insulin and exenatide have 
entered or completed phase II clinical trials and it remains to be seen if they can 
progress to further clinical trials.   
The programs all involve proteins/peptides less than 6kDa, except for interferon 
α which is targeted to throat receptors and so doesn’t have to overcome the 
stability and permeability issues of oral systemic delivery.  The oral delivery of 
larger proteins to the systemic circulation does not look like becoming a reality 
soon.  However the success of Tarsa Therapeutics phase III clinical trial with 
calcitonin suggests it may not be long before relatively large, hydrophilic 
peptides can be administered orally.   
Emerging oral protein/peptide drug delivery strategies in preclinical or entering 
clinical trials seem mainly to be based on modified nanoparticles.  Access 
Pharmaceuticals have formulated protein and peptide drugs in nanoparticles 
coupled to cobalamin, a vitamin B12 analog.  NOD Pharmaceuticals are 
currently conducting phase I clinical and preclinical trials with oral insulin and 
exenatide mucoadhesive nanoparticles.  NanoMega Corp have encapsulated 
insulin in chitosan shelled gamma γ-PGA nanoparticles and Oshadi drug 
administration have blended insulin with inert silica nanoparticles, a 
polysaccharide, suspended them in oil and loaded into enteric capsules.   
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1.13 Oral protein/peptide drug delivery success and future perspective 
Numerous strategies for oral protein and peptide delivery have been attempted 
and shown some improvement in bioavailability compared to the drugs alone.  
Oral bioavailabilities of protein and peptide drugs are generally less than 5%, 
table 1.3, and most of the delivery strategies attempted have not raised them to 
more than 10%, relative to injected doses.  The most successful strategies, 
which have raised oral bioavailabilities to ~20%, and those which have proved 
successful in clinical trials are combinations of many strategies.  They combine 
encapsulation of the protein/peptide drug in multiparticulates, capsules or 
tablets with protease inhibitors and permeability enhancers, especially medium 
chain fatty acids.  They may also be enteric coated or conjugated to targeting 
ligands.   
As many of these delivery strategies may disrupt normal digestive processes 
and compromise the barrier function of the GI tract to incoming toxins 
implications of their long term use should be considered.  Oral bioavailabilities 
should be reproducible and reliable to achieve a regulatory filing but 
incompatibility of hydrophilic protein and peptide drugs with hydrophobic 
delivery carriers can produce uncontrolled drug release (Yang et al., 2011, Fan 
et al., 2011, Anderson et al., 2001, Yang et al., 2012, Carino et al., 2000).  
Reproducible bioavailabilities may also be compromised by intra or inter subject 
variation in the GI environment as protein and peptide drug absorption is so 
highly dependent on its characteristics.  Those drugs with a wide therapeutic 
window, such as the currently orally available desmopressin, may be more 
compatible for oral delivery due to this variability.  Octreotide and calcitonin 
have large therapeutic windows and this may partly explain the progression of 
their oral formulations to phase III clinical trials. 
Despite the failures encountered during clinical trials and the suspension of 
many projects oral protein/peptide drug formulations are closer than they ever 
have been.  The success of Tarsa Therapeutics’ oral salmon calcitonin in 
clinical trials increases the probability that other protein and peptide drugs will 
soon be orally available. 
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Oral bioavailabilities are still much lower than those of injected doses and 
therefore much higher doses must be administered orally to have the same 
effect.  For more expensive protein and peptide drugs this could preclude their 
oral delivery.  The toxicity implications of administering relatively large doses of 
protein and peptide drugs orally must also be considered. 
Challenges for the future may be the scaling up for manufacture of the more 
complex particulate delivery formulations.  Research and clinical trials have 
mainly focused on the delivery of oral peptides rather than proteins.  Their 
larger size seems to multiply the challenges of oral delivery and this may have 
deterred development.  While oral peptide delivery may soon be more widely 
available oral protein delivery to the systemic circulation may take longer and 
require strategies more specifically designed for them. 
1.14 Aims of project 
The aims of this project are to: 
 Gain a greater understanding of the role of the GI tract in oral 
bioavailability limitations of protein and peptide drugs 
o Investigate the effects of protein/peptide size/structure on 
intestinal stability 
o  Identify regions of the intestinal tract which orally delivered 
protein/peptide drugs need to be protected from 
o Identify the most favourable region/s of the intestinal tract for oral 
protein/peptide drug delivery 
 Use this knowledge and research of previously attempted strategies to 
formulate rational oral protein/peptide delivery strategies 
 Utilise formulation methods which provide the least threat to 
maintenance of fragile protein/peptide structure  
 Produce formulations that cause minimal disruption to the GI tract in 
terms of digestion and cell membrane disruption 
 Produce formulations with efficient encapsulation of protein and peptide 
drugs and which effectively control their release 
 Test oral protein/peptide delivery strategies in vitro to determine their in 
vivo potential  
 Investigate and remedy any limitations of these delivery strategies 
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Chapter 2 
Investigation of the intestinal stability of lactase 
and development of its oral formulations 
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2.1 Introduction 
While very few of the protein and peptide drugs listed in the BNF are orally 
available there are some proteins available as oral nutritional supplements.  It is 
unknown how effective these are as they are not subject to the rigorous clinical 
testing of pharmaceutical drugs.  However, further investigation into their 
delivery strategies may provide useful information about how to deliver protein 
and peptide drugs orally.   
One such protein available as an oral nutritional supplement is the intestinal, 
digestive enzyme lactase.  Lactase supplements are available to relieve the 
symptoms of lactose intolerance and are advised to be taken with dairy food, 
replacing the enzyme no longer produced in the small intestine. 
As lactase supplements are easily obtainable an assessment of their 
formulations and ability to overcome the delivery obstacles described in chapter 
1 should provide a good basis for development of oral protein/peptide drug 
delivery strategies.  As lactase needs to be delivered to the small intestine and 
not to the systemic circulation to elicit its therapeutic effect only its intestinal 
instability rather than its permeability need be addressed.  This also makes it a 
good candidate to begin development of oral protein/peptide delivery strategies 
2.1.1 Lactase structure and function 
Lactase is a large, multi-domain protein with quaternary structure and is part of 
the β-galactosidase family of enzymes found in Eukaryotes and Prokaryotes.  
The β-galactosidase of E.coli has been most extensively studied structurally 
(figure 2.1) and was first sequenced in 1970 (Fowler and Zabin, 1970).  It is a 
464kDa homotetramer of four 1024 amino acid polypeptide chains (Kalnins et 
al., 1983).  Each of the four units consists of five domains.  One of these 
contains the active site which is made up of elements from two subunits of the 
tetramer.  The disassociation of the tetramer into dimers removes critical 
elements of the active site. 
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Figure 2.1 Computer simulation image based on X-ray diffraction of E.coli       
β-galactosidase (Juers et al., 2000) 
In humans, lactase is a gastrointestinal enzyme found mainly along the brush 
border membrane of enterocytes that line the villi of the small intestine.  Studies 
of human intestinal lactase showed a 145,000MW band for the polypeptide 
analysed by SDS-PAGE (Harvey et al., 1995).  The lactase was also found to 
have an isoelectric point of 4.8 and optimum activity at pH 4.5-6.   
The function of intestinal lactase is to hydrolyse lactose, the primary 
disaccharide in mammalian milk, to glucose and galactose (Montalto et al., 
2006).  It is secreted by neonatal mammals, including humans, to allow them to 
digest their mother’s milk.  Once weaning has been completed lactase 
production stops for the majority (Schulzke et al., 2009); 60% of human adults 
no longer produce lactase and are therefore unable to digest lactose (Itan et al., 
2009).  Lactase persistence evolved as milk digestion proved advantageous 
providing a relatively constant source of Vitamin D and calcium (Itan et al., 
2009). 
2.1.2 Lactose intolerance 
Absence of lactase in lactose intolerance sufferers means any lactose 
consumed will not be digested but remain throughout the GI tract.  Undigested 
lactose is fermented by colonic bacteria resulting in the formation of gas 
causing abdominal pain, bloating, flatulence and nausea (Schulzke et al., 2009).   
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Unabsorbed lactose and fermentation products raise the osmotic pressure of 
the colon causing water to enter resulting in diarrhoea.  These symptoms arise 
approximately 30 minutes to two hours after the consumption of lactose. 
Lactose intolerant individuals are often advised to avoid any lactose containing 
foods or drinks, however, these foods are a useful source of Vitamin D, calcium 
and phosphorus and reducing intake of them can result in decreased bone 
mineral density (Montalto et al., 2006).   
To avoid the symptoms of lactose malabsorption and gain the benefits from the 
consumption of dairy foods lactose can be pre-hydrolysed by the addition of 
lactase (Montalto et al., 2006) or oral lactase supplements can be taken to 
digest consumed lactose.   
2.1.3 Lactose pre-hydrolysis 
Addition of lactase to milk significantly reduced hydrogen production by lactose 
intolerance sufferers (Montalto et al., 2005).  Pre-hydrolysis of lactose avoids 
risking loss of lactase activity in the acidic stomach when orally administered.  
Consumption of lactase tablets (Lactaid) with whole milk resulted in more 
hydrogen production, detected in the breath, than pre-hydrolysed milk 
(Onwulata et al., 1989).  The oral lactase may have been inactivated in the 
stomach before it could digest lactose, enabling its fermentation and hydrogen 
production in the gut.  
The sugars produced by pre-hydrolysis, glucose and galactose, however are 
sweeter than lactose and unpalatable to many.  To avoid this lactase can be 
microencapsulated before its addition to milk.  This prevents lactose hydrolysis 
and increased sweetness by preventing contact between enzyme and 
substrate.  Once the milk is consumed the microparticles release lactase and 
digestion can commence.  Liposomes have been investigated as possible 
carriers but encapsulation efficiency is low, <30%, and long-term stability in milk 
is poor (Kim et al., 1999, Rao et al., 1995, Rodriguez-Nogales and Lopez, 
2006).  Encapsulation in fatty acid esters proved more promising with an 
encapsulation efficiency of 70% (Kwak et al., 2001).  Their stability was also 
better; when added to milk there was no decrease in lactose or increase in 
sweetness detected during storage for 8 days.   
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However, it is unknown how this system will behave in vivo and if it will be able 
to release an active enzyme which can digest lactose. There was also an off 
taste to the milk possibly caused by the fatty acid esters. 
2.1.4 Orally delivered lactase  
2.1.4.1 Oral lactase stability 
For orally delivered lactase to digest lactose in the small intestine it must first 
pass through the stomach and arrive in the small intestine in an active form.  In 
chapter 1 gastric instability was frequently observed for large, three-dimensional 
proteins like lactase, such as ovomucoid (Zheng et al., 2010), chicken egg yolk 
immunoglobulin (Li et al., 2009) and other digestive enzymes (Scocca et al., 
2007, Massicotte et al., 2008).  This may be caused by changes in amino acid 
ionisation, due to the acidic pH, which result in disruption of bonds stabilising 
the secondary and tertiary structure of proteins.  Lactase suffered more than 
90% loss of enzymatic activity after two hours incubation at pH 1.2 (Alavi et al., 
2002).  Orally delivered lactase may also be susceptible to degradation by 
enzymes in the stomach and small intestine. 
2.1.4.2 Alternative lactase origin 
O’Connel & Walsh found a lactase from Aspergillus niger van Tiegh that had 
optimum activity at pH 2.5 and a 68% retention of activity after exposure to 
simulated gastric conditions (O'Connell, 2009).  This may be a more suitable 
source of lactase for oral supplements, however it is only 10% active at pH 6.8.  
To overcome this a two segment capsule was developed combining the gastric 
active enzyme and a lactase active in the small intestine to allow continuous 
lactose hydrolysis in the proximal intestine.   
2.1.4.3 Oral lactase supplements 
Oral lactase supplements have a better palatability than pre-hydrolysed dairy 
food but have been shown to be less effective at preventing lactose 
malabsorption (Onwulata et al., 1989).  Despite its acid sensitivity (Alavi et al., 
2002) many lactase supplements don’t include any enteric coating eg, Lactaid, 
Dairy Ease, Dairy Relief.   
83 
 
An assessment of the stability of lactase supplements revealed that those 
without enteric coating were almost completely inactivated after 2 hours 
incubation in acid, regardless of the presence of pepsin, table 2.1.  This 
highlights the instability of lactase in acid and the necessity of enteric coating for 
oral delivery of active lactase to the small intestine.  The supplements were 
however resistant to pancreatin digestion in simulated intestinal media, pH 6.8, 
(O'Connell and Walsh, 2006). 
Table 2.1 Active lactase release from supplements following 2 hours incubation 
in simulated gastric fluid (SGF) with and without pepsin 
Lactase supplement Active lactase 
remaining (%) in SGF 
Active lactase remaining 
(%) in SGF + pepsin 
Lactaid (non-enteric) 3.57 1 - 
Non-enteric product 1 6 2 2 2 
Non-enteric product 2 0 2 0 2 
Enteric product 3 100 2 100 2 
Enteric product 4 90 2 90 2 
1 (Alavi et al., 2002), 2 (O'Connell and Walsh, 2006) 
While these tests in simulated fluids provide an insight into the intestinal stability 
of lactase they may not give as accurate a reflection of in vivo behavior as 
incubation in animal/human intestinal fluids would. 
Currently dosage instructions for oral lactase supplements advise taking >5000 
lactase units per meal.  A more protective oral lactase formulation may enable a 
reduction in the amount of lactase that needs to be administered to successfully 
control lactose intolerance, reducing production costs. 
It can be argued that these tests are not completely representative as they only 
show what would happen in a fasted stomach.  The dosage instructions for the 
supplements indicate they should be taken with food which would raise the 
stomach pH to about pH 5-6.  At this pH lactase would not be denatured.  
However, the pH drops post ingestion so that after 30 minutes the gastric pH is 
between pH 2.5 and 3.5 and falls further to values of 1.5–2.2 (Dressman et al., 
1990).  At this pH the enzymatic activity of the non-enteric lactase would be lost.  
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2.1.5 Existing oral enzyme delivery strategies 
Enzymes currently available as oral dosage forms are the pancreatic enzymes 
amylase, lipase and trypsin which comprise pancreatin used to treat pancreatic 
insufficiency.  Like lactase they are intestinal enzymes necessary for the 
digestion of food in the small intestine.  As with lactase they have demonstrated 
their instability in gastric conditions (Aloulou et al., 2008).  Therefore to enable 
these enzymes to reach the small intestine in an active form they are mainly 
administered as gastric resistant formulations, table 2.2.   
Table 2.2 Pancreatin products available and their enteric excipients 
Pancreatin product Dosage form Enteric excipients 
Creon 10000, 
25000, 40000, micro 
Capsules containing gastro 
resistant granules, 
minimicrospheres (0.7-1.6mm), 
gastro resistant granules alone 
Hypromellose 
phthalate 
Nutrizym 10, 22 Capsules containing enteric coated 
minitablets 
Methacrylic acid 
copolymer, type C 
(Eudragit L30D)  
Pancrex V granules, 
Forte tablets, 
powder, tablets 
Granules, tablets, powder Opaseal P17-0200 
containing polyvinyl 
acetate phthalate  
Pancrex V Capsules Capsules None 
Pancrease HL 
Capsules 
Capsules containing enterically 
coated minitablets 
Methacrylic acid-
ethyl acrylate 
copolymer (1:1) 
 
Enteric coating of the pancreatin enzymes improved in vivo efficacy compared 
to uncoated products (Delchier et al., 1991, Dutta et al., 1988, Naikwade et al., 
2009).  In addition in one study all the subjects expressed a preference for the 
enteric coated product due to its better control of symptoms associated with 
pancreatic insufficiency (Naikwade et al., 2009).   
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Delayed enzyme release has been reported for some of the enteric coated 
tablets (Aloulou et al., 2008).  To overcome this dosage form size has been 
reduced to enable mixing with the food contents of the stomach and accelerated 
enzyme release.  Reduction of pancreatin dosage size from tablets to 
microspheres reduced Gl symptoms (Beverley et al., 1987). 
Pancreatin encapsulated in enteric Eudragit L100 microparticles preserved 
99.78% of enzyme activity after acid incubation and more rapidly released 
pancreatin upon pH rise to pH 6.8 than pancreatin tablets (Naikwade et al., 
2009).  In vivo this should allow more opportunity for digestion as the enzymes 
are more rapidly released and will be available over more of the small intestine. 
2.1.6 Lactase microparticles 
Single unit, enteric coated dosage forms, such as tablets, have been observed 
to disintegrate 1.5-2 hours post-gastric emptying rather than immediately (Cole 
et al., 2002).  This can result in reduced bioavailability and symptom control.  
Pancreatin microspheres were shown to be superior to tablets in terms of rapid 
release at pH 6.8 and alleviation of pancreatitis symptoms (Naikwade et al., 
2009, Beverley et al., 1987).  Microparticles are able to suspend in gastric fluids 
unlike larger dosage forms allowing reliable and fast gastric emptying.  The 
increased surface area to volume ratio also enables rapid drug release.  
Lactase microparticles consisting of pH dependent and independent polymers 
have been formulated to take advantage of their beneficial release profile. 
Non-enteric polymers used to produce microparticles encapsulating or 
adsorbing lactase include poly(lactic acid) (PLA) (Hayashi et al., 1994, 
Stivaktakis et al., 2005) and poly (lactic-co-glycolic acid) (PLGA) (Stivaktakis et 
al., 2004, Stivaktakis et al., 2005).  Their applicability for oral lactase delivery is 
questionable however due to the lack of specific gastric protection.  None of 
these formulations were tested in vivo or in vitro in SGF.  Release was tested in 
phosphate buffered saline and lactase was immediately burst released, up to 
41% in one hour (Hayashi et al., 1994).  If this occurred in vivo upon dispersal in 
gastric fluids lactase activity would be destroyed.  The homogenisation step 
used to prepare these particles was also shown to damage lactase reducing its 
antigenicity by 45%. 
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Coupling of wheat germ agglutinin (WGA) to PLGA microparticles was used to 
increase the residence time of lactase in the small intestine (Ratzinger et al., 
2010).  This increased mucoadhesion in vitro but there were no studies to 
investigate the stability of WGA attachment in vitro in SGF or in vivo.  It is also 
not known if this system can prolong lactase residence time for long enough for 
it to fully digest consumed lactose. 
2.1.7 Enteric microparticles 
Existing non-enteric lactase supplements have proved unsatisfactory for 
protecting lactase in simulated gastric fluids.  Researched oral lactase delivery 
strategies have either not been tested in or provided insufficient protection in 
simulated gastric conditions, or not shown satisfactory activity in small intestinal 
conditions.  While enteric coated tablets/capsules can provide gastric protection 
they may suffer from a delayed enzyme release at small intestinal pH 
preventing complete lactose digestion.  To combine the advantages of enteric 
protection and reduced dosage form size enteric microparticles of lactase have 
been produced. 
The pH responsive polymer alginate (Dashevsky, 1998) and fatty acid esters 
(Kim et al., 2006) were used to produce lactase loaded microparticles.  
However neither were tested in vivo and only the fatty acid ester particles were 
tested in SGF.  There was 15.2% lactase release in SGF in an hour, which 
would be denatured, and upon pH rise there was a slow lactase release.  At   
pH 6 there was only 45% lactase release after 3 hours which rose to 80% at pH 
7 in an hour.  This delay could result in lactose persistence.   
Alavi et al and Squillante et al produced pH responsive microparticles 
encapsulating lactase with Eudragit L100 (dissolves above pH 6) and Eudragit 
S100 (dissolves above pH 7) (Alavi et al., 2002, Squillante et al., 2003).  The oil 
in oil emulsification solvent evaporation preparation method used produced 
particles with a mean diameter of 53-195µm which should enable rapid gastric 
emptying and lactase release.  A high entrapment efficiency of >80% was 
achieved but there was a 32% loss of lactase activity during processing, 
possibly due to the use of high shear homogenisation (Squillante et al., 2003).  
Reducing temperature and homogenisation speed had a protective effect on 
activity.   
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The Eudragit L100 microparticles were able to prevent lactase release during 
dissolution studies in 0.1N HCl (Squillante et al., 2003).  Upon pH rise to pH 6.8 
there was only 25% released after 20 minutes and 65% after 100 minutes.  This 
release rate was quite slow and could result in incomplete lactose digestion.  
Lactase release was determined not by its activity but by its UV absorbance and 
therefore it is unknown if the microparticles actually preserved lactase activity.   
Both of these microparticle production methods used homogenisation and 
careful control of temperature.  Homogenisation has been shown to have a 
detrimental effect on lactase activity (Stivaktakis et al., 2005).  A simpler oil in oil 
emulsion solvent evaporation method of microparticle preparation has been 
used by Kendall et al. to produce prednisolone loaded microparticles composed 
of Eudragit L100 with the novel use of sorbitan sesquioleate as surfactant 
(Kendall et al., 2009).  This method doesn’t require temperature control, uses a 
slower emulsification speed, 1000rpm instead of 8000rpm (Alavi et al., 2002), 
and uses the less toxic ethanol instead of acetone or methanol to dissolve the 
polymer.  Eudragit L100 microparticles produced were <40µm, uniform, 
spherical and had high encapsulation efficiency (>80%) and yield (>90%).  They 
restricted release of the encapsulated drug in acid media and rapidly released 
the drug at pH 6.8.  When administered orally to rats the drug was rapidly 
released and detected in the blood plasma.  This method, previously just 
employed for the encapsulation of small molecules, has the potential to be used 
for the novel encapsulation of a large biological, lactase, in Eudragit L100 
microparticles to provide protection in the stomach and target the small intestine 
for rapid, active enzyme release.   
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2.2 Aims 
 To discover the stability of lactase throughout the gastrointestinal tract 
using simulated and porcine gastrointestinal fluids and human faecal 
fluids 
o To use this knowledge for rational design of oral lactase delivery 
vehicles  
o To investigate the oral stability of large molecular weight proteins 
with a tertiary structure 
 To assess the stability of oral lactase supplements in the gastrointestinal 
fluids which were identified as damaging to lactase activity 
o To identify the formulation components that aid oral lactase 
stability 
 To produce oral lactase formulations based on the results of the 
intestinal stability study, lactase supplements testing and previous oral 
delivery strategies for lactase and other enzymes 
o To characterise them in terms of physical characteristics (size, 
morphology), loading and encapsulation efficiency 
o To assess their in vitro lactase release and ability to preserve 
lactase activity in simulated gastrointestinal conditions 
o To analyse and investigate failure to retain lactase activity in 
simulated gastrointestinal conditions 
o To adapt formulations to overcome any failures in lactase 
protection/release 
 
2.3  Materials 
Lactase (β-Galactosidase), from Aspergillus oryzae (9.9units/mg solid) 
standardised with dextrin and pancreatin from porcine pancreas, activity at least 
3x USP specifications were from Sigma Aldrich.  Enzeco fungal lactase 
concentrate was from the Enzyme Development Corporation (81.51units/mg).  
Hydrochloric acid 37%, specific gravity 1.18 was from BDH.  Pig gastric and 
intestinal fluids were collected from freshly slaughtered pigs and immediately 
frozen and stored at -80oC.  Human faecal fluids were from healthy individuals 
not taking antibiotics.   
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Faecal basal media materials:  Bacteriological peptone and yeast extract were 
from Oxoid.  Sodium chloride, L-cysteine hydrochloride, vitamin K, resazurin 
sodium salt and sodium hydroxide were from Fisher Scientific.  Dipotassium 
hydrogen orthophosphate and magnesium sulphate 7-hydrate were from BDH.  
Calcium chloride dihydrate was from VWR.  NaHCO3 and haemin were from 
Sigma Aldrich.  Bile salts were from Fluka Analytical.  Tween 80 was from Fluka 
Chemika. 
Lactase supplements analysed are listed and described in table 2.3. 
Microcrystalline cellulose (Avicel) and croscarmellose sodium (Ac-Di-Sol) were 
from FMC Biopolymer.  Magnesium stearate, sodium chloride and citric acid 
monohydrate were from Fisher Scientific.  Triethyl citrate, sodium bicarbonate, 
soybean oil, monobasic potassium phosphate, sodium carbonate (anhydrous), 
o-Nitrophenyl-β-D-galactopyranoside (ONPG), ≥98%, fluorescein 5 (6)-
isothiocyanate (FITC), magnesium hydroxide and phosphate buffered saline 
(PBS) tablets were from Sigma Aldrich.  Glycerol monostearate was from Alfa 
Aesar.  Polysorbate 80 was from Fluka Chemika.  Trisodium citrate dehydrate, 
glacial acetic acid and ethanol 96% v/v were from BDH AnalaR. 
Eudragit L100 was a gift from Degussa/ Evonik (Darmstadt, Germany), sorbitan 
sesquioleate (Alacel 83) was from Sigma Aldrich.  Liquid paraffin BP was 
supplied by JM Loveridge Plc.  Sodium phosphate, tribasic, anhydrous was 
from Alfa Aesar.  n-hexane was from Fisher Scientific.  Lipoid S100 
phosphatidylcholine from soybean (soy lecithin) was from Lipoid GMBH.  
Lysosensor yellow/blue dextran 10,000 MW anionic, fixable was from Invitrogen 
Molecular Probes.   
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Table 2.3 The ingredients, lactase content and dosage instructions for lactase supplements tested 
Supplement 
Lactase 
units/weight, per 
capsule/tablet Other ingredients Dosage Instructions 
Lactase 3500 (Solgar) 
3500 units Mannitol, microcrystalline cellulose, guar gum, magnesium 
stearate, vanilla sugar 
With or just prior to dairy 
food  
Say yes to dairy (Natural 
Organics Laboratories) 
3000 units Fructose, di-calcium phosphate, stearic acid, natural 
vanilla, magnesium stearate 
Chew immediately before 
or after meal of dairy food 
Lactaid Original (McNeil 
Nutritionals) 
3000 units 
Mannitol, Cellulose, Sodium Citrate, Magnesium Stearate 
Swallow or chew with first 
bite of dairy foods 
Lactase  (Quest) 
200mg di-Calcium Phosphate, Microcrystalline Cellulose, 
Magnesium Stearate 
With meals lactose 
containing food/drink 
Dairy-Zyme (Countrylife) 
3000 units Cellulose (capsule shell), cellulose, magnesium stearate, 
silica 
Immediately before or after 
consuming dairy products 
Super lactase enzyme 
(Holland & Barrett) 
1750 units Soya Bean Oil, Capsule Shell, Emulsifier (Soya Lecithin), 
Thickener (Yellow beeswax) 
Just before eating lactose 
containing food or drink  
Up and Up 
1750 units Microcrystalline cellulose, polyalditol, mannitol, dicalcium 
phosphate, crospovidone, magnesium stearate, sodium 
citrate, silicon dioxide Take with dairy food 
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2.4 Methods 
2.4.1 Lactase activity-ONPG assay 
o-nitrophenyl-β-D-galactopyranoside (ONPG) is a substrate for lactase and 
used in an assay to measure its activity (USP 35-NF 30).  When lactase cleaves 
ONPG a yellow compound, o-nitrophenol (ONP), is released.  This absorbs light 
at 420nm and the level of absorbance can be used to determine how much 
active lactase is present.  One lactase activity unit is defined as the quantity of 
enzyme that will liberate 1µmol of ONP per minute at 37ºC at a pH of 4.5. 
ONPG solution was prepared in a solution of glacial acetic acid, 4N sodium 
hydroxide and DI water adjusted to pH 4.50 ± 0.05.  Lactase activity was 
determined by adding the sample (0.5ml) to be analysed to 3.7mg/ml ONPG 
solution (1ml) which had been incubated at 37°C for 10 minutes. This was 
incubated at 37°C, 100rpm in a Gallenkamp shaking incubator and removed 
after 15 minutes when 10% sodium carbonate solution (1.25ml) was added to 
stop the reaction.  DI water (10ml) was added before measuring the absorbance 
at 420nm using a UV/Vis spectrophotometer (Cary 3E).  Sample activity was 
measured with reference to a calibration curve of lactase standards prepared in 
the relevant media. 
2.4.2 Intestinal stability 
100µl of a 500µg/ml lactase solution was added to 9.9ml of simulated gastric 
fluid (SGF) and simulated intestinal fluid (SIF) with and without pancreatin (final 
lactase concentration of 5µg/ml).  These were placed in a Gallenkamp shaking 
incubator at 37°C and agitated at 100rpm.  Samples (0.5ml) were removed after 
0, 5, 10, 20, 30, 60, 90 and 120 minutes and tested for lactase activity using the 
ONPG assay.  Lactase stability was not tested in SGF with pepsin due to its 
complete activity loss in SGF alone rendering this test inexpedient. 
SGF was prepared by dissolving 2g NaCl in DI water, adding 7ml of 
concentrated HCl and making up to 1 litre with DI water.  The pH was adjusted 
to pH1.2 ± 0.5 with concentrated HCl and 5N NaOH.  SIF was prepared by 
dissolving 6.8g of monobasic potassium phosphate in 250ml DI water and then 
adding 77ml of 0.2N NaOH before making up to 1 litre with DI water.   
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The pH was adjusted to pH 6.8 ± 0.5 with concentrated HCl and 5N NaOH 
before addition of pancreatin at a concentration of 10g/litre. 
Pigs are omnivores like humans so assessing stability in pig intestinal fluids 
should provide information on its stability in humans.  While possibly not 
completely reflecting what would happen in human intestinal fluids in vivo these 
results give a general picture of intestinal stability.  300μl of a 120µg/ml lactase 
solution was added to 900μl of gastric (pH 2.31), duodenal (pH 6.55), jejunal 
(pH 6.79), ileal (pH 6.86) and descending colonic fluids (pH 7.06) from a pig.  
The pig intestinal fluids were prepared by centrifuging at 10,000rpm for 10 
minutes and the supernatant was used for testing.  These mixtures were placed 
in a Gallenkamp shaking incubator at 37°C and agitated at 100rpm.  100µl 
samples were taken after 0, 5, 10, 20, 30, 60, 90 and 120 minutes and diluted 
by the addition of 500µl PBS to give a final lactase concentration of 5µg/ml and 
then analysed for active lactase using the ONPG assay. 
300μl of a 120µg/ml lactase solution was added to 900μl of human faecal slurry 
and placed in a Gallenkamp shaking incubator using the parameters used in the 
previous tests. 100µl samples were taken at 0, 5, 10, 20, 30, 60, 90 and 120 
minutes and diluted by the addition of 500µl PBS to give a final lactase 
concentration of 5µg/ml and analysed for active lactase using the ONPG assay.  
The stability of lactase in these intestinal fluids was defined as the amount of 
active lactase recovered at each time point as a percentage of the total active 
lactase added initially.  Changes in lactase concentration due to removal of 
samples were accounted for. 
Active lactase recovered (%) = 
                                                
                                     
 x100 
2.4.2.1 Human faecal slurry 
Initially the basal medium was prepared as described here using the excipients 
listed in table 2.4.  Peptone water and yeast extract were weighed into a glass 
bottle containing 1.3L of distilled water and autoclaved at 130°C for 20 minutes.   
Sodium chloride, dipotassium hydrogen orthophosphate, magnesium sulphate 
7-hydrate, calcium chloride dihydrate were weighed into a 200ml volumetric 
flask with approximately 150ml of distilled water and stirred to dissolve.   
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Polysorbate 80 was added and stirred completely until dissolved.  The stopper 
was kept tightly closed to avoid dissolution of oxygen.  L-cysteine and the bile 
salts were added and stirred until completely dissolved.  Vitamin K, Haemin and 
the resazurin solution were added and stirred until completely dissolved.  
Sodium bicarbonate was added and stirred until dissolved and then the volume 
was made up to 200ml with distilled water.  The solution was filtered using 
0.45µm filters (Millex GP, Millipore, Ireland) into the autoclaved 1.3L solution 
containing the peptone water and yeast extract in a Laminar flow cabinet. 
Table 2.4 Composition of basal medium (Hughes et al., 2008) 
Ingredient Quantity per 1.5L 
Peptone Water 3.0g 
Yeast Extract 3.0g 
Sodium chloride 0.15g 
Dipotassium hydrogen orthophosphate 0.06g 
Magnesium sulphate 7-hydrate 0.015g 
Calcium chloride dihydrate 0.01g 
Sodium bicarbonate 3.0g 
Haemin 0.0075g (Dissolved in 2 drops NaOH 
1M) 
L-cysteine HCl 0.75g 
Bile salts 0.75g 
Polysorbate 80 3.0ml 
Vitamin K 15µl 
Resazurin solution 0.025% (prepared 
in DI water) 
6.0ml 
 
Freshly voided human faeces from volunteers on no medication and who had 
not taken antibiotics in the previous 6 months were used to prepare the faecal 
slurry.  In an anaerobic workstation, maintained at 37°C with a relative air 
humidity of 70%, the faecal material was diluted with phosphate buffered saline 
(PBS) pH 6.8±0.05 solution to obtain a 40% w/w slurry.  The slurry was 
homogenised with an Ultra Turrax (IKA T18 Basic) at a speed of 18,000rpm/min 
until no large solid agglomerates could be seen.   
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The slurry was sieved through an open mesh fabric (Sefar NitexTM, pore size 
350µm) to remove any unhomogenised fibrous material.  The basal media was 
then added to the faecal slurry to achieve a 1:1 dilution.  This slurry was then 
used to test the stability of lactase. 
2.4.3 Lactase supplements  
Lactase supplements, listed in table 2.3, were tested for residual lactase activity 
following exposure to simulated gastric and small intestinal environments using 
the USP (724) method for testing drug release from enteric coated articles.  The 
supplements, in triplicate, were placed in 750ml 0.1N HCl, pH 1.2 ± 0.05, for     
2 hours at 37±0.5°C, stirring at 50rpm to simulate gastric conditions in a USP II 
paddle apparatus dissolution bath.  After 2 hours 250ml of pre warmed, to 37°C, 
0.2M tribasic sodium phosphate was added and the pH adjusted to pH 6.8 ± 
0.05 to simulate the transition into the small intestine. Stirring continued at 
50rpm for a further 45 minutes and was increased to 250rpm for the final 30 
seconds.  Samples were removed, filtered using 0.45µm Millex filters and tested 
for lactase activity using the ONPG assay. 
Each lactase supplement was also placed in 1 litre of pH 6.8 phosphate buffer 
for 2 hours and 45 minutes and stirred at 50rpm, increasing to 250rpm for the 
final 30 seconds.  The temperature was 37°C throughout.  This was done to 
determine the total active lactase released from each supplement in simulated 
small intestinal conditions and compare this to active lactase released when the 
supplements were first placed in acid.  All tests were carried out in triplicate.  
Samples were filtered using 0.45µm Millex filters and tested for lactase activity 
using the ONPG assay. 
Units of active lactase per tablet were calculated using a standard curve of 
measured lactase activity in pH 6.8 phosphate buffer.  The difference in active 
lactase remaining following dissolution in 0.1N HCl shifting to pH 6.8 phosphate 
buffer compared to incubation in pH 6.8 phosphate buffer was calculated by 
subtracting the former from the latter.  The percentage loss in lactase activity 
was calculated using the following equation: 
Lactase activity loss (%) = 
                                               
                         
 x100 
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2.4.4 Self emulsifying dosage form with soy bean oil  
Oil based dosage forms are frequently used for oral nutritional supplements 
including lactase.  These are administered as a pre-concentrate consisting of a 
drug, oil, surfactant and co surfactant that form an oil in water (o/w) emulsion 
when dispersed in the GI tract.  These formulations are known as self 
emulsifying drug delivery systems (SEDDS).  The emulsion formed may offer 
protection to the drug by forming an oily barrier between it and the acidic pH of 
the stomach and GI enzymes.  A water in oil microemulsion of insulin provided 
in vitro stability enhancement in simulated gastric fluid with pepsin (Toorisaka et 
al., 2005). 
An oil based formulation of lactase was created by homogenising soy bean oil 
(2g), soy lecithin (400mg) and lactase (400mg) together at 24,000rpm for 1 
minute using an Ultra Turrax T25 Ika-Werke small probe emulsifier to re-create 
an existing oral lactase supplement.  During emulsification the mixture was 
placed on ice to prevent lactase denaturation caused by increasing heat.  The 
appearance of the formulation upon mixing with aqueous media (pH 6.8 
phosphate buffer) was visualised using a light microscope. 
Active lactase content of the formulation was determined by placing 10mg of the 
liquid in 10ml pH 6.8 ± 0.05 phosphate buffer. Samples were placed in a 
Gallenkamp shaking incubator at 100rpm, 37±0.5°C for 1 hour.  Samples were 
taken and diluted 25 times with pH 6.8 phosphate buffer and analysed for active 
lactase content using the ONPG test.  Loading was determined by calculating 
the amount of active lactase (mg) per mg of SEDD formulation.  The loading 
efficiency was calculated using the equation below.  The total active lactase is 
the amount of lactase theoretically present if all added initially was incorporated 
into the SEDD formulation without any losses. 
Loading efficiency (%) =
                       
                     
 x100 
The ability of this formulation to protect lactase in acid was assessed by placing 
25mg in 7.5ml of 0.1N HCl, pH 1.2 ± 0.05, for 2 hours.  These samples were 
agitated in a shaking incubator at 100rpm and 37±0.5°C.  After 2 hours 2.5ml of 
0.2M tribasic sodium phosphate was added to raise the pH to 6.8 ± 0.05.   
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The samples were replaced in the Gallenkamp shaking incubator and agitated 
using the same parameters for a further 45 minutes.  Samples were withdrawn 
and tested for active lactase release using the ONPG assay.  Active lactase 
release was calculated using the equation below.  The theoretical active lactase 
is all the lactase that could potentially be released from the formulation. 
Active lactase release (%)=
                                 
                                    
x100 
The percentage of active lactase released from this formulation was compared 
to that from the Holland and Barrett lactase supplement using one way ANOVA 
to assess if there was a significant difference (Minitab 15).  Results were 
considered significant if p≤0.05. 
2.4.5 Enteric coated lactase tablets 
Tablets were prepared by dry blending  microcrystalline cellulose (Avicel), a 
filler and compression aid, (77%, 30.8g), croscarmellose sodium (AcDiSol), a 
disintegrant, (2%, 0.8g) and lactase (20%, 8g) for 10 minutes using a Pascall 
Engineering roller mixer.  Magnesium stearate, a lubricant, (1%, 0.4g) was then 
added and blended for 1 minute.  Placebo tablets were made by substituting 
lactase for microcrystalline cellulose (97%, 38.8g).  The powder mix was fed 
into a single punch tabletting machine (Manesty, Speke, UK) fitted with a 
biconvex 8mm punch and die set (Holland, Nottingham, UK).  The force used to 
make the tablets was 35kN for placebo tablets (without lactase) and 31.5kN for 
lactase tablets.  The crushing strength of the tablets was measured using a 
Copley tablet hardness tester, acceptable limits were >80, <150N.  Tablets 
were weighed and the height of the punches adjusted to gain the desired tablet 
weight of 200mg (40mg lactase). 
Tablets (40g) were coated with the enteric polymer Eudragit L100 using a 
Strea-1 bottom spray fluidised bed spray coater (Aeromatic AG, Bubendorf, 
Switzerland).  The coating solution, with a solids content of 10% w/w, consisted 
of Eudragit L100 (7g) dissolved in ethanol (77g) with a plasticizer, triethyl citrate 
(1.4g, 20% w/w of the dry polymer) and glidant, glyceryl monostearate (GMS) 
(0.35g, 5% w/w of the dry polymer) with polysorbate 80 (0.14g, 2% w/w of the 
dry polymer).   
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A 10% GMS dispersion was prepared by adding 7.5g GMS (10% w/w) and 3g 
polysorbate 80 (40% w/w based on GMS) to 64.5g water (86% w/w).  This was 
stirred and heated to 70-80°C until the solution cleared.  The dispersion was 
cooled to room temperature and added to the Eudragit L100 solution.   
The coating solution was sprayed at a rate of 0.25g/min using an atomising 
pressure of 0.2 bar fed by a Minipuls 3 Gilson peristaltic pump.  The fan 
capacity of the coating machine was 16.5 (air flow 165m3/hour) and the drying 
temperature was 30°C.  Coating commenced and at regular intervals tablets 
were removed and weighed to determine the coating extent.  A weight gain of 
8.89mg per tablet was required (5mg/cm2) for effective enteric coating.  Once 
this level of coating had been achieved coating was halted and the tablets 
further fluidised for 15 minutes in the coater to dry.  The tablets were cured in a 
Gallenkamp incubator at 30°C overnight.  The tablets were weighed again to 
determine the final weight gain and amount of polymer applied per cm2. 
2.4.5.1 Active lactase content of tablets 
Lactase tablets (200mg), both coated and uncoated, were placed in 1 litre of pH 
6.8 ±0.05 phosphate buffer in USP II paddle dissolution apparatus.  Samples 
were stirred at 50rpm at 37°C for 2 hours and 45 minutes, increased to 250rpm 
for the final 30 seconds.  Samples were taken at the end of this period and 
active lactase content of the tablets was determined using the ONPG assay.  All 
tests were carried out in triplicate.  The amount of active lactase (mg) per tablet 
was calculated using a calibration curve of lactase in pH 6.8 phosphate buffer.  
The loading efficiency was calculated using the equation below.  The total 
active lactase is the amount of lactase which would be present in the tablets if 
all the lactase was successfully loaded into the tablets. 
Loading efficiency (%)=
                                
                             
x100 
2.4.5.2 In vitro release from enteric lactase tablets 
The USP II paddle apparatus was employed to assess the enteric behaviour of 
the coated and uncoated tablets using the USP (724) method for testing drug 
release from enteric coated articles.   
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Coated and uncoated lactase tablets (200mg) were placed in vessels containing 
750ml of 0.1N HCl, pH 1.2±0.05, for 2 hours, at 37±0.5°C, and stirred at 50rpm 
to simulate gastric conditions.  After 2 hours 250ml of 0.2M tribasic sodium 
phosphate pre-equilibrated to 37±0.5°C was added to each vessel to raise the 
pH to 6.8±0.05 to simulate small intestinal conditions.  Dissolution proceeded 
for a further 45 minutes and the paddle speed was increased to 250rpm for the 
final 30 seconds.  Samples were taken after 60 and 120 minutes acid incubation 
and 0, 10, 20, 30 and 45 minutes pH 6.8 phosphate buffer incubation.  Samples 
were diluted with pH 6.8 phosphate buffer if necessary prior to testing.  Samples 
were tested for active lactase release using the ONPG assay.  All tests were 
carried out in triplicate.  Active lactase release was calculated using the 
equation below.  The theoretical active lactase concentration is the 
concentration of lactase in the sample if all the loaded lactase was released 
from the tablets. 
Active lactase released (%)=
                                                       
                                                
x100 
2.4.6 Preparation of enteric lactase microparticles 
This method is based on that of Kendall et al. with the substitution of 
prednisolone for lactase.  Eudragit L100 (3g) was dissolved in ethanol (30ml).  
Lactase (200mg) was suspended in the ethanol to prepare microparticles with a 
drug to polymer weight ratio of 1:15.  This suspension of lactase in Eudragit 
L100 solution was emulsified into liquid paraffin (200ml) containing 1% (w/w) of 
sorbitan sesquioleate (Arlacel 83) as an emulsifying agent, using a Heidolph 
RZR1 stirrer (5cm diameter propeller) at 1000rpm.  Stirring was carried out for 
18 hours at room temperature to allow solvent evaporation and particle 
solidification.  The microparticles formed were recovered by vacuum filtration 
through a Pyrex sintered glass filter (pore size 4; 5-15μm) and washed three 
times with n-hexane (50ml).  Blank microparticles containing no lactase were 
also prepared using the same parameters.  All microparticle formulations were 
prepared in triplicate. 
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2.4.6.1 Particle size and yield 
The volume median diameter of the microparticles was measured using laser 
light scattering with a Malvern Mastersizer X with a 45mm lens (Malvern 
Instruments Ltd., Malvern, UK).  The microparticles were suspended in 0.1N 
HCl and added dropwise into the magnetically stirred small volume diffraction 
chamber, containing 0.1N HCl until obscuration of 15-20% was achieved.  
Particle size analysis of each formulation was carried out in triplicate, and the 
polydispersity (span) was calculated as [D(v, 0.9)-D(v, 0.1)]/D(v, 0.5) which are 
the particle diameters at the 90th, 50th and 10th percentile respectively of the 
particle size distribution curve. 
The yield of particle production was calculated using the equation below.  The 
theoretical mass of microparticles expected is the total mass of polymer and, if 
used, of lactase utilized to produce the microparticles. 
Yield (%)=
                                      
                                         
x100 
2.4.6.2 Particle morphology 
The morphology and size of the microparticles were examined by scanning 
electron microscopy (SEM) under a Philips Quanta 200F, Eindhoven, The 
Netherlands.  Microparticles were fastened on a SEM stub using carbon 
adhesive pads and then coated with gold using an Emitech K550 sputter coater.  
Routine, high vacuum imaging at 5kV was used to reveal surface morphology of 
the microparticles. 
The microparticles were visualized again using SEM at a lower voltage of 1kV 
and under a reduced vacuum.  The particles were not sputter coated.  These 
conditions were used to minimize the loss of any morphological details of the 
microparticles caused by sputter coating and using a higher voltage beam. 
The morphology of the blank microparticles was visualized to an even greater 
degree of detail by employing an SEM with a new type of back scatter 
secondary electron detector (directional backscatter detector) that enabled the 
use of a low voltage beam, 500V and 300V, which revealed further surface 
detail not visible when using a high voltage beam (FEI, Eindhoven).   
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This new detector has a better efficiency at low voltage and more surface detail 
can be revealed than conventional low vacuum imaging using the large field 
detector or gaseous detection.  The microparticles were imaged before and 
after being placed in 0.1N HCl.  
2.4.6.3 Encapsulation efficiency and active lactase loading 
300mg of lactase microparticles were filled into gelatin capsules and placed in  
1 litre of pH 6.8±0.05 phosphate buffer for 45 minutes at 37±0.5°C using a USP 
II paddle apparatus dissolution bath.  Paddle speed was 50 rpm and increased 
to 250rpm for the final 30 seconds.  Samples were withdrawn and tested for 
lactase activity using the ONPG assay.  The amount of active lactase (units) 
released was used to calculate the encapsulation efficiency of active lactase in 
the microparticles using the equation below. The total units of lactase added 
was the amount of lactase used to produce the microparticles.  Drug loading 
was determined by measuring the units or mgs of active lactase per mg of 
microparticles. 
Encapsulation efficiency (%) =
                         
                            
 x100 
2.4.6.4  Differential scanning calorimetry (DSC) 
A DSC 7 differential scanning calorimeter (Perkin Elmer Instruments) calibrated 
with indium was used to assess the thermal behaviour of lactase alone, blank 
Eudragit L100 microparticles and lactase loaded Eudragit L100 microparticles.  
Samples (2-4mg) were accurately weighed and placed in a non-hermetic 
aluminium pan.  Pyris Thermal Analysis Software was used to record and 
analyse the data.  Modulated DSC was conducted on the samples starting at -
20°C and ending at 300°C at a heating rate of 3°C/minute, period of 60 seconds 
and an amplitude of ± 1°C. 
2.4.6.5 Enteric protection- in vitro release of active lactase 
USP II paddle apparatus was employed to determine if the microparticles could 
prevent lactase release and protect its activity in simulated gastric conditions.  
The microparticles were placed in 750ml 0.1N HCl, pH 1.2±0.05, for 2 hours at 
37°C and 50rpm stirring speed to simulate gastric conditions.   
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The pH was raised to 6.8±0.05 to mimic the small intestine and dissolution 
proceeded for a further 45 minutes.  This was done by adding 250ml of 0.2M 
tribasic sodium phosphate.  The paddle speed was raised to 250rpm for the 
final 30 seconds.  Samples were withdrawn and the amount of active lactase 
determined by the ONPG assay.  All tests were carried out in triplicate.  Active 
lactase release was calculated using the equation below.  The theoretical active 
lactase is the amount of lactase expected if all the encapsulated lactase was 
released and was active. 
Active lactase release (%)=
                                 
                                    
x100 
2.4.7 Spray drying lactase 
To minimize uncontrolled release of lactase from Eudragit L100 microparticles 
in acid its particle size was reduced by spray drying.  Drugs previously exhibited 
burst release, 30%+, from Eudragit L100 nanoparticles at pH 1.2 (Devarajan 
and Sonavane, 2007, Eerikainen et al., 2004, Raffin, 2006).  Reduction of drug 
particle size increased encapsulation efficiency and reduced burst release 
(Thote and Gupta, 2005).  Spray drying can be used to produce protein 
particles of a controlled size and shape.  Despite the use of high temperatures 
the cooling effect of solvent evaporation during spray drying protects the 
protein.  Spray drying the protein bovine serum albumin reduced its in vitro 
burst release from PLGA microspheres by 60% (Costantino et al., 2000).  
Lactase particle size has previously been successfully reduced to 2-4µm by 
spray drying (Broadhead et al., 1994). 
Lactase was dissolved in DI water and spray dried using a Buchi mini spray 
dryer B-191 to reduce its particle size using these conditions: 
Aspirator: 85% 
Inlet Temperature: 190°C 
Pump: 3ml/min (15%) 
To determine the lactase activity of the spray dried samples they (10mg) were 
dissolved in DI water (200ml).  The ONPG assay was used to assess lactase 
activity and this was compared to a calibration curve of lactase.   
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The following equation was used to determine the activity of spray dried lactase 
(units/mg) relative to non-spray dried lactase (9.9 units/mg). 
Units/mg spray dried lactase=
                              
                                     
x 9.9 units/mg  
The morphology and size of the spray dried and non-spray dried lactase was 
visualized using SEM.  Spray dried and non-spray dried lactase were dispersed 
in ethanol and then filtered by vacuum filtration through a Pyrex sintered glass 
filter (pore size 4; 5-15μm).  Their morphology was then examined again.  Spray 
dried lactase was encapsulated within Eudragit L100 microparticles using the 
method described above for non-spray dried lactase.  Differences in 
encapsulation efficiency compared to non spray dried lactase were assessed by 
one-way ANOVA and deemed to be significant if p≤0.05, Minitab 15. 
2.4.8 Fluorescent labeling and visualization of lactase 
Lactase-FITC conjugation was carried out to visualise its location in the 
microparticles.  1mg/ml FITC was prepared in anhydrous DSMO (1ml) and 
800µl of this was added to 10ml of 1mg/ml Enzeco lactase solution prepared in 
sodium bicarbonate buffer.  Sodium bicarbonate buffer was prepared by 
dissolving 17.3g NaHCO3 and 8.6g of Na2CO3 in 1 litre of DI water.  The FITC 
lactase mixture was magnetically stirred wrapped in foil and in the dark for two 
hours.  This was injected into a dialysis cassette which was placed in a large 
beaker of DI water and magnetically stirred in the dark.  The water was changed 
regularly and dialysis proceeded overnight.   
The dialysed FITC-lactase conjugation was freeze dried with a Virtis Advantage 
freeze drier.  Initially the sample was frozen at -38⁰C for 2 hours.  It then was 
subjected to two drying phases; primary drying (sublimation) and secondary 
drying (desorption).  Both drying phases were conducted under vacuum at a 
pressure of 200 mTorr.  The primary drying phase proceeded at -30⁰C for 2 
hours and at -10⁰C for 2 hours.  The shelf temperature of the freeze dryer was 
at 0⁰C for 20 hours during the secondary drying phase. 
The freeze dried FITC-lactase conjugation was added to 3g of Enzeco lactase 
and dissolved in 200ml of DI water.   
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This was spray dried using an inlet temperature of 190°C, 85% Aspirator, 15% 
pump setting (3ml/min) using a Buchi mini spray dryer B-191.  Eudragit L100 
microparticles were prepared as before but in darkness.  
The microparticles were visualised using CFLM, using a Zeiss LSM 510 
microscope, to visualise the fluorescent protein in and on the microparticles .  A 
Z-section was used to visualise FITC-lactase throughout the microparticles.  
Eudragit L100 alone was also visualised to ensure it produced no fluorescence. 
2.4.9 Active lactase burst released from microparticles below pH 6 
To quantify differences in burst release of non-spray dried and spray dried 
lactase from Eudragit L100 microparticles below the pH threshold of the 
polymer the particles were dispersed in pH 4.5 buffer.  At this pH any released 
lactase will be active and therefore can be quantified using the ONPG method. 
Gelatin capsules were filled with 30mg of microparticles encapsulating 
unmodified lactase or spray dried lactase.  These were placed in 75ml of        
pH 4.5±0.05 buffer and stirred on a magnetic stirrer for 2 hours, 2 ml was 
withdrawn to detect active lactase release using the ONPG assay.  2ml of       
pH 4.5 buffer was added to the reaction mixture to replace the withdrawn 
sample and then 25ml of 0.2M tribasic sodium phosphate was added to raise 
the pH to 6.8±0.05.  Stirring continued for 45 minutes then samples were 
withdrawn and analysed for active lactase release.  Differences in lactase 
release from the two sets of microparticles were assessed for significance using 
one-way ANOVA and judged to be significant if p≤0.05, Minitab 15. 
pH 4.5 buffer was prepared by mixing 470ml of 0.1M citric acid with 530ml of 
0.1M trisodium citrate and adjusting the pH to pH 4.5±0.05 using concentrated 
HCl and 5N NaOH.  0.1M citric acid was prepared by dissolving 21.01g of citric 
acid in 1 litre of DI water.  0.1M trisodium citrate was prepared by dissolving 
29.41g of trisodium citrate dihydrate in 1 litre of DI water. 
2.4.10  Encapsulation of pH sensitive marker 
The interior pH of microparticles has been monitored previously using pH 
sensitive markers.   
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Lysosensor yellow/blue® dextran (Ding and Schwendeman, 2008) was 
encapsulated in PLGA microspheres to detect increasing interior acidity from 
degrading PLGA.  Confocal laser scanning microscopy was used to detect 
shifts in the marker’s emission spectrum to different wavelengths depending on 
the pH.   
Lysosensor yellow/blue dextran 10kDa was encapsulated within Eudragit L100 
microparticles to monitor the interior pH.  5mg of lysosensor was suspended in 
the Eudragit L100 solution in ethanol (300mg in 3ml) prior to adding to 20ml 
liquid paraffin with 1% sorbitan sesquioleate.  This oil in oil emulsion was stirred 
at 1500rpm for approximately 18 hours at room temperature to allow solvent 
evaporation and particle solidification.  The microparticles formed were 
recovered by vacuum filtration as before and washed three times with n-hexane 
(50ml).  The reaction mixtures were covered and kept in the dark throughout.   
The microparticles were visualised with CFLM, using a Zeiss LSM 710 
microscope, using a 10x lambda scan to detect the effect of surrounding pH on 
the encapsulated contents. The excitation wavelength used was 405nm.  
Microparticles were visualised dry, with 0.1N HCl and pH 6.8 phosphate buffer 
and their emission over wavelengths 430-720nm monitored.  
2.4.11  Cryosectioning microparticles 
Blank microparticles were glued to an AFM sample holder with cyanacrylate 
glue.  These were trimmed with a cryotrim 45 diamond blade and then 
sectioned with an ultrasonic knife, feed 30nm, at a sectioning speed of 
0.6mm/sec on water.  The sections were picked up with a Perfect Loop and 
mounted on C-flat TEM grids.  The carbon film of the grid contained 2μm holes.  
This was performed by Diatome Ltd, Switzerland.  The sections were then 
examined by transmission electron microscopy.  The sectioned microparticles 
were also examined by SEM. 
2.4.12  Surface area analysis 
The surface area of the Eudragit L100 microparticles without lactase (blank), 
with spray dried lactase and non-spray dried lactase was calculated using the 
mean dv0.5 size as the diameter of the microparticles.   
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This was divided by two to give the radius and this value used in the following 
equation to calculate the surface area of each sphere: 
A=4r2 
Where A is area of the sphere and r radius of each sphere. 
BET was also used to determine the surface area of the microparticles.  Surface 
area was measured using a Micromeritics TriStar 3000 by Agenda1 Analytical 
Services, Bradford.  Molecules of an adsorbate gas were physically adsorbed 
onto the particle surfaces, including the internal surfaces of any pores, under 
controlled conditions within a vacuum chamber. An adsorption isotherm was 
obtained by measuring the pressure of the gas above the sample as a function 
of the volume of gas introduced into the chamber. The linear region of the 
adsorption isotherm was then used to determine the volume of gas required to 
form a monolayer across the available particle surface area, using BET theory, 
as described by the following equation  
 
      
     
 
   
  
 
 
  
  
 
   
 
where ν is the volume of gas, P is the pressure, P0 is the saturation pressure, 
νm is the volume of gas required to form a monolayer and c is the BET 
constant. Plotting relative pressure, φ (=P/P0), and volume allows the volume of 
a monolayer to be determined from the gradient and intercept of the line. The 
specific surface area can then be calculated using the cross sectional area of 
the gas molecules, the molecular volume of the gas and the weight of the 
sample. 
The specific surface area can also be calculated from the results of a laser 
diffraction measurement using the following equation: 
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Vi is the relative volume in class i with a mean class diameter of di, ρ is the 
density of the material, and D[3,2] is the surface area weighted mean diameter. 
This was carried out automatically using the laser diffraction system software 
during microparticle size analysis using the Malvern Mastersizer. In carrying out 
this calculation, it is assumed that the particles are perfectly smooth, solid 
spheres. 
2.4.13  Enteric microparticles with antacids 
Antacids have previously been administered with acid labile drugs to raise 
gastric pH and maintain drug activity.  Antacids co-administered with pancreatic 
enzyme supplements increased pH and enzyme activities in vivo (Graham, 
1982).  The acidic degradation products of PLGA nanoparticles can decrease 
the pH of the interior of the particles and destabilize acid labile peptides and 
proteins.  To overcome this antacids were encapsulated in PLGA nanoparticles 
with insulin and this reduced its degradation in SGF and increased its oral 
bioavailability in rats (Sharma et al., 2012).  The ability of co-encapsulated 
antacids to raise the interior pH of PLGA microspheres was detected by shifts in 
the emission spectrum of an encapsulated marker (Li and Schwendeman, 
2005).   
Co-encapsulation of antacids in enteric microparticles may provide additional 
protection to encapsulated lactase.  Acid may encounter lactase near the 
surface of microparticles, antacids can provide local neutralization and increase 
lactase preservation during gastric transit. 
Enteric microparticles with Eudragit L100 were prepared as described above 
with the addition of an antacid (1g) to the Eudragit L100 solution.  The antacids 
used were magnesium hydroxide and sodium bicarbonate.  They were 
suspended in the solution of the polymer prior to addition of lactase.  The yield, 
size and morphology of the microparticles were evaluated as described before.   
To determine the active lactase content of the microparticles, 10mg of lactase 
microparticles with co-encapsulated antacid were placed in 10ml of phosphate 
buffer, pH 6.8±0.05.  Samples were placed in a Gallenkamp shaking incubator 
at 37±0.5°C and agitated at 100rpm for one hour.   
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At the end of this period samples were diluted 20 times with pH 6.8 phosphate 
buffer and the active lactase content determined by the ONPG assay.  Loading 
and encapsulation efficiency were determined as in section 2.4.6.3.   
The ability of these microparticles to protect encapsulated lactase in gastric 
conditions was assessed by placing 100mg of microparticles in 7.5ml of 0.1N 
HCl, pH 1.2±0.05, for 2 hours.  These samples were agitated in a Gallenkamp 
shaking incubator at 100rpm and 37±0.5°C.  After 2 hours 2.5ml of 0.2M tribasic 
sodium phosphate was added to raise the pH to 6.8 ± 0.05.  The samples were 
replaced in the incubator and agitated for a further 45 minutes.  Samples were 
withdrawn and tested for active lactase content using the ONPG assay.  The 
samples from the microparticles containing magnesium hydroxide were diluted 
10 times prior to testing.  Active lactase release was calculated as in section 
2.4.6.5.   
Differences in particle size, span, encapsulation efficiency and active lactase 
release following dissolution of the lactase microparticles with antacids 
compared to those without were assessed by one-way ANOVA, Minitab 15.  
Results were considered to be significant if p≤0.05.  Differences in active 
lactase release from the microparticles with antacids were also compared to the 
Holland and Barrett lactase supplement. 
2.4.14  Self emulsifying dosage forms with soy bean oil and lactase 
microparticles 
An oil based formulation of lactase Eudragit L100 microparticles was created by 
homogenising soy bean oil (2g), soy lecithin (400mg) and lactase microparticles 
(500mg) together at 24,000rpm for 1 minute using an Ultra Turrax T25 Ika-
Werke small probe emulsifier.  During emulsification the mixture was placed on 
ice. 
Active lactase content was determined by placing 10mg of the liquid in 10ml pH 
6.8±0.05 phosphate buffer. Samples were placed in a Gallenkamp shaking 
incubator at 100rpm and 37±0.5°C for 1 hour.  Samples were taken, diluted 25 
times with pH 6.8 phosphate buffer and analysed for active lactase content 
using the ONPG test.  Loading and encapsulation efficiency were determined 
as in section 2.4.6.3.   
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The ability of this formulation to protect lactase in acid was assessed by 
placing150mg in 7.5ml of 0.1N HCl, pH 1.2±0.05, for 2 hours.  These samples 
were agitated in a shaking incubator at 100rpm and 37±0.5°C.  After 2 hours 
2.5ml of 0.2M tribasic sodium phosphate was added to raise the pH to 6.8±0.05.  
The samples were replaced in the incubator and agitated for a further 45 
minutes.  Samples were withdrawn and tested for active lactase release using 
the ONPG assay.  Active lactase release was calculated as in section 2.4.6.5.  
Active lactase release was compared to release from lactase in soy bean oil, 
lactase microparticles and lactase microparticles with co-encapsulated 
magnesium hydroxide after dissolution using one-way ANOVA, Minitab 15.  
Differences were judged to be significant if p≤0.05. 
2.5 Results and Discussion 
2.5.1 Intestinal stability 
Lactase stability was assessed in simulated and pig gastrointestinal fluids and 
human faecal fluids.  The results were used to design oral formulations of 
lactase. 
2.5.1.1 Gastric fluids 
Lactase was rapidly denatured in SGF, pH 1.2, without pepsin, table 2.5.  After 
5 minutes less than 1% of the initial lactase was active.  Similarly lactase 
activity was quickly reduced in porcine gastric fluid, only 6% remaining after 5 
minutes.  Lactase was not tested in SGF with pepsin as it was completely 
denatured in SGF alone. 
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Table 2.5 Active lactase recovery after incubation in SGF and porcine gastric 
fluids.  Data represents means ± standard deviation (SD). 
Sample 
(minutes) 
Active lactase recovered  
(%) SGF no pepsin 
Active lactase recovered  
(%) pig gastric fluid 
0 3.7 ± 5.2 38.9 ± 6.1 
5 0.3 ± 0.1 6.2 ± 2.4 
10 0.4 ± 0.1 5.6 ± 0.3 
20 0.3 ± 0.4 7.5 ± 3.3 
30 0.3 ± 0.3 4.9 ± 0.7 
60 -0.5 ± 0.8 4.7 ± 0.5 
90 -1.2 ± 0.8 3.6 ± 0.4 
120 -1.4 ± 0.9 4.5 ± 2.5 
 
2.5.1.2 Small intestinal fluids 
Lactase incubation in simulated and porcine small intestinal fluids resulted in 
minimal lactase degradation, table 2.6.  
Lactase stability with pancreatin has previously been shown (O'Connell and 
Walsh, 2006).  Active lactase recovery was actually above 100% in many 
samples.  This could be due to the method used to assess active lactase 
recovery.  The ONPG reaction is based on the catalytic conversion of ONPG to 
yellow coloured ONP.  Possibly the pancreatin and intestinal enzymes in the 
small intestinal samples were also able convert ONPG to ONP giving an inflated 
value for active lactase recovery.  Lactase is a small intestinal enzyme so it may 
also have been present in the small intestinal fluids increasing the amount of 
active lactase measured in the sample.  O’Connel and Walsh also detected 
similarly high (>100%) levels of lactase activity after incubation of lactase 
supplements in simulated intestinal fluid (O'Connell and Walsh, 2006).
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Table 2.6 Active lactase recovery after incubation in SIF and porcine small intestinal fluids.  Data represents means ± SD. 
Sample 
(mins) 
Active lactase (%) 
SIF 
Active lactase (%)   
SIF pancreatin 
Active lactase (%) 
duodenal fluid 
Active lactase (%) 
 jejunal fluid 
Active lactase  
(% ) ileal fluid 
0 104.7 ± 4.8 125.2 ± 9.4 114.2 ± 1.4 109.8 ± 1.8 108.3 ± 2.7 
5 106.8 ± 7.7 128.3 ± 1.3 109.4 ± 7.9 109.3 ± 1.5 102.6 ± 3.8 
10 104.1 ± 3.0 133.4 ± 2.6 109.7 ± 1.4 104.4 ± 0.7 99.5 ± 7.7 
20 110.3 ± 13.3 136.4 ± 4.2 105.1 ± 4.8 102.5 ± 1.1 101.2 ± 8.7 
30 107.8 ± 3.0 138.6 ± 2.9 100.5 ± 9.2 105.3 ± 2.6 103.6 ± 5.1 
60 106.8 ± 8.4 143.6 ± 2.5 88.1 ± 3.5 77.3 ± 2.6 106.3 ± 7.7 
90 112.7 ± 5.7 146.1 ± 5.9 86.4 ± 7.1 74.3 ± 3.8 103.0 ± 8.1 
120 96.1 ± 5.7 132.9 ± 23.6 98.8 ± 5.5 97.7 ± 1.7 96.0 ± 1.6 
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There was also greater than100% active lactase recovery following incubation 
in SIF without pancreatin.  Possibly this fluid provides a more conducive 
environment for lactase activity than the pH 6.8 sodium phosphate buffer which 
the lactase standards were prepared in.  Variations in lactase activity may have 
also arisen due to temperature variation on different days of testing, increasing 
or decreasing the rate of the enzymatic reaction, and the time between 
removing the sample and analysing its UV absorbance.  Theoretically the 
reaction should be immediately halted by the addition of sodium carbonate but 
this may not have been immediately effective.  Another variability factor could 
be the viscosity of the small intestinal fluids which may have caused uneven 
lactase distribution giving rise to varying results in sampled active lactase. 
 2.5.1.3 Colonic fluids 
Lactase activity was not diminished by incubation in porcine colonic and human 
faecal fluids, table 2.7.  As with the small intestinal fluids there was a greater 
than 100% recovery of active lactase.  This again could be due to the enzymatic 
activity of these samples. 
Table 2.7 Active lactase recovery after incubation in porcine colonic and human 
faecal fluids.  Data represents means ± SD. 
 
 
 
Sample 
(minutes) 
Active lactase recovered  
(%) pig colonic fluid 
Active lactase recovered  
(%) human faecal slurry 
0 124.2 ± 4.8 98.3 ± 3.1 
5 121.6 ± 8.6 121.9 ± 22.6 
10 106.7 ± 5.6 111.1 ± 10.4 
20 112.9 ± 13.7 111.2 ± 17.0 
30 120.2 ± 8.0 144.0 ± 3.1 
60 132.5 ± 5.4 119.3 ± 4.6 
90 129.9 ± 15.0 133.0 ± 6.9 
120 148.1 ± 5.0 132.8 ± 3.4 
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2.5.1.4 Overall intestinal stability  
Lactase is completely denatured by the acidic pH of the gastric environment, 
figure 2.2.  This result is in agreement with Alavi et al who found a greater than 
90% loss of lactase activity after incubation at pH 1.2 (Alavi et al., 2002).  In the 
small and large intestine it retains its activity, figure 2.2.  As it is a small 
intestinal enzyme it is logical that it should be stable and active in the small and 
large intestinal environment.   
The acidic pH of the gastric environment may alter the ionisation of its 
constituent amino acids and this would disrupt the bonds holding together its 
secondary, tertiary and quaternary structure.  The disassociation of the lactase 
tetramer into dimers removes critical elements of the active site resulting in a 
lack of enzymatic activity.  This loss of activity in gastric conditions has been 
observed previously with similarly large proteins such as ovomucoid (Zheng et 
al., 2010), chicken egg yolk immunoglobulin (Li et al., 2009) and other digestive 
enzymes (Scocca et al., 2007, Massicotte et al., 2008).  Possibly their higher 
structures render them more susceptible to acidic pH than peptides with a less 
complex structure. 
The stability of lactase in small and large intestinal fluids may be a result of the 
complexity of its structure.  Its polypeptide chains are involved in secondary, 
tertiary and quaternary structures which may make individual peptide bonds 
less accessible to digestive enzymes.  However if entering the small intestine 
after the stomach lactase may have been sufficiently unfolded by the gastric pH 
to expose its primary structure and peptide bonds to enzymatic digestion. 
Figure 2.3 maps the overall lactase stability throughout the GI tract showing 
where it needs to be protected.  Oral delivery strategies for lactase should 
protect it from the acidic pH of the stomach and release it in the favourable 
environment of the small intestine.   
To digest lactose locally, in the intestine, it should be taken just before or with 
lactose containing food.  The lactase should be released from the stomach into 
the small intestine with food in an active form so that it can begin digestion of 
lactose immediately and completely.  Any delay may result in no or incomplete 
lactose digestion causing the symptoms associated with lactose intolerance. 
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Figure 2.2 Active lactase recovered after incubation in simulated, porcine and 
human intestinal fluids.  Error bars show mean ± SD. 
 
Figure 2.3 Map of the stability of lactase throughout the gastrointestinal tract 
from studies in simulated and porcine intestinal fluids.  Error bars show      
mean ± SD. 
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2.5.2 Lactase supplements 
After elucidating the stability of lactase in the intestinal fluids, and thus the 
requirements for an oral formulation of lactase, an investigation into currently 
available oral lactase supplements was conducted.  The aim of this was to 
discover if these supplements were able to overcome the gastric stability barrier 
and what aspects of their formulations enable them to do this. 
Oral lactase supplements for lactose intolerance sufferers were tested in 
conditions which simulate gastric pH and the transition to small intestinal pH to 
predict their in vivo behaviour.  Supplements were only exposed to simulated 
gastric and intestinal media without enzymes as the stability studies 
demonstrated that it was the acidic pH alone which caused lactase 
denaturation.  
For all oral lactase supplements there was a greater than 95% loss of active 
lactase after dissolution in 0.1N HCl prior to pH increase to pH 6.8, table 2.8 
and figure 2.4.  The Holland and Barrett supplement had the most active lactase 
recovered after acid incubation, 4.5% remained.  However for all other 
supplements tested there was a greater than 99% loss in active lactase. 
 
Figure 2.4 Residual active lactase released from supplements after incubation 
in 0.1N HCl prior to pH rise to pH 6.8.  Error bars show mean ± SD.
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Table 2.8 Active lactase units detected per supplement after incubation in pH 6.8 phosphate buffer for 2 hours or in 0.1N HCl for 2 hours 
and 45 minutes in pH 6.8 phosphate buffer.  Data represents means ± SD. 
Supplement Units/dosage pH 6.8 Units/dosage pH 1.2 to 6.8 Difference (units) 
Active lactase remaining 
pH 1.2 to 6.8 (%) 
Solgar 2171.93 ± 110.11 -13.65 ± 4.59 2185.58 ± 4.59 -0.6 ± 0.2 
Yes to dairy 1698.35 ± 58.19 4.26 ± 6.09 1694.09 ± 6.09 0.3 ± 0.4 
Lactaid 1912.82 ± 66.46 -5.07 ± 4.21 1917.89 ± 4.21 -0.3 ± 0.2 
Quest 1023.95 ± 74.49 5.54 ± 8.92 1018.41 ± 8.92 0.5 ± 0.9 
Dairy Zyme  1073.86 ± 47.27 7.67 ± 5.55 1066.19 ± 5.55 0.7 ± 0.5 
Holland & Barrett  1274.85 ± 28.65 57.16 ± 3.00 1217.69 ± 3.00 4.5 ± 0.2 
Up and Up 1705.51 ± 50.76 0.33 ± 0.25 1705.18 ± 0.25 0.0 ± 0.0 
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All the supplements, except the Holland and Barrett supplement, were tablet or 
capsule powder based formulations without enteric protection.  Therefore it is 
unsurprising they were unable to protect lactase in acid.  Similar testing of 
lactase supplements in SGF also concluded enteric protection was vital for 
lactase activity survival (Alavi et al., 2002, O'Connell and Walsh, 2006).  Only 
enteric supplements preserved lactase activity, >90%, after SGF incubation.   
All of the supplements tested have dosage instructions advising them to be 
taken with or before eating lactose containing foods.  The arrival of food may 
neutralise stomach acid and stop lactase inactivation.  However, should the 
lactase supplement arrive in the stomach before food it is likely to be 
immediately denatured.  Additionally the pH of the stomach will drop post food 
ingestion and return to values which would denature any non-enteric lactase. 
The Holland and Barrett lactase supplement is a liquid formulation based on soy 
bean oil.  Soy bean oil has been used as the oil phase of microemulsions and 
demonstrated its ability to enhance drug stability and absorption in vivo (Piao et 
al., 2006, Wu, 2009, Hauss, 1997, Yi, 2000).  The higher active lactase 
recovery found with this supplement may be due to the formation of an oil in 
water emulsion when dispersed in SGF.  This type of formulation tends to be 
used to increase the bioavailability of hydrophobic drugs which can dissolve in 
the oil phase such as cyclosporine A.  However lactase is a hydrophilic protein 
and upon dispersion in gastric fluids it is more likely to partition into the acidic 
aqueous phase than remain in the protective oil phase.  Therefore only 4.5% of 
the lactase in the supplement remained active after incubation in 0.1N HCl.  
This small proportion of lactase may have been protected from the acidic pH by 
the oily barrier.  Water in oil microemulsions have previously enhanced the 
stability of peptide/protein drugs in vitro and in vivo; calcitonin (Fan et al., 2011) 
and insulin (Sharma et al., 2010, Toorisaka et al., 2003, Elsayed et al., 2009, 
Toorisaka et al., 2005).   
2.5.3 Self emulsifying dosage forms with soy bean oil 
The assessment of lactase supplements revealed only the Holland and Barrett 
supplement produced any measurable active lactase recovery after dissolution 
in 0.1N HCl and pH 6.8 phosphate buffer.  It is thought that the oil phase of this 
formulation is able to provide a protective barrier against acid.   
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Therefore a recreation of this formulation was attempted using soy bean oil as 
the oil phase and soy lecithin as a stabiliser. 
Small, spherical droplets of soy bean oil with lactase were formed upon 
dispersal of the formulation in pH 6.8 phosphate buffer, figure 2.5.  This 
demonstrated what would happen when dispersed in the gastric and intestinal 
fluids.  However it can’t be seen if lactase remains in the oily phase or partitions 
into the external aqueous phase. 
There was a high loading efficiency demonstrating that the soy bean oil and 
method of preparation did not have a detrimental effect on lactase activity, table 
2.9.  Dispersal of the oily formulation did not impair lactase activity.  Exposure of 
lactase to the oil/water interface created upon dispersion could have changed it 
structurally and caused activity loss.   
 
 
Figure 2.5 Light microscope image of soy bean oil, lactase and soy lecithin 
formulation upon dispersion in pH 6.8 phosphate buffer 
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Table 2.9 Loading efficiency, loading of active lactase in soy bean oil and active 
lactase release after dissolution in 0.1N HCl followed by pH rise to 6.8.  Data 
represents means ± SD. 
Formulation 
Loading  
efficiency (%) 
Active lactase 
loading (mg/mg) 
Active lactase 
release (%) 
Lactase, soy 
bean oil  106.7 ± 60.9 0.08 ± 0.05 0.7 ± 0.7 
 
After dissolution in 0.1N HCl and pH 6.8 phosphate buffer there was a very 
small amount of active lactase released, 0.7%, from the lactase/soy bean oil 
formulation.  Lactase is a hydrophilic enzyme and so upon dispersion in the 
aqueous 0.1N HCl it may move into this aqueous phase where it will be 
destroyed.  A very small amount remains protected in the oil droplets.  This 
formulation was significantly inferior (p≤0.05) to the Holland and Barrett 
formulation in terms of active lactase recovery after dissolution; 4.5% to 0.7%.  
One reason for this may be that the Holland and Barrett formulation was in a 
capsule and also contained beeswax.  These may have provided additional 
barriers to acid denaturation of lactase.   
The amounts and ratios of soybean oil, soy lecithin and lactase in the Holland 
and Barrett formulation were not known so could not be replicated exactly.  
Further testing to discover ideal ratios of the formulation components is needed 
to produce a more protective formulation.  Possibly a water in oil emulsion, 
formed before administration, could provide protection to lactase in an inner 
aqueous phase within a protective external oil phase.  Upon dispersion in 
gastric fluids more of the lactase may remain in the inner aqueous phase 
droplets within the protective oil rather than partitioning immediately into the 
denaturing gastric fluids. 
2.5.4 Enteric lactase tablets 
The intestinal stability study demonstrated lactase susceptibility at gastric pH.  
Analysis of stability of the non-enteric lactase supplements in 0.1N HCl revealed 
that none of them preserved more than 5% of their active lactase.   
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The most promising lactase formulation, soy bean oil based, was replicated but 
didn’t manage to preserve even 1% of the formulated lactase in 0.1N HCl.  
These findings demonstrated that for lactase to be successfully orally delivered 
to the small intestine it requires enteric protection.   
To provide gastric protection a lactase tablet formulation with enteric coating 
was developed and tested.  Lactase supplements with enteric coating were able 
to protect enzyme activity during acid incubation (O'Connell and Walsh, 2006).  
Pancreatic enzymes had an increased efficacy when enteric coated (Delchier et 
al., 1991, Dutta et al., 1988, Naikwade et al., 2009). 
Lactase tablets were coated with the enteric polymer Eudragit L100 giving a 
weight gain of 10.66mg per tablet and 8.39mg of polymer was applied per tablet 
giving a coating of 4.72mg/cm2.  There was a high loading efficiency of active 
lactase in the tablets demonstrating the efficiency of the process and its 
suitability, table 2.10.  The greater than 100% loading efficiency of lactase could 
be due to non uniform blending of the tablet powder mixture. 
Table 2.10 Active lactase loading and loading efficiency in uncoated and 
Eudragit L100 coated lactase tablets.  Data represents means ± SD. 
Sample 
Active lactase 
(mg/tab) 
Loading efficiency 
(%) 
Uncoated lactase tablet 45.21 ± 2.85 113.0 ± 7.1 
Eudragit L100 coated lactase tablet 43.22 ± 1.22 108.1 ± 3.1 
 
2.5.4.1 In vitro release 
There was no active lactase released from the uncoated tablets after dissolution 
in 0.1N HCl and then pH 6.8 phosphate buffer, table 2.11 and figure 2.6.  Active 
lactase was released from enteric coated tablets after 10 to 20 minutes 
dissolution above the pH threshold of the enteric polymer, pH 6.  There was 
complete active lactase release after 30 minutes dissolution in pH 6.8 
phosphate buffer. 
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Table 2.11 In vitro active lactase release from uncoated and enteric coated 
tablets after 2 hours in 0.1N HCl and 45 minutes in pH 6.8 phosphate buffer.  
Data represents means ± SD. 
Time (mins) 
Coated tablet active 
lactase released (%) 
Uncoated tablet active lactase 
released (%) 
0 0.0 ± 0.0 0.0 ± 0.0 
60 -0.7 ± 0.5 -1.0 ± 0.0 
120 (pH1.2) -0.6 ± 0.5 -1.0 ± 0.0 
120 (pH6.8) -0.8 ± 0.7 -1.3 ± 0.0 
130 -0.8 ± 0.7 -0.8 ± 0.0 
140 21.4 ± 14.3 -1.1 ± 0.3 
150 102.6 ± 8.5 -1.3 ± 0.1 
165 107.1 ± 8.5 -1.3 ± 0.0 
 
Figure 2.6 Active lactase release from uncoated and enteric coated tablets in 
0.1N HCl for 2 hours and pH 6.8 phosphate buffer for 45 minutes.  Error bars 
show mean ± SD. 
2.5.5 Eudragit L100 microparticles 
Enteric coated tablets successfully protected lactase from acid denaturation.  
However, during dissolution studies there was a delay in lactase release once 
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There was no release for the first 10 minutes at pH 6.8 and it took 30 minutes 
for there to be complete lactase release.  Single unit, enteric coated dosage 
forms, such as capsules and tablets, have previously demonstrated their 
inability to disintegrate rapidly (Cole et al., 2002).  This has implications for the 
digestion of lactose as it would allow lactose to persist undigested in the 
intestine.  Lactase needs to be immediately available for lactose digestion as 
soon as it reaches the small intestine.  Administering the tablets before food 
may achieve this but the emptying time of the tablets from the stomach and 
their dissolution are highly variable.   
To overcome this delayed release, the dosage size can be reduced to increase 
the surface area and achieve faster lactase release.  There was an increase in 
the rapidity of enzyme release and greater alleviation of symptoms when 
pancreatin microparticles were administered compared to tablets (Naikwade et 
al., 2009, Beverley et al., 1987).   
Microparticles composed of non enteric polymers have been formulated to 
encapsulate lactase.  However these have either prematurely released lactase 
in SGF or rapidly burst released their lactase making them unsuitable for oral 
lactase delivery (Kim et al., 2006, Hayashi et al., 1994).  Additionally the 
preparation of PLGA and PLA microparticles involved homogenisation which 
can damage lactase integrity (Hayashi et al., 1994, Stivaktakis et al., 2004, 
Stivaktakis et al., 2005). 
Enteric microparticles would be able to prevent lactase exposure to gastric pH, 
empty from the stomach with food and due to their large surface area should 
rapidly release lactase. The enteric polymer Eudragit L100, which was used to 
coat lactase tablets, has been used to produce pH sensitive microparticles 
encapsulating lactase.  Squillante et al demonstrated their prevention of lactase 
release in acid but didn’t show if the lactase retained its activity (Squillante et 
al., 2003).  The release rate was also quite slow, only 25% of the encapsulated 
lactase was released after 20 minutes in pH 6.8 phosphate buffer and 65% was 
released in 100 minutes.  Alavi et al also encapsulated lactase in Eudragit L100 
microparticles employing an oil in oil emulsification solvent evaporation method 
(Alavi et al., 2002).   
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However these methods of microparticle preparation involved homogenisation 
which was shown to be damaging to lactase (Hayashi et al., 1994). 
Eudragit L100 was used to produce microparticles encapsulating lactase 
(Kendall et al., 2009).  This method has been used to encapsulate small 
molecular weight drugs.  This method has advantages over the other methods 
used to produce Eudragit L100 lactase microparticles as it doesn’t require 
temperature control, uses a slower emulsification speed (1000rpm instead of 
8000rpm (Alavi et al., 2002)) and uses the less toxic ethanol instead of acetone 
or methanol to dissolve the polymer. 
The blank and lactase loaded microparticles produced were less than 50µm and 
uniformly sized, figure 2.7 and table 2.12.  SEM images confirmed this, figures 
2.8 and 2.9.  These are smaller than those produced previously to encapsulate 
lactase 53-57µm (Squillante et al., 2003) and 195µm (Alavi et al., 2002) and 
therefore they should empty more rapidly from the stomach with food.  The yield 
was greater than 90% and there was complete active lactase encapsulation, 
table 2.12.  This demonstrates the suitability of this method for producing 
microparticles with lactase as there was no enzyme destruction caused during 
preparation.   
The mean encapsulation efficiency of active lactase was 80% for Squillante et 
al and only 60% for Alavi et al.  In addition these methods were also damaging 
to lactase resulting in a 32% loss of activity during processing for Squillante et 
al.  Alavi et al were able to preserve greater than 80% of lactase activity during 
processing but this was still not as compatible with lactase encapsulation as the 
Kendall et al method.  The size, yield and encapsulation efficiency of lactase 
within Eudragit L100 microparticles was comparable to small molecular weight 
drugs encapsulated using the Kendall et al method.  This demonstrates the 
suitability of this method to successfully encapsulate macromolecules, including 
proteins, within enteric microparticles.   
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Table 2.12 Size, span, yield, encapsulation efficiency and lactase loading of blank and lactase loaded Eudragit L100 microparticles.  
Data represents means ± SD.  
Microparticles Mean Size (μm) Span Yield (%) 
Encapsulation 
efficiency (%) 
Active lactase 
loading (units/mg) 
Active lactase 
loading (mg/mg) 
Blank 32.89 ± 1.51 1.02 ± 0.23 94.7 ± 4.9 - - - 
Lactase 27.26 ± 0.68 0.94 ± 0.08 94.9 ± 2.5 102.5 ± 7.4 0.63 ± 0.05 0.064 ± 0.005 
 
  
 
 
 
 
 
 
Figure 2.7 Frequency curve of lactase microparticle size (image from Malvern Mastersizer) 
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Figure 2.8 (a) and (b) SEM images of blank Eudragit L100 microparticles, 
sputter coated, in a high vacuum and visualized with a 5kV beam 
 
Figure 2.9 (a) and (b) SEM images of microparticles encapsulating lactase, 
sputter coated, in a high vacuum and visualized with a 5kV beam 
DSC analysis of lactase, blank Eudragit L100 microparticles and lactase loaded 
microparticles revealed the encapsulated lactase was unchanged and 
crystalline, figures 2.10-12.  Due to its insolubility in ethanol it has been 
encapsulated as a solid suspension.  The DSC traces reveal that the thermal 
degradation profile of lactase did not change upon its encapsulation in Eudragit 
L100 microparticles but it is clearly associated with the particles. 
125 
 
 
Figure 2.10 DSC thermograph of blank Eudragit L100 microparticles  
 
Figure 2.11 DSC thermograph of lactase 
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Figure 2.12 DSC thermograph of lactase loaded Eudragit L100 microparticles 
There was no active in vitro lactase release after incubating the microparticles 
in 0.1N HCl, to simulate gastric conditions, and then raising the pH to 6.8, figure 
2.13.  Lactase was active and completely released in pH 6.8 buffer so it has not 
been denatured during its preparation and its release is not restricted at this pH.  
The microparticles were visibly intact at the end of the acid phase but possibly 
the lactase was burst released into the acid and immediately denatured or the 
acid has came into contact with encapsulated lactase.   
Squillante et al demonstrated that their Eudragit L100 microparticles did prevent 
lactase release in 0.1N HCl and released it in pH 6.8 phosphate buffer.  
However, lactase release was determined by its UV absorption, not its activity.  
Therefore it was unknown whether the released lactase was active.   
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Figure 2.13 Active lactase release from Eudragit L100 microparticles after        
2 hours in 0.1N HCl and 45 minutes at pH 6.8.  Error bars show the mean ± SD. 
2.5.6 Spray drying lactase 
The failure of the microparticles to release active lactase after dissolution 
initially in acid led to the theory that the lactase may not be completely 
encapsulated within the microparticles and/or that it is prematurely burst 
released.  This means that lactase would be in contact with 0.1N HCl and would 
be denatured before the pH rise when it should theoretically be released in an 
active form.  As the lactase is suspended and not dissolved in the polymer 
solution prior to emulsification its particle size will determine the extent of its 
encapsulation.  The lactase powder was visualised using SEM to determine its 
particle size, figure 2.14. 
 
Figure 2.14 SEM image of lactase powder 
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SEM images revealed that some of the lactase particle sizes were greater than 
30µm.  As the mean size of the microparticles produced using the Kendall et al 
method was <50µm the lactase may not have been completely encapsulated 
and therefore was exposed at the microparticle surface and burst released.   
Reducing drug particle size reduced their burst release (Prinn et al., 2002, 
Thote and Gupta, 2005).  Spray drying has been used to successfully reduce 
the size of protein particles (Costantino et al., 2000) and lactase particle size 
has been reduced  to 2-4µm by spray drying (Broadhead et al., 1994).  The 
lactase powder was spray dried to reduce its size and increase its chances of 
retention in the microparticles in acid.  Figure 2.15 shows the particle size was 
reduced by spray drying to less than 10µm.  The lactase particles remained this 
size after dispersal in ethanol so they should remain small enough for 
successful encapsulation in the microparticles, figure 2.16.  Ideally the particle 
size of lactase before and after spray drying would have been assessed using a 
Malvern Mastersizer, as for the microparticles.  However there was not enough 
material available to do this.  The spray dried lactase was tested for activity and 
it was shown that spray drying had only reduced its activity a little from 9.9 to 
9.11units/mg. 
 
Figure 2.15 (a) and (b) SEM images of spray dried lactase 
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Figure 2.16 (a) and (b) SEM images after spray dried lactase has been added 
to ethanol 
2.5.7 Eudragit L100 microparticles with spray dried lactase 
The spray dried lactase with a reduced size was encapsulated in Eudragit L100 
microparticles.  The microparticles produced were uniformly sized and less than 
50µm, table 2.13 and figure 2.17 and the SEM images confirmed this, figure 
2.18.  The yield was 99% but encapsulation efficiency of active lactase was 
significantly (p≤0.05) reduced to 84% compared to non-spray dried lactase, 
table 2.13.  Possibly the smaller size of the lactase meant it escaped 
encapsulation. 
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Table 2.13 Size, span, yield, encapsulation efficiency and spray dried lactase loading of Eudragit L100 microparticles.  Data represents 
means ± SD.  
Microparticles 
Mean size 
(μm) Span Yield (%) 
Encapsulation 
efficiency (%) 
Active lactase 
loading (units/mg)  
Active lactase 
loading (mg/mg) 
Spray dried lactase 30.25 ± 2.07 0.83 ± 0.31 99.4 ± 1.3 84.1 ± 3.1 0.48 ± 0.02 0.048 ± 0.00 
 
 
Figure 2.17 Frequency curve of microparticle size with spray dried lactase (image from Malvern Mastersizer)
131 
 
 
Figure 2.18 (a) and (b) SEM images of Eudragit L100 microparticles with spray 
dried lactase, sputter coated and imaged in a high vacuum with a 5kV beam. 
Lactase was fluorescently labeled and spray dried to visualize its encapsulation 
within Eudragit L100 microparticles.  The Eudragit L100 polymer was viewed 
alone using CFLM and shown not to fluoresce.  Fluorescently labeled lactase 
was visible within the microparticles demonstrating its encapsulation within the 
particles, figure 2.19.  Some fluorescent lactase is visible at the surface of the 
microparticles which could be susceptible to denaturation in acid.  Lactase at or 
near the surface may also be burst released from the microparticles upon 
dispersal in 0.1N HCl. 
 
Figure 2.19 CFLM image of encapsulated, spray dried FITC labelled lactase in 
Eudragit L100 microparticles 
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2.5.7.1 In vitro release  
Despite lactase size reduction there was no active lactase released from the 
microparticles during dissolution studies in 0.1N HCl (pH 1.2) and then pH 6.8 
phosphate buffer, despite the particles remaining visibly intact in acid.  This lack 
of active lactase may be caused by immediate lactase release from the 
microparticles in 0.1N HCl.  Premature burst release of encapsulated drug from 
Eudragit L100 microparticles at pH 1.2 has been observed previously 
(Devarajan and Sonavane, 2007, Eerikainen et al., 2004, Raffin, 2006). 
To determine if the lactase was burst released the microparticles were initially 
placed in pH 4.5 buffer, a pH below the pH 6 threshold of the polymer.  At pH 
4.5 lactase is active so any lactase released can be quantified and an estimate 
of lactase released in 0.1N HCl can be made.   
There was a burst release of 64% of non-spray dried lactase from the 
microparticles at pH 4.5, table 2.14 and figure 2.20.  Spray drying the lactase 
significantly (p≤0.05) reduced this to 8%.  Lactase released prematurely into 
0.1N HCl would have been instantly denatured.  These results demonstrated 
that spray drying lactase, reducing its size, allowed a more complete 
encapsulation of lactase and reduced its burst release.  After pH rise to pH 6.8 
there was an almost complete release of active lactase from the microparticles 
with non-spray dried lactase, 85%, and spray dried lactase, 80%, in 45 minutes.  
This was a faster and more complete release of encapsulated lactase than from 
the microparticles produced by Squillante et al which only released 65% of 
encapsulated lactase after 100 minutes in pH 6.8 phosphate buffer (Squillante 
et al., 2003). 
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Table 2.14 Active lactase release from Eudragit L100 microparticles with non-
spray dried and spray dried lactase in either 0.1N HCl or pH 4.5 buffer for 2 
hours and 45 minutes in pH 6.8 phosphate buffer.  Data represent means ± SD. 
Microparticles 
Active lactase 
release (%)          
pH 1.2 to 6.8 
Active lactase 
release (%)    
pH 4.5 
Active lactase 
release (%)        
pH 4.5 to 6.8 
Non-spray dried lactase -0.2 ± 0.8 64.1 ± 5.6 84.5 ± 7.7 
Spray dried lactase -0.3 ± 0.7 8.5 ± 2.6 80.1 ± 3.8 
 
Figure 2.20 Active lactase release from Eudragit L100 microparticles with non-
spray dried and spray dried lactase in pH 4.5 buffer for 2 hours and 45 minutes 
in pH 6.8 phosphate buffer.  Error bars show mean ± SD. 
Spray drying lactase prevented over 90% of the lactase being prematurely 
released from the microparticles.  However, despite lactase not being released 
in 0.1N HCl when the pH rose above pH 6 there was still no active lactase 
released.  Possibly acid is able to penetrate the microparticles and denature the 
lactase within.  When the pH is raised and the microparticles break down the 
lactase that is released may already have been denatured.  A similar situation 
occurred for the enzymes lactate dehydrogenase (LDH) and alpha amylase 
(AMY) encapsulated in Eudragit S100 microparticles (Scocca et al., 2007).  
Despite the microparticles remaining visually intact after acid incubation there 
was a 46% loss of LDH activity and 74% loss of AMY activity suggesting acid is 
able to come into contact with these encapsulated enzymes.   
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It was found that release of drugs with a molecular weight less than 300Da from 
Eudragit L100 microparticles was not controlled in acid (Alhnan, 2010).  This 
suggests that it is possible for these smaller drug molecules to move out of the 
microparticles and therefore it seems logical that the surrounding media is able 
to move into the microparticles.  This would enable acid to enter the 
microparticles and denature encapsulated lactase. 
2.5.8 Exploration of Eudragit L100 microparticle porosity 
To ascertain if acid was able to enter the microparticles a marker, whose 
emission wavelength varied depending on the pH of its environment, was 
encapsulated in the Eudragit L100 microparticles.  The marker Lysosensor 
yellow/blue® dextran had previously shown its ability to detect the pH of the 
interior of PLGA microspheres (Ding and Schwendeman, 2008).  Figure 2.21 
shows that the peak emission wavelength of the encapsulated marker in dry 
conditions or pH 6.8 buffer was about 490nm.  When the microparticles were 
placed in acid the peak emission wavelength shifted to approximately 515nm.  
The shift in emission to a longer wavelength indicated a decrease in the interior 
pH of the microparticles.  This showed acid was able to permeate the 
microparticles and encounter the encapsulated marker. 
Figure 2.21 Emission from lysosensor yellow/blue dextran marker in Eudragit 
L100 microparticles in dry conditions, pH 6.8 phosphate buffer and 0.1N HCl 
2.5.9 Surface morphological investigation 
SEM images produced in a low vacuum and using low accelerating voltage on 
non-coated microparticles revealed that some had visible pores figures 2.22 
and 2.23.   
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These pores were found in particles with encapsulated non-spray dried and 
spray dried lactase and appeared to be 1µm in diameter or less.  Possibly 
sputter coating was able to cover or melt some of these pores so they were not 
visible previously.  These images may explain why lactase is released from 
microparticles below pH 6.  The pores would also allow acid to enter the 
particles and denature lactase before it is released.  However, these pores were 
not visible in all the microparticles so don’t fully explain how all the 
encapsulated lactase is denatured in 0.1N HCl. 
 
Figure 2.22 (a) and (b) SEM images of microparticles with non-spray dried 
lactase, they were not coated and visualised in a low vacuum with a 1kV beam 
 
Figure 2.23 (a) and (b) SEM images of microparticles with spray dried lactase, 
they were not coated and visualised in a low vacuum with a 5 and 1kV beam 
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To further investigate the surface morphology of the microparticles, and 
elucidate how acid is able to penetrate them, blank microparticles were 
visualised under a Quanta 250F SEM with a new type of back scatter electron 
detector that performs well at low accelerating voltages.  This configuration 
revealed surface structures not seen when using the conventional higher 
voltage beam.  There appeared to be small ‘lumps’ and crystals on the surface 
of the microparticles, figure 2.24.   
 
 
Figure 2.24 (a), (b), (c) and (d) SEM images of blank Eudragit L100 
microparticles generated using an SEM with a new back scatter detector 
allowing the use of a 500 volt beam 
 
After the microparticles had been placed in 0.1N HCl and visualised again these 
surface structures disappeared, figure 2.25.  As these crystals appear on the 
surface of the blank microparticles they cannot be lactase.   
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They are most likely either to be Eudragit L100 or the surfactant.  As they 
disappear in acid they are unlikely to be the acid resistant polymer and more 
likely to be residual sorbitan sesquioleate surfactant not removed during 
washing. 
 
Figure 2.25 (a) and (b) SEM images of blank Eudragit L100 microparticles after 
acid incubation generated using an SEM with a new back scatter detector 
enabling the use of a 500 volt beam 
Currently instruments which could be used to determine the chemical nature of 
these surface structures use a beam with a voltage higher than 500V.  As they 
appear to be sensitive to high voltages they would be burnt off and unable to be 
identified. 
Possibly removal of these surface structures during acid incubation may be 
linked to acid entry into the particles. Their removal may damage the surface of 
the microparticles allowing acid entry.  It may show that the microparticle 
surface is not made up purely of acid resistant Eudragit L100 and this other 
component, which is not acid resistant, could allow acid ingress into the interior 
of the microparticles. 
2.5.10  Interior morphological investigation 
The interior of the microparticles was investigated by sectioning them.  
Cryosections of particles on a sample block show that there are visible pores 
within the microparticles, figure 2.26.   
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When the sections were placed on a grid it appeared that there were pores with 
a diameter of 2µm and smaller ones with a diameter of about 500nm, figure 
2.27. 
 
Figure 2.26 Cryosections of blank Eudragit L100 microparticles on sample 
block 
 
Figure 2.27 TEM image of sectioned blank Eudragit L100 microparticles 
mounted on a C flat grid with 2μm holes 
TEM images of sections from blank, unmodified lactase and spray dried lactase 
loaded microparticles revealed there were visible pores inside all of them, figure 
2.28.   
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2.28 (a)                                                   2.28 (b) 
 
2.28 (c) 
Figure 2.28 (a), (b) and (c) TEM images of cryosections of (a) blank Eudragit 
L100 microparticles, (b) non-spray dried lactase loaded microparticles and      
(c) spray dried lactase loaded microparticles 
The pore shape is slightly deformed in the TEM images, this is due to the 
preparation procedure and doesn’t exactly reflect their shape within the 
microparticles.   
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As the microparticles were sectioned on water some of the pores seen in the 
lactase loaded microparticles probably resulted from the water soluble lactase 
dissolving.  However, there were pores visible in the blank microparticles so not 
all the pores in the lactase loaded particles are due to the lactase dissolving. 
Pores visible in the sections from non-spray dried lactase loaded microparticles 
were round, relatively large and spread throughout the microparticles.  The 
pores visible in the sections from spray dried lactase loaded microparticles were 
smaller, angular shaped and more concentrated in the centre of the section.  
These differing images reveal variations in lactase encapsulation.  When 
lactase is not spray dried the encapsulated lactase is large and round and found 
throughout the particle.  Spray drying lactase resulted in smaller and more 
angular lactase particles and this is reflected in the pores visible in the TEM of 
the microparticle section.  The smaller lactase particles were also more deeply 
embedded within the microparticles.  These images provide further evidence as 
to why more non-spray dried lactase was burst released from the microparticles 
than spray dried lactase as more of it was present towards the surface. 
SEM images of blank, sectioned microparticles also revealed the presence of 
pores, figure 2.29.  Pores within the microparticles may provide channels for the 
acid to permeate the particles and encounter encapsulated lactase.  This will 
result in the lactase being denatured before it is released from the 
microparticles. 
 
Figure 2.29 (a) and (b) SEM images of cryosectioned blank Eudragit L100 
microparticles 
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2.5.11  Eudragit L100 microparticle surface area 
The surface area of the microparticles was assessed using three different 
methods.  The first method calculated the surface area of an individual 
microparticle using the mean dv 0.5 measured by the Malvern Mastersizer 
using an equation to determine sphere surface area.  This calculation assumes 
a perfectly spherical and smooth microparticle.   
Specific surface area was calculated by the Malvern Mastersizer during size 
analysis by dividing the total area of the microparticles by the total weight.  This 
method also assumes the particles are perfectly smooth and solid spheres.  
Surface area was also determined using BET.  This utilizes adsorption of gas to 
the surface of the particles to determine surface area.  Unlike the other two 
methods this does not assume the microparticles are smooth and perfectly 
spherical.  It will be affected by particle porosity and roughness.  If the 
microparticles do have pores, which could allow acid to enter, the BET surface 
area will increase relative to the surface area calculated using the other two 
methods. 
The surface area calculated from the sphere surface area equation was directly 
linked to the mean size of the microparticles and increased with increasing size, 
table 2.15.  The specific surface area calculated by the Malvern Mastersizer 
increases with finer particles.  The total area of the particles will increase as 
their size decreases for a given weight of particles.  The results in table 2.15 
correlate with that theory as the microparticles with non-spray dried lactase are 
the smallest (largest surface area) and the blank microparticles are largest 
(smallest surface area).   
The surface areas determined by BET showed the same rank order of surface 
area however there was a greater difference between the surface areas of the 
different microparticles.  The BET results imply pores were introduced into the 
microparticle surface by encapsulation of lactase and possibly were responsible 
for acid influx into the particles.  When the larger, non-spray dried lactase was 
encapsulated more porous particles were formed than with the spray dried 
lactase.  This could explain why more non-spray dried lactase was released in 
0.1N HCl.  
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Table 2.15 Surface areas of blank, non-spray dried lactase and spray dried 
lactase loaded Eudragit L100 microparticles.  Data represents means ± SD. 
Microparticles 
Calculated surface 
area (µm²) 
Specific surface area 
from Mastersizer 
(m²/ml) 
BET Surface 
Area (m²/g)  
Blank 3405.24 ± 315.83 0.29 ± 0.00 0.25 
Non-spray dried 
lactase 2335.45 ± 117.18 0.32 ± 0.01 0.63 
Spray dried 
lactase 2887.31 ± 390.42 0.31 ± 0.01 0.37 
 
2.5.12  Eudragit L100 microparticles with antacids 
Eudragit L100 microparticles with spray dried lactase restricted its release in 
acid.  However, they did not prevent the entry of the acid into the particles.  This 
was possibly due to pores within the microparticles. 
To counteract degradation in the stomach additional excipients can be added to 
raise gastric pH.  Antacids co-administered with pancreatic enzymes were able 
to increase their in vivo activity (Graham, 1982).  However lowering the pH of 
the stomach could impair its ability to destroy ingested toxins.  Alternatively 
rather than using antacids to increase the pH of the stomach, if they are 
encapsulated within enteric microparticles only their interior pH is raised.  
Antacids were co-encapsulated with insulin in PLGA nanoparticles to neutralise 
acidity produced by PLGA degradation (Sharma et al., 2012, Li and 
Schwendeman, 2005).  The antacids, magnesium hydroxide and sodium 
bicarbonate, were encapsulated in Eudragit L100 microparticles with spray 
dried lactase to neutralise acid influx in the stomach preventing lactase 
denaturation. 
Eudragit L100 microparticles with magnesium hydroxide were significantly 
(p≤0.05) larger, greater than 200µm, and had a significantly (p≤0.05) greater 
span than those without, table 2.16 and figure 2.30.  This suggests magnesium 
hydroxide may have affected the formation of the microparticles resulting in 
larger particles or aggregates of particles.   
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The encapsulation efficiency was also significantly (p≤0.05) reduced compared 
to when lactase alone was encapsulated, 55%.  Possibly there is some 
denaturation of the lactase caused by the inclusion of magnesium hydroxide 
and therefore active lactase encapsulation is reduced.  The effect of 
magnesium hydroxide on microparticle formation may also have reduced 
lactase encapsulation.  Further work to find an optimal ratio of magnesium 
hydroxide to polymer for formation of discrete microparticles should be carried 
out. 
Eudragit L100 microparticles with sodium bicarbonate were significantly 
(p≤0.05) larger than the particles without but were still less than 100µm 
suggesting the addition of sodium bicarbonate caused less aggregation than 
magnesium hydroxide, table 2.16 and figure 2.31.  There was also complete 
encapsulation of active lactase suggesting there was no detrimental effect of 
sodium bicarbonate on lactase activity or encapsulation. 
 
Figure 2.30 Frequency curve of the size of lactase microparticles with 
encapsulated magnesium hydroxide (image from Malvern Mastersizer) 
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Table 2.16 Size, span, yield, encapsulation efficiency and lactase loading of blank and lactase loaded Eudragit L100 microparticles with 
encapsulated magnesium hydroxide or sodium bicarbonate.  Data represents means ± SD.  
Microparticles Mean Size (μm) Span Yield (%) 
Encapsulation 
efficiency (%) 
Active lactase loading 
(mg/mg) 
Blank magnesium hydroxide 285.09 ± 89.83 2.03 ± 0.45 91.9 ± 5.4   
Lactase magnesium hydroxide 243.74 ± 51.79 2.31 ± 0.25 91.0 ± 4.1 55.2 ± 26.9 0.026 ± 0.01 
Blank sodium bicarbonate 98.66 ± 44.08 2.38 ± 0.65 92.3 ± 5.7   
Lactase sodium bicarbonate 88.57 ± 42.49 1.93 ± 0.48 91.9 ± 7.3 108.7 ± 34.9  0.052 ± 0.02 
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Figure 2.31 Frequency curve of the size of lactase microparticles with 
encapsulated sodium bicarbonate (image from Malvern Mastersizer) 
Morphological analysis using SEM showed incorporation of magnesium 
hydroxide into the microparticles seemed to cause the microparticles to 
aggregate or not form separate particles, figure 2.32 and 2.33.  There are some 
individual microparticles of less than 100µm but most are joined together in 
aggregates. 
 
Figure 2.32 (a) and (b) SEM images of blank Eudragit L100 microparticles with 
encapsulated magnesium hydroxide 
146 
 
 
Figure 2.33 (a) and (b) SEM images of Eudragit L100 microparticles with 
encapsulated lactase and magnesium hydroxide 
The incorporation of sodium bicarbonate into Eudragit L100 microparticles also 
caused some aggregation but these were smaller than those with magnesium 
hydroxide.  The particles formed were spherical and less than 100µm even 
when joined into aggregates, figures 2.34 and 2.35. 
 
Figure 2.34 (a) and (b) SEM images of blank Eudragit L100 microparticles with 
encapsulated sodium bicarbonate 
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Figure 2.35 (a) and (b) SEM images of Eudragit L100 microparticles with 
encapsulated lactase and sodium bicarbonate 
2.5.12.1 In vitro release 
There was 9% of encapsulated active lactase released from the microparticles 
with magnesium hydroxide but only 0.1% from the microparticles with sodium 
bicarbonate after dissolution in 0.1N HCl and pH 6.8 phosphate buffer, table 
2.17.  The pH of 0.1N HCl after the microparticle dispersal for two hours 
showed the buffers had not been released from the microparticles to an extent 
that they neutralised the acid, table 2.17.   
Table 2.17 Active lactase release after 2 hours in 0.1N HCl and 45 minutes in 
pH 6.8 phosphate buffer from Eudragit L100 microparticles with magnesium 
hydroxide or sodium bicarbonate and the pH of 0.1N HCl after 2 hours with 
microparticles.  Data represents means ± SD. 
Lactase 
microparticles 
Active lactase recovery 
(%) pH 1.2 to 6.8 
pH of 0.1N HCl after 2 
hours with particles 
Magnesium hydroxide  9.2 ± 2.5 1.25 ± 0.28 
Sodium bicarbonate  0.1 ± 0.2 1.08 ± 0.06 
 
Encapsulated magnesium hydroxide was able to neutralise some of the 
incoming acid and protect almost 10% of the encapsulated lactase.  It didn’t 
neutralise the external media so should have none of the detrimental effects of 
raising gastric pH.   
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Protection may also have occurred due to the larger size of the aggregated 
particles.  The proportion of active lactase released after dissolution was 
significantly higher from the microparticles with magnesium hydroxide than from 
those without it and from the Holland and Barrett lactase supplement.  Sodium 
bicarbonate was unable to protect the encapsulated lactase.  Possibly a greater 
amount of sodium bicarbonate is needed to do this or its location within the 
microparticles doesn’t allow lactase protection. 
It would be useful to encapsulate a pH sensitive marker within these 
microparticles to determine if the encapsulated antacids are able to neutralise 
acid entering the microparticles. 
2.5.13  Eudragit L100 microparticles and soy bean oil 
Eudragit L100 microparticles with encapsulated spray dried lactase were also 
formulated in soy bean oil with soy lecithin to provide a barrier to acid influx.  
Soy bean oil was able to preserve 4.5% of lactase activity after acid incubation 
of the Holland and Barrett lactase supplement.  Replication of this supplement 
only resulted in 0.65% activity preservation.  This may have been due to the 
hydrophilic lactase partitioning into the aqueous 0.1N HCl.  However this would 
not be an issue for lactase encapsulated within Eudragit L100 microparticles.  
Eudragit L100 microparticles are more lipophilic and so would be more likely to 
remain in the protective oily droplets.   
There was a significantly (p≤0.05) higher active lactase release, 3.6%, from the 
lactase microparticles in soy bean oil, table 2.18 , than from lactase alone in soy 
bean oil, table 2.9.  The microparticles may provide a further barrier to acid than 
the soy bean oil droplets alone.  Lactase alone is also more able to partition into 
the acidic aqueous phase.  Soy bean oil limited acid influx into the 
microparticles and significantly (p≤0.05) increased active lactase release 
following incubation in acid compared to lactase microparticles alone.  However, 
co-encapsulation of magnesium hydroxide in the microparticles was significantly 
(p≤0.05) better at preserving lactase activity in acid. 
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Table 2.18 Encapsulation efficiency, loading of active lactase in a soy bean oil 
formulation of lactase microparticles and active lactase release after dissolution 
in 0.1N HCl and pH 6.8 phosphate buffer.  Data represents means ± SD. 
Formulation 
Encapsulation 
efficiency (%) 
Active lactase 
loading 
(mg/mg) 
Active 
lactase 
release (%) 
Lactase microparticles 
and soy bean oil 101.6 ± 29.7 0.002 ± 0.00 3.6 ± 3.9 
Lactase microparticles 102.5 ± 7.4 0.064 ± 0.01 -0.2 ± 0.8 
 
2.5.14  Overall assessment of oral lactase delivery strategies 
The lactase Eudragit L100 microparticles with co-encapsulated magnesium 
hydroxide were superior in terms of active lactase preservation in simulated 
gastric conditions to the currently available Holland and Barrett lactase 
supplement, a lactase soy bean oil formulation, Eudragit L100 microparticles, 
Eudragit L100 microparticles with co-encapsulated sodium bicarbonate and the 
microparticles formulated in soy bean oil, figure 2.36.  
Figure 2.36 Active lactase release from existing and developed oral lactase 
formulations after dissolution in acid and pH 6.8 phosphate buffer.  Error bars 
show mean ± SD. 
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2.6 Conclusion  
Investigations into the stability of lactase in simulated and porcine 
gastrointestinal fluids and human faecal fluids demonstrated its instability in 
acidic conditions and stability in small and large intestinal fluids.  These results 
confirmed protection from acid is essential for active lactase delivery to the 
small intestine. 
All the oral lactase supplements subjected to dissolution testing initially in acid 
and then pH 6.8 phosphate buffer lost more than 95% of their initial lactase 
activity.  The only supplement that was able to preserve more than 1% of the 
initial lactase activity after acid incubation was the Holland and Barrett soy bean 
oil based formulation.  The others were non-enteric, powder based formulations.  
The oil may have acted as a barrier between lactase and acid preventing its 
degradation.  The Holland and Barrett supplement still only protected 4.5% of its 
lactase.  This may be due to hydrophilic lactase partitioning into the damaging 
acidic aqueous fluids and not remaining in the protective soy bean oil droplets.  
An attempt to recreate this formulation resulted in inferior lactase protection to 
the original supplement.  This may have been due to a lack of some elements of 
the original formulation and non-optimised excipient ratios.   
Due to the acid sensitivity of lactase and the low protection offered by the oil 
based formulation enteric formulations were investigated.  Enteric coated 
lactase tablets completely preserved lactase activity during two hours 
incubation at pH 1.2.  Active lactase release upon pH rise to pH 6.8 was not 
immediate, no lactase was released during the first 10 minutes and was only 
completely released after 30 minutes.  This release rate may not be rapid 
enough to prevent lactose persistence and fermentation.  A slow release rate 
has previously been reported for enteric coated pancreatin tablets and a 
reduction in dosage form size was found to be beneficial for faster release and 
greater alleviation of symptoms (Aloulou et al., 2008, Beverley et al., 1987, 
Naikwade et al., 2009).   
Eudragit L100 microparticles encapsulating lactase were produced using a 
slightly different method (Kendall et al., 2009) to those previously used to 
formulate lactase (Alavi et al., 2002, Squillante et al., 2003).   
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Smaller microparticles with an increased encapsulation efficiency and no loss of 
lactase activity were produced.  This method, previously used to encapsulate 
only low molecular weight drugs, demonstrated its suitability and superiority 
over previously used methods to encapsulate macromolecules, such as protein 
and peptide drugs. 
However, following pH shift dissolution from pH 1.2 to pH 6.8 there was no 
active lactase release.  It was thought this occurred due to lactase being burst 
released prematurely into the acid and destroyed.  At pH 4.5, below the pH 6 
threshold of the polymer, there was a burst release of 64% of the lactase.  To 
overcome this lactase was spray dried to reduce its particle size.  This reduced 
the burst release of lactase to 8% at pH 4.5 and fluorescently labelled spray 
dried lactase was shown to be encapsulated within the microparticles and not 
just at the surface.  However after dissolution initially in 0.1N HCl there was still 
no active lactase released.  More than 90% of the encapsulated lactase is not 
released below pH 6 so therefore the acid may be able to enter the 
microparticles.   
A marker encapsulated in the microparticles showed acid influx into the 
particles by a shift in its emission wavelength.  SEM images showed pores in 
some of the particles, which had not been sputter coated, which could explain 
the burst release of some of the encapsulated lactase.  However this doesn’t 
explain the complete loss of lactase activity.  Visualisation using an SEM with a 
new type of back scatter secondary electron detector and low voltage beam 
revealed small surface structures on the microparticles which disappeared upon 
acid incubation.  Currently it is not possible to determine the identity of these 
structures.  Possibly their disappearance in acid is linked to acid ingress.  
Visualisation of cryosections of the microparticles showed a porous interior 
which may provide a route by which acid can come into contact with 
encapsulated lactase. 
Surface area analysis of the microparticles suggested encapsulation of lactase 
increased their porosity.  The particles with non-spray dried lactase were more 
porous than those with spray dried lactase which may explain why more of this 
lactase was burst released in acid. 
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To neutralise acid entering the microparticles the antacids sodium bicarbonate 
and magnesium hydroxide were co-encapsulated with lactase in Eudragit L100 
microparticles.  This increased the size of the microparticles and, with 
magnesium hydroxide especially, caused aggregation of the microparticles.  
Sodium bicarbonate was only able to preserve 0.1% of the encapsulated 
lactase after dissolution in acid initially.  Magnesium hydroxide however was 
able to protect 9.2% of the encapsulated lactase.  It achieved this without 
neutralising the external acid demonstrating its potential as an oral delivery 
strategy that would not impair the acidic barrier of the stomach. 
The microparticles were also formulated in soy bean oil to limit acid influx.  
There was a 3.6% recovery of active lactase after dissolution from pH 1.2 to 
6.8.  This is more than for lactase alone in soybean oil.  Possibly this is because 
there are now two barriers between lactase and acid.  Additionally lactase is 
more hydrophilic than the Eudragit L100 microparticles so is more likely to 
partition from the protective oily phase into the acidic aqueous phase.   
Eudragit L100 microparticles with co-encapsulated magnesium hydroxide were 
superior in terms of active lactase preservation in simulated gastric conditions to 
the currently available Holland and Barrett lactase supplement and the other 
oral formulations tested.  However even this formulation only preserved 
approximately 9% of the activity of encapsulated lactase after dissolution in 
acid.  While this is significantly inferior to the protection offered by enteric 
tablets the benefits these microparticles offer in terms of rapid gastric emptying 
and enzyme release make them worth further development.  Future success of 
this Eudragit L100 microparticle formulation is dependent on overcoming or 
eliminating permeability to acid. 
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Chapter 3 
Investigation of the intestinal stability of insulin 
and development of is oral formulations 
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3.1 Introduction 
Chapter 2 investigated the intestinal stability and oral formulation strategies for 
a large protein, lactase.  This chapter will focus on the oral delivery of a small 
protein, insulin, that requires not only stabilisation in the intestinal tract but also 
permeation enhancement to elicit its therapeutic action.  As the timing and 
duration of insulin availability is vital to control glycemic excursions in diabetic 
patients following food ingestion oral delivery strategies will also have to provide 
a consistent and predictable insulin absorption.  This chapter will seek to 
analyse its intestinal stability comprehensively and use this information to 
produce an oral insulin formulation. 
Chapter 2 demonstrated that the release of a large protein, lactase, could be 
controlled in the gastrointestinal tract by encapsulation in enteric Eudragit L100 
microparticles.  The method used to produce these microparticles enabled a 
high encapsulation efficiency and did not impair lactase functionality.  These 
particles were not impermeable to the influx of acid so will need further 
development to protect acid labile protein and peptide drugs.  They may still be 
able to provide protection from intestinal enzymes.  Smaller proteins or peptides 
which lack the structural complexity of lactase may be more compatible with 
encapsulation in these microparticles as they may not be so affected by acid 
influx.   
3.1.1 Insulin structure and function 
Insulin is a peptide hormone of 5.8kDa consisting of 51 amino acids in two 
polypeptide chains, an A chain with 21 amino acids and B chain with 30 amino 
acids, figure 3.1.  Insulin was the first pure protein therapeutic molecule 
discovered, in 1922 (Khafagy el et al., 2007), and the first protein to have its 
sequence determined, in 1951. 
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A chain 
Gly-Ile-Val-Glu-Gln-Cys-Cys-Ala-Ser-Val-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn 
B Chain 
Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-
Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Ala 
Figure 3.1 Insulin sequence and structure 
The two polypeptide chains of insulin have alpha helical and beta pleated sheet 
secondary structures, visualized by x-ray diffraction, figure 3.2.  These are 
stabilized into a three dimensional, tertiary structure by three disulphide bridges 
and other interactions including Van der Waals forces.  Insulin is stored as an 
inactive hexamer held together by zinc ions and hydrophobic interactions.  It is 
broken down to its active monomeric form to exert its action. 
 
Figure 3.2 Computer simulation image based on X-ray diffraction of insulin 
(Timofeev et al., 2010) 
Insulin is produced in the pancreas and regulates carbohydrate and fat 
metabolism.  The binding of insulin to receptors causes cells in the liver, muscle 
and fat tissue to take up glucose from the blood and store it as glycogen 
maintaining blood glucose levels within very narrow limits, 70-110mg/dL for a 
fasting adult.  Higher than normal levels of blood glucose is known as 
hyperglycemia, lower than normal levels is known as hypoglycemia. 
S S 
S S 
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When the control of insulin on blood glucose levels fails it results in diabetes.  
This is characterized by persistent hyperglycemia and is life threatening.  Type 
1 diabetics no longer produce insulin and type 2 diabetes results from 
resistance of cells to insulin and insufficient insulin production by the pancreas.   
Type 1 diabetics rely on daily administration of exogenous insulin to reduce 
dangerously high blood glucose levels and stay alive.  It is estimated more than 
30 million people globally have type 1 diabetes.  Type 2 diabetics are not 
dependent on insulin but more than 40% use it to maintain blood glucose levels.  
The global insulin market was estimated to be worth approximately $12 billion in 
2011. 
3.1.2 Current administration of insulin 
Insulin is currently available only as an injectable in the US and Europe.  
Generally insulin is self administered subcutaneously, rarely intramuscularly or 
intravenously.  An insulin dosage regimen is tailored individually to suit 
particular diets and lifestyles.  There are various forms of insulin available with 
rapid, intermediate and long lasting action.  These forms can be used in 
combination to provide the best maintenance of blood glucose levels. 
The parenteral route is not ideal due to the stress, pain, non-compliance, risks 
and cost issues of injections.  The chronic nature of insulin injections for the 
treatment of diabetes can cause local hypertrophy and fat deposition at the 
injection site.  Insulin injections can also cause hyperinsulinemia, hypoglycemia 
and weight gain. 
Reformulation of insulin to provide alternative, non-parenteral medicines has 
been and continues to be a popular research topic due to the negatives 
associated with injections and the large number of users.  Recombinant DNA 
has aided this process as large amounts of insulin can now be made.  Pfizer, in 
collaboration with Nektar Therapeutics, delivered the first non parenteral insulin 
formulation to the EU and US market in 2006, Exubera, an inhaled form of 
insulin for pulmonary delivery.  However there was insufficient market uptake 
and withdrawal by Pfizer in 2007.  Its lack of acceptance may have been due to 
difficulties with accurate dosing and the need to still inject insulin to maintain a 
basal insulin level due to Exubera’s short action. 
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A buccally delivered insulin, Oral-lyn, which is administered into the mouth by a 
spray (RapidMist device) has been developed by Generex and is available for 
treatment of type 1 and 2 diabetes in some countries, including India, but not 
the US or Europe.  Insulin delivered by this system is absorbed from the buccal 
mucosa so does not have to overcome the delivery challenges of the GI tract. 
3.1.3 Oral insulin 
As well as the benefits of oral delivery over parenteral in terms of compliance, 
ease of use and costs oral delivery of insulin is advantageous as it is a more 
physiological delivery route than that by subcutaneous injection.  Orally 
delivered insulin would be absorbed from the GI tract into the portal vein, its 
delivery to the liver and binding to receptors there mimicking the normal 
physiologic route of insulin.  Orally delivered insulin may also reduce the risks of 
hypoglycemia seen with subcutaneously delivered insulin due to a reduced 
systemic exposure. 
Attempts at oral insulin delivery initiated by Dr Joslin soon after its discovery in 
1922 have been reported in oral insulin reviews (Heinemann and Jacques, 
2009, Kalra et al., 2010).  These trials had to be halted due to lack of metabolic 
control, possibly due to its low oral bioavailability.  Oral delivery of insulin may 
also pose some risks as it is a known mitogen.  Due to the frequency of insulin 
administration the effects of excipients of its oral formulations would also have 
to be considered. 
3.1.4 Barriers to oral delivery 
The oral bioavailability of insulin in rats was found to be less than 1% (Takeuchi 
et al., 1996, Tozaki et al., 2001).  This is a result of poor intestinal stability and 
permeability. 
Insulin was degraded in gastric conditions, only 0-10% remained intact after 5 
minutes incubation in simulated gastric fluid (SGF) with pepsin (Jain et al., 
2012, Han et al., 2012, Qi and Ping, 2004, Makhlof et al., 2011b) and was 
completely degraded in 3 minutes in gastric fluid from a pig (Werle et al., 2008).  
Insulin is soluble and stable in weak acids so it may not be the acidic pH of 
these fluids causing its degradation but pepsin as insulin contains several 
peptide bonds which would be vulnerable to pepsin digestion.   
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Insulin was also vulnerable to small intestinal enzymes.  Only 10% remained 
intact after two hours incubation in simulated intestinal fluid with pancreatin 
(Jain et al., 2012).  Of the three main luminally secreted intestinal enzymes 
insulin was most vulnerable to chymotrypsin and was completely degraded by it 
within 15 minutes (Werle et al., 2008).  Insulin was more stable with trypsin and 
elastase.  After three hours 92.5% of insulin remained intact with trypsin 
(Schilling and Mitra, 1991) and 35% remained intact with elastase (Werle et al., 
2008).  In porcine small intestinal fluids insulin was completely degraded within 
a few minutes due to the combined digestive effects of these enzymes (Werle et 
al., 2008). 
Despite the reduced proteolytic activity of the large intestine insulin was found 
to be vulnerable to degradation here.  It was degraded in rat cecal contents with 
a degradation half life of 34 minutes (Tozaki et al., 1997, Tozaki et al., 1995).  
Its degradation is due to microbial enzymes and fermentation.  Any oral insulin 
targeted to the colon would have to overcome this. 
The intestinal permeability of insulin is limited by its large size, limiting its 
paracellular uptake, and its hydrophilicity limiting its passive, transcellular 
transport.  Insulin absorption from the intestinal segments of a rat was found to 
be greatest from the ileum, then the duodenum and least from the jejunum (Han 
et al., 2012).  These differences in absorption may be due to reduced proteolytic 
activity in the ileum and the presence of M cells in Peyer’s patches which are a 
portal for macromolecule uptake.  The thick mucus covering the cells in the 
jejunum may have reduced insulin absorption. 
3.1.5 Oral insulin delivery strategies 
The oral delivery strategies described in chapter 1 have been widely explored 
for the oral delivery of insulin.  Representative examples of these strategies and 
their in vitro/in vivo effects are presented in table 3.1. 
While these strategies increased oral insulin pharmacological availability and 
efficacy compared to an insulin solution from negligible levels, their relative 
availabilities compared to subcutaneous insulin were less than 15% if used 
exclusively.   
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When strategies were combined, as with ligand attachment to insulin-loaded 
nanoparticles, oral insulin availability increased above 20% (Chalasani et al., 
2007, Petrus et al., 2007, Jain et al., 2012).   These strategies can disrupt 
normal digestive processes and possibly enable absorption of potentially 
harmful molecules so the long term effects of administering them chronically 
needs to be considered. 
3.1.6 Commercial oral insulin delivery 
Despite extensive research very few strategies have been tested in humans.   
Clinical data may not have been published due to the competitive nature of oral 
insulin formulation development.  The strategies that have progressed furthest 
clinically are those that have been or are being pursued by companies, table 
3.2.   
The oral insulin formulations that have progressed furthest clinically are those of 
Diabetology (Kalra et al., 2010, Luzio et al., 2010), Emisphere (Heise et al., 
2004), Biocon (Kalra et al., 2010, Khedkar et al., 2010), Oramed (Kidron et al., 
2008, Eldor et al., 2010a) and Diasome (Schwartz et al., 2008).  These 
strategies have demonstrated safety and tolerability in phase I and II clinical 
trials and increased insulin levels and reduced glucose levels in healthy, type 1 
or type 2 diabetic volunteers.  They produced relative bioavailabilities of 
between 5 and 10% relative to subcutaneous insulin and glucose reductions of 
7-55% (Kidron et al., 2008, Eldor et al., 2010a, Kalra et al., 2010, Khedkar et al., 
2010, Luzio et al., 2010, Heise et al., 2004).  The high number of discontinued 
projects is usually the result of poor metabolic control. 
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Table 3.1 Examples of delivery strategies tested in vitro and in vivo for the oral delivery of insulin 
Pharmacological availability (PA), relative to subcutaneous insulin 
1 (Agarwal et al., 2001), 2 (Tozaki et al., 1997), 3 (Morishita et al., 1993), 4 (Bai et al., 1996), 5 (Kraeling and Ritschel, 1992), 6 (Tozaki et 
al., 2001), 7 (Takeuchi et al., 1996), 8 (Zhang et al., 2012a), 9 (Wood et al., 2006), 10 (Wood et al., 2010), 11 (Zhang et al., 2012b), 12 
(Toorisaka et al., 2012), 13 (Niu et al., 2012), 14 (Sun et al., 2011a), 15 (Chalasani et al., 2007), 16 (Petrus et al., 2007), 17(Jain et al., 2012), 
18 (Niu et al., 2011), 19 (Cui et al., 2006b), 20 (Yang et al., 2012), 21 (Damge et al., 1997), 22 (Toorisaka et al., 2003), 23 (Sharma et al., 
2010) 
 
Enzyme 
inhibition 
Colon 
targeted 
delivery 
Mucoadhesion Permeation 
enhancers 
Ligand attachment Colloidal carriers 
Increased in vitro 
protection1-4 
 Increased in vitro 
mucoadhesion7-12 
  Increased in vitro protection 
and in vivo oral efficacy 
Lipsomes18, PLGA 
nanoparticles 7.6-12.7% oral 
PA, rats 8, 17, 19-20 , poly (alkyl 
cyanoacrylate) nancapsules21, 
emulsions22 , microemulsions23  
6.15% oral PA, 
rats5 
3.38-5.02% 
oral PA 
rats/dogs5-6 
Chitosan-  10.5% 
oral PA rats8 
Bile salts with 
liposomes13/ PLGA 
nanoparticles14 
~11% oral PA rats 
Vitamin B1215-16, 
folate17 attached to 
nanoparticles >20% 
oral PA rats 
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Company- oral insulin Delivery strategy Clinical stage 
Biocon- IN105 
(continuing work of Nobex 
Corporation) 
Insulin conjugation to amphiphilic oligomer alkylated-
PEG provides enzymatic protection, increased 
permeation. Permeation enhancer sodium caprate 
included in formulation 
Phase III –type 2 diabetics, failed to meet 
primary endpoint, 2011 
Phase I/II- type 2 diabetics  
Phase I- type 1 diabetics, 2011 
Oramed ORMD-0801 Protease inhibitor (eg aprotinin), omega-3 fatty acids 
for insulin preservation, EDTA absorption enhancer, 
tablet enteric coated with Eudragit L100 
Phase I/II- type 2 diabetics 
Phase I/II- type 1 diabetics, 2008 
 
Diabetology-Capsulin 
July 2012- partnership with USV 
Limited announced to develop for 
Indian market 
Axcess technology- absorption enhancer and 
solubiliser in enteric coated capsules 
Phase I/II- type 1 and 2 diabetics, 2005 
Emisphere Eligen technology- synthetic, non acylated amino acid 
carrier 4-CNAB used to expose hydrophobic residues 
of insulin enabling transcellular uptake 
Phase I/IIa- type 2 diabetics, discontinued 
with type 1 diabetics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2 Commercial insulin strategies past and present and their clinical testing status 
 
162 
 
Novo Nordisk and Merrion- 
NN1953 
Gastrointestinal permeation technology (GIPET), 
matrices of medium chain fatty acids to open 
paracellular channels loaded in enteric capsule  
Phase I-completed 2012, no results yet 
NOD Pharmaceuticals-Nodlin Bioadhesive nanoparticles Phase I- completed 2012, significant 
glucose response 
Oshadi Drug Administration Blend with inert silica nanoparticles and 
polysaccharide suspended in oil and loaded in enteric 
capsules 
Phase I- type 1 diabetics 2011 
Access Pharmaceuticals Insulin/insulin nanoparticles coupled to vitamin B12 
analog cobalamin 
Proof of principle in animal models 
NanoMega Medical Corporation Chitosan-γ-PGA nanoparticles Blood glucose reductions in rats 
Diasome Liposomes with hepatocyte targeting molecule Phase II/III-type 2 diabetics commenced 
2008- discontinued 
Provalis, Cortecs Ltd- Macrulin Water in oil microemulsion Phase II- type 2 diabetics- efficacy shown 
but discontinued 
Eli Lilly and AutoImmune-AI 401  Phase II- type 1 diabetics- delay disease 
onset, but no effect  on those less than 20 
years old, discontinued 
Apollo Life Sciences- Oradel Nanoparticles attached to vitamin B12 Phase I- discontinued 
Endorex Liposomes- orasomes Stable in vitro, discontinued 
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Only the formulations of Diasome and Biocon have reached phase III clinical 
trials.  The results of Diasome’s trials have not been reported and there has 
been no news of this project since 2009.  Biocon’s recent phase III trial with 
type 2 diabetics failed to meet its primary goal of lowering HbA1c levels by 0.7% 
relative to a placebo.  This is a marker of average plasma glucose levels over 
time.  It is thought this may not necessarily be due to a lack of efficacy but 
behavioural modifications of those taking the placebo.  It did however produce a 
statistical reduction in post prandial glucose levels and this project is still being 
pursued. 
High inter subject variability of insulin absorption has been commonly observed 
during clinical trials and been seen with the formulations of Biocon (Kalra et al., 
2010, Khedkar et al., 2010), Emisphere (Heise et al., 2004) and Diabetology 
(Whitelow et al., 2005).  This could result in inconsistent blood glucose control.  
This may be due to the inter-individual GI variability, intra individual variation in 
insulin absorption has not been explored. 
Necessarily to fulfil its function insulin must be administered usually before, 
rarely after, food.  Food ingestion hampered the oral efficacy of the formulations 
of Biocon (Khedkar et al., 2010), Emisphere and Diasome (Blair Geho et al., 
2009) increasing glycemic excursions.  Possibly they are delayed in the 
stomach where degradation may occur, if not enteric coated, and arrival in the 
small intestine is postponed.  Timing of administration, with regards food 
ingestion, should be optimised to minimise absorption delays but also to ensure 
it is present at therapeutic levels following a meal. 
Onset of insulin absorption and subsequent blood glucose reduction was 
affected by enteric coating.  Enteric coated formulations of Oramed and 
Diabetology had a much slower and prolonged insulin absorption and glucose 
reduction than the non-enteric formulations of Biocon and Emisphere.  This 
could be due to a gradual rather than immediate dissolution of the coating.  
Insulin levels increased following administration of the enteric formulations 80 to 
250 minutes post dosing and glucose levels were still reducing after seven 
hours (Kidron et al., 2008, Eldor et al., 2010a, Kidron et al., 2009, Whitelow et 
al., 2005).   
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In contrast insulin absorption and glucose reduction for the non-enteric 
formulations was rapid reaching maximum levels 20 to 50 minutes post dosing 
and only lasting for 80 minutes, possibly due to their lack of enzyme protection 
(Khedkar et al., 2010, Kidron et al., 2004, Kapitza et al., 2010). 
Enteric coated formulations will be able to maintain a basal level of insulin over 
a longer period but prandial glucose control may be hampered due to its slow 
absorption.  Additionally its sustained effects may cause late post prandial 
hypoglycaemia.  Non-enteric formulations may provide better, faster control of 
post prandial glycemia but their short duration may necessitate the use of a 
longer acting insulin to maintain basal levels.   
Despite the progress which has been made with oral insulin delivery strategies, 
on average, their relative biopotency compared to subcutaneous insulin is 
approximately 10%.  Therefore 10 times as much insulin would have to be 
administered orally to have the same effect as a subcutaneous dose, incurring 
higher costs.   
3.1.7 Enteric multiparticulates 
Insulin encapsulation in enteric micro or nanoparticles can provide protection 
from pepsin and a more prolonged glucose reduction than non-enteric 
formulations reducing the need for additional insulin.  Their small size will allow 
them to be suspended in gastric fluids, unlike larger dosage forms, enabling 
reliable, fast and uniform gastric emptying.  Enteric tablets/capsules are more 
affected by the presence of food than smaller dosage forms (Al-Habet and 
Rogers, 1989, Adair et al., 1992).  Their increased surface area also enables 
rapid drug release. This could reduce the delay and variability in insulin 
absorption found with enteric capsules or tablets and lessen the risk of late post 
prandial hypoglycaemia.   
3.1.7.1 In vitro testing 
Enteric polymers, used to coat or form micro and nanoparticulates, have 
restricted insulin release to less than 25%, in vitro, in acidic conditions, table 
3.3, however their ability to protect insulin from pepsin digestion was only tested 
in a few cases.   
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Table 3.3 Insulin release from enteric micro/nanoparticulates in acid and at small intestinal pH, and its protection from pepsin 
 
HPMCP/HP55= hydroxypropylmethylcellulose phthalate 
1 (Makhlof et al., 2011b), 2 (Wu et al., 2012b), 3 (Sonaje et al., 2010a), 4 (Cui et al., 2007), 5 (Wu et al., 2012a), 6 (Zhang et al., 2012b),        
7 (Naha et al., 2008), 8 (Sonia and Sharma, 2012), 9 (Mundargi et al., 2011a), 10 (Jain et al., 2006), 11 (Jain et al., 2005), 12 (Agarwal et al., 
2008), 13 (Han et al., 2012), 14 (Sajeesh and Sharma, 2010), 15 (Sajeesh et al., 2010), 16 (Carr and Peppas, 2010), 17 (Wood et al., 2006), 
18 (Sonaje et al., 2010b), 19 (Lin et al., 2007), 20 (Lin et al., 2008), 21 (Ubaidulla et al., 2007a), 22 (Ubaidulla et al., 2007b)
Enteric formulation Acid release (%) Pepsin protection  
(% degraded) 
Release at small 
intestinal pH (%) 
HPMCP/HP55 (nanoparticles) <20% 2 hours1-5 70% 2 hours1 60-85% 2 hours4-5 
Eudragit L100/S100/L30D (nanoparticles, microparticles) <20% 2 hours6-11  Up to 55-90% 2 hours6-
7, 9-12  
Hyaluronic acid nanoparticles <10% 2 hours13 55% 2 hours13 80% 2 hours13 
Poly (methacrylic acid) complexation hydrogel microparticles <20% 2 hours14-17  60-90% 2 hours14-15, 17 
Chitosan-poly(γ-glutamic acid) (γ-PGA) nanoparticles <25% 2 hours3, 18-20  75-85% 2 hours18-20 
Chitosan phthalate microspheres 20%, 2 hours21-22 12% 2 hours21-22 Up to 55% 2 hours21-22 
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Results showed a disparity between the proportion of encapsulated insulin 
released in acid and the proportion protected from pepsin.  HPMCP cross-linked 
chitosan nanoparticles prevented 85% of insulin release at pH 1.2 in two hours, 
however only 30% remained intact after the same period with pepsin (Makhlof 
et al., 2011b).  Similar results were found with hyaluronic acid nanoparticles 
which prevented >90% of insulin release at pH 1.2 in two hours but only 
protected 45% with pepsin (Han et al., 2012).  Although insulin was not 
released from the particles pepsin was still able to digest it.  It seems unlikely 
that pepsin was able to penetrate into the particles as it is a large protein, 
35kDa, and the release of the smaller insulin, 5.8kDa, was restricted.  Insulin 
may have been present at or near the surface of the particles and therefore 
pepsin was able to digest it. 
The only formulation that provided comparable insulin release in acid and 
protection from pepsin were the chitosan phthalate microspheres (Ubaidulla et 
al., 2007a, Ubaidulla et al., 2007b).  Approximately 20% of encapsulated insulin 
was released at pH 2 and 88% was protected from pepsin digestion.  In this 
study only 47% of unprotected insulin was degraded with pepsin in two hours 
which is a surprisingly high figure compared to other studies where it was 
rapidly degraded (Jain et al., 2012, Han et al., 2012, Makhlof et al., 2011b, Qi 
and Ping, 2004).  The source of pepsin, its concentration or experimental 
conditions may not comparable to other studies and the protection of insulin 
should be viewed considering this. 
Release at the threshold pH of the enteric formulations was greater than 55% 
within two hours in all cases.  Insulin release from nanoparticles loaded in 
enteric coated capsules was slower, 50-68% released over four hours (Wu et 
al., 2012b, Sonaje et al., 2010a).  This implies insulin absorption may be faster 
in vivo from enteric micro and nanoparticles than enteric capsules or tablets.   
3.1.7.2 In vivo testing 
When orally administered to rats or rabbits enteric micro/nanoparticles enabled 
insulin absorption and blood glucose reduction, table 3.4, insulin solutions had a 
negligible effect.   
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Table 3.4 In vivo glucose reduction and pharmacological availability, relative to subcutaneous (sc) insulin, of orally administered insulin 
loaded enteric micro/nanoparticles in rats/rabbits 
 
1 (Wu et al., 2012a), 2 (Makhlof et al., 2011b), 3 (Cui et al., 2007), 4 (Wu et al., 2012b), 5 (Naha et al., 2008), 6 (Mundargi et al., 2011a),         
7 (Zhang et al., 2012b), 8 (Jain et al., 2005), 9 (Han et al., 2012), 10 (Sajeesh et al., 2010), 11 (Lin et al., 2007), 12 (Sonaje et al., 2010b),        
13 (Ubaidulla et al., 2007a)
Enteric formulation T max for glucose 
reduction 
Duration of glucose 
reduction 
Pharmacological 
availability (%) 
HPMCP/HP55 nanoparticles 3-12 hours1-3 24 hours1-2 6.27-11.3%1-4 
Eudragit L100/S100/L30D (nanoparticles, microparticles) 2-4 hours5-8 3-8 hours6-8 2.65%7 
Hyaluronic acid nanoparticles 7 hours9 8 hours9  
Poly(methacrylic acid) complexation hydrogel microparticles 2 hours10 10 hours10 2.45%10 
Chitosan-γ-PGA nanoparticles 5-6 hours11-12 10-24hours11-12 16%12 
Chitosan phthalate microspheres 5 hours13 20 hours13 18.66%13 
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They may have increased insulin availability by limiting its release in the 
stomach, minimising degradation.  Duration of glucose reduction and insulin 
pharmacological availability may be underestimated as some of these 
experiments were halted before glucose levels returned to basal levels.  The 
anticipated faster glucose response and shortened period of glucose lowering 
by administering enteric multiparticulates rather than larger capsules or tablets 
was not observed, table 3.4.  The fastest glucose response was produced by 
the poly(methacrylic) acid hydrogel and Eudragit particles.  Maximum glucose 
reductions occurred two to four hours post dosing which is comparable to the 
enteric capsules and tablets of Oramed and Diabetology (Kidron et al., 2008, 
Eldor et al., 2010a, Kidron et al., 2009, Whitelow et al., 2005).  Possibly the 
particulates aggregated delaying dissolution.   
Eudragit nano/microparticles restricted insulin release in vitro in acid and 
released up to 90% encapsulated insulin upon pH rise.  Of the enteric 
multiparticulate formulations tested they offer the best potential for protection, 
faster glucose reduction and shortened period of glucose reduction.  However, 
these particles had lower insulin pharmacological availabilities than some of the 
other formulations, particularly those with chitosan (Makhlof et al., 2011b, 
Sonaje et al., 2010b, Ubaidulla et al., 2007a).  Chitosan can increase 
mucoadhesion and paracellular absorption.  Enteric protection alone may not be 
sufficient for acceptable oral insulin pharmacological availability but additional 
excipients can increase this. 
3.1.7.3 Methods of production 
As the methods used to produce enteric multiparticulates often entail the use of 
solvents and high shear forces there is a risk of denaturing insulin during its 
encapsulation.  Their more complex formation, compared to enteric coating of 
capsules or tablets, may explain why they have not been popular so far with 
companies.  The ideal method should be simple and use the least damaging 
parameters possible. 
The majority of enteric nano/microparticles are produced using a water in oil in 
water (w/o/w) double emulsion solvent evaporation method.   
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This involves potentially damaging solvents such as dichloromethane (DCM), 
and using sonication, homogenisation, centrifugation and lyophilisation (Wu et 
al., 2012a, Cui et al., 2007).   
Eudragit L100 and S100 particles encapsulating insulin have been formed by 
double emulsion solvent evaporation (Mundargi et al., 2011a, Jain et al., 2005, 
Jain et al., 2006) and oil in oil (o/o) emulsion solvent evaporation (Morishita et 
al., 1993).  The advantages of the o/o method over the double emulsion method 
were the use of less toxic ethanol to dissolve the polymer and no 
homogenisation.  Insulin encapsulation in HPMCP microspheres was increased 
from 30 to 70% by the o/o method (Qi and Ping, 2004).  Hydrophilic insulin may 
have escaped encapsulation by migration to the outer aqueous phase in the 
w/o/w method whereas this is not possible for the o/o method.  In vitro insulin 
release in acid was reduced from 20% to nothing and insulin recovery increased 
from 40% to 80% with pepsin when encapsulated by the o/o method.  More 
insulin may be present at the surface of the w/o/w produced microparticles due 
to its localisation at the oil water interface.  Insulin loaded particles produced by 
the o/o method significantly reduced glucose levels when orally administered to 
rats, those produced by the w/o/w method had a weak effect.   
In chapter 2 the o/o emulsion solvent evaporation method of Kendall et al. was 
used to encapsulate the large protein, lactase, in enteric Eudragit L100 
microparticles (Kendall et al., 2009).  Uniformly sized particles of <100µm with 
high yields, >90%, and encapsulation efficiencies, >80%, were formed.  Lactase 
activity was not impaired using this method demonstrating its suitability for 
protein encapsulation.  Spray dried lactase release in acid was restricted by the 
particles although they were possibly permeable to acid.  Insulin needs 
protection from pepsin, which these particles could provide, and as it is soluble 
and active in weak acids may not be as vulnerable to any incoming acid.  This 
method is simpler than a w/o/w method and avoids the use of potentially 
damaging homogenization, centrifugation or lyophilisation.  These 
microparticles may be able to provide a more rapid and uniform small intestinal 
release and faster insulin absorption than larger enteric coated dosage forms.  
They also offer the potential to minimize the variability and food effects on 
insulin absorption. 
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3.2 Aims 
 To model the stability of insulin throughout the gastrointestinal tract using 
simulated and porcine gastrointestinal fluids and human faecal fluids; 
o To use this knowledge for rational design of oral insulin delivery 
vehicles  
o To gain an insight into the oral stability of small proteins  
 To produce oral insulin formulations which have the potential ; 
o To protect insulin from identified intestinal stability challenges 
o To minimise insulin absorption variability and vulnerability to food 
effects seen with clinically trialled insulin formulations 
o To provide sufficiently rapid post prandial glucose control 
o To prolong insulin absorption enough to not require administration 
of additional insulin 
o To not prolong glucose reduction for so long post prandially that 
hypoglycaemia occurs 
 To formulate insulin using parameters which are least potentially 
damaging to insulin integrity and most conducive for the desired release 
characteristics 
 Assessment of oral insulin formulations 
o To characterise them in terms of physical characteristics (size, 
polydispersity, morphology), loading and encapsulation efficiency 
o To assess their in vitro insulin release and ability to protect insulin 
3.3 Materials 
Human recombinant insulin, pepsin from porcine gastric mucosa, 469 units/mg 
solid, 924 units/mg protein, pancreatin from porcine pancreas, activity at least 
3x USP specifications and trifluoroacetic acid were from Sigma Aldrich.  
Hydrochloric Acid 37%, specific gravity 1.18, was from BDH.  Acetonitrile HPLC 
grade and sodium hydroxide were from Fisher Scientific.  Pig gastric and 
intestinal fluids were from freshly slaughtered pigs and were immediately frozen 
and stored at -80oC.  Human faecal fluids were from healthy individuals not 
taking antibiotics. 
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Faecal basal media materials:  Bacteriological peptone and yeast extract were 
from Oxoid.  Sodium chloride, L-cysteine hydrochloride, vitamin K, resazurin 
sodium salt and sodium hydroxide were from Fisher Scientific.  Dipotassium 
hydrogen orthophosphate and magnesium sulphate 7-hydrate were from BDH.  
Calcium chloride dihydrate was from VWR.  NaHCO3 and haemin were from 
Sigma Aldrich.   Bile salts were from Fluka Analytical.  Tween 80 was from 
Fluka Chemika. 
Eudragit L100 was a gift from Degussa/ Evonik (Darmstadt, Germany), sorbitan 
sesquioleate (Alacel 83), monobasic potassium phosphate and phosphate 
buffered saline tablets (PBS) were from Sigma Aldrich.  Liquid paraffin BP was 
supplied by JM Loveridge Plc.  Sodium phosphate, tribasic, anhydrous was 
from Alfa Aesar.  n-hexane and citric acid were from Fisher Scientific.  Ethanol, 
96% v/v was from BDH.   
3.4 Methods 
3.4.1 Insulin intestinal stability 
400µl of a 2mg/ml insulin solution (prepared in 0.001N HCl) was added to 1.6ml 
of simulated gastric fluid (SGF) with and without pepsin and simulated intestinal 
fluid (SIF) with and without pancreatin (final insulin concentration of 0.4mg/ml).  
These were placed in a Gallenkamp shaking incubator at 37°C and agitated at 
100rpm.  Samples (0.15ml) were removed after 0, 15, 30, 60, 90 and 120 
minutes and added to either 0.45ml 0.002M NaOH to raise the pH of acidic 
fluids or 0.01N HCl to lower the pH of small intestinal fluids to halt the reaction 
(final insulin concentration 0.1mg/ml).  These samples were analysed for insulin 
content using HPLC.  SGF and SIF were prepared as described in chapter 2, 
section 2.4.2.   
400μl of a 2mg/ml insulin solution was added to 1.6ml of gastric (pH 3.62), 
duodenal (pH 6.77), jejunal (pH 6.94), ileal (pH 7.48) and descending colonic 
fluids (pH 7.4) from a pig, giving a final insulin concentration of 0.4mg/ml.  The 
intestinal contents were centrifuged at 10,000rpm for 10 minutes and the 
supernatants used to test stability.  These mixtures were placed in a 
Gallenkamp shaking incubator using the parameters used for the simulated 
intestinal fluids.   
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Samples (0.15ml) were removed after 0, 15, 30, 60, 90 and 120 minutes and 
added to either 0.45ml 0.002M NaOH to raise the pH of acidic fluids or 0.01N 
HCl to lower the pH of small and large intestinal fluids to halt the reaction (final 
insulin concentration 0.1mg/ml).  These samples were then filtered and 
analysed for insulin content using HPLC.  
400µl of a 2mg/ml insulin solution was added to 1.6ml of human faecal slurry 
and placed in a Gallenkamp shaking incubator using the parameters used in the 
previous tests (final insulin concentration 0.4mg/ml). Samples (0.15ml) were 
removed after 0, 15, 30, 60, 90 and 120 minutes and added to 0.45ml 0.01N 
HCl to lower the pH to halt the reaction (final insulin concentration 0.1mg/ml).  
These samples were centrifuged at 10,000rpm for 10 minutes and the 
supernatants analysed for insulin content using HPLC.  The human faecal slurry 
was prepared as described in chapter 2, section 2.4.2.1. 
Insulin recovery in the withdrawn samples was calculated using the equation 
below.  The theoretical concentration of the sample is the concentration of 
insulin assuming 100% recovery.  This value was calculated with respect to 
changes in the sample volume during the course of the experiments. 
Insulin recovered (%)=
                                      
                                         
x100 
3.4.2 HPLC method 
Samples were run in a mobile phase of 0.1% (v/v) trifluoroacetic acid in water 
and 0.1% trifluoroacetic acid in acetonitrile (30-60%) at 40°C over a run time of 
23 minutes at a flow rate of 1ml/min.  20µl samples were injected onto and 
separated with a Discovery 300°A C18 column and detected at 210nm. 
3.4.3 Eudragit L100 microparticle preparation 
This method is based on that of Kendall et al. with the substitution of 
prednisolone for insulin. Eudragit L100 (300mg) was dissolved in ethanol (3ml).  
Recombinant human insulin (5mg) was suspended in the ethanol to prepare 
microparticles with a drug to polymer weight ratio of 1:60 and stirred for at least 
30 minutes.  This suspension of insulin in Eudragit L100 solution was emulsified 
into liquid paraffin (20ml) containing 1% (w/w) of sorbitan sesquioleate (Arlacel 
83) as an emulsifying agent, using a Heidolph RZR1 stirrer at 1500rpm.   
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Stirring was carried out for 18 hours at room temperature to allow solvent 
evaporation and particle solidification.  The microparticles formed were 
recovered by vacuum filtration through a Pyrex sintered glass filter (pore size 4; 
5-15μm) and washed three times with n-hexane (50ml).  Blank microparticles 
containing no insulin were also prepared using the same parameters.  All 
microparticle formulations were prepared in triplicate. 
The particle size and yield were determined as described in chapter 2, section 
2.4.6.1.  The morphology and size of the microparticles were examined by 
scanning electron microscopy (SEM) (Philips XL30, Eindhoven, Holland) with 
routine, high vacuum imaging at 5kV  as described in chapter 2, section 2.4.6.2. 
3.4.4  Encapsulation efficiency and insulin loading 
Microparticles with encapsulated insulin (20mg) were added to 1ml pH 6.8±0.05 
phosphate buffer, in triplicate, and placed in a Gallenkamp shaking incubator at 
100rpm, 37°C for 45 minutes to determine insulin encapsulation efficiency and 
loading.  After 45 minutes samples were centrifuged at 10,000rpm for 10 
minutes and 0.15ml of the supernatant added to 0.45ml 0.01N HCl to solubilise 
insulin.  This was analysed for insulin content using HPLC.  Drug loading was 
determined by measuring the μgs of insulin per mg of microparticles.  
Encapsulation efficiency was calculated using the equation below.  The total 
amount of insulin added was the initial insulin added during formation of the 
microparticles. 
Encapsulation efficiency (%) =
                                               
                                  
 x100 
3.4.5 In vitro insulin release 
To determine if the microparticles were able to protect insulin in gastric 
conditions they (20mg) were added to 0.75ml SGF, pH 1.2±0.05, with and 
without pepsin and placed in a Gallenkamp shaking incubator at 100rpm, 37°C 
for 2 hours.  Samples with SGF alone were centrifuged and 0.5ml of 
supernatant removed and analysed for burst released insulin by HPLC.  0.5ml 
of SGF without pepsin was added to replace the withdrawn sample. After 2 
hours 0.25ml of tribasic sodium phosphate was added to all samples to 
increase the pH to 6.8±0.05.   
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Samples were replaced in the shaking incubator and the experiment continued 
for a further 45 minutes.  Samples were centrifuged for 10 minutes at 
10,000rpm and 0.15ml of the supernatants added to 0.45ml 0.01N HCl to stop 
the reaction.  The samples were analysed for insulin release using HPLC.  All 
tests were carried out in triplicate. 
Insulin microparticles (20mg) were added to 1ml of pig gastric fluid and placed 
in a Gallenkamp shaking incubator for 2 hours at 100rpm, 37°C.  After this 
period samples were centrifuged at 10,000rpm for 10 minutes and the 
supernatants discarded.  The microparticles were resuspended in pH 6.8±0.05 
phosphate buffer and replaced in the shaking incubator for a further 45 minutes.  
Samples were again centrifuged using the same parameters.  0.15ml of the 
supernatant was added to 0.45ml 0.01N HCl to halt the reaction and this was 
analysed for insulin content by HPLC. 
Insulin release was calculated using the equation below.  The theoretical insulin 
concentration is the insulin concentration expected if it was all released. 
Insulin release (%)=
                                      
                                         
x100 
3.4.6 Stability testing of insulin with citric acid  
0.2ml of insulin solution (2mg/ml in 0.001N HCl) and 2mg of citric acid were 
added to 1ml of SIF with pancreatin.  This was placed in a Gallenkamp shaking 
incubator at 100rpm, 37°C for 30 minutes.  The pH was measured (pH 4) and 
the sample analysed for insulin content by HPLC.  Insulin recovery was 
calculated using the equation below.  The theoretical insulin concentration is the 
concentration of insulin expected if all was recovered. 
Insulin recovered (%)=
                                       
                                         
x100 
3.4.7 Eudragit L100 microparticles with citric acid 
This method is based on that of Kendall et al. with the addition of citric acid to 
the polymer and insulin suspension.  Eudragit L100 (300mg) was dissolved in 
ethanol (3ml).  Citric acid (100mg or 30mg) was added to this solution. 
Recombinant human insulin (5mg) was suspended in this and stirred for at least 
30 minutes.  Microparticle production and harvest were carried out as before.  
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Blank microparticles containing no insulin were also prepared using the same 
parameters.  All microparticle formulations were prepared in triplicate.  The yield 
was calculated as described in chapter 2, section 2.4.6.1, and morphology of 
the microparticles was visualized using SEM as before. 
The microparticles (20mg) containing 30mg citric acid, in triplicate, were placed 
in 1ml SIF without pancreatin or 1ml SGF with pepsin for 2 hours in a 
Gallenkamp shaking incubator at 37°C, 100rpm.  The SGF samples were 
centrifuged at 10,000rpm for 10 minutes and the supernatants discarded.  
Microparticles were resuspended in either SIF without pancreatin or SIF with 
pancreatin and replaced in the shaking incubator using the same parameters for 
a further 45 minutes.  Samples were centrifuged again using the same 
parameters and 0.15ml of the supernatants added to 0.45ml 0.01N HCl to halt 
the reaction.  These samples were analysed for insulin content using HPLC.  
Insulin release was calculated using the equation in section 3.4.6.  The pH of 
the samples was measured at the completion of the experiment. 
3.5 Results  
3.5.1 Insulin intestinal stability 
Incubation of insulin in SGF and SIF without enzymes for two hours resulted in 
almost complete intact insulin recovery, table 3.5, figure 3.3.  This suggests 
insulin primary structure is stable at gastric pH, pH 1.2, and small intestinal pH, 
pH 6.8.  The disulphide bonds which hold the A and B chains of insulin together 
appear not to break at this pH and therefore the structure remains intact.  This 
stability at low pH has previously been demonstrated during a study assessing 
the crystalline structure of insulin (Whittingham et al., 2002).  There were some 
conformational changes at low pH compared to neutral pH but the most 
important dimer forming contacts were preserved.  This may be due to the 
stability of the disulphide bridges and the lack of critical salt bridges which 
would be weakened by protonation.  However with enzymes, pepsin and 
pancreatin, insulin was immediately and completely degraded, figure 3.3.  
Previously insulin was completely degraded within 5 minutes with pepsin 
(Makhlof et al., 2011b) and 90% degraded with pancreatin (Jain et al., 2012).  
Insulin contains peptide bonds susceptible to pepsin and small intestinal 
enzymes resulting in this rapid digestion.   
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Table 3.5 Insulin recovery in SGF, without pepsin, and SIF, without pancreatin.  
Data represents means ± SD. 
Sample (min) Insulin recovered (%) SGF Insulin recovered (%) SIF 
0 95.0 ± 4.9 87.2 ± 9.9 
15 96.4 ± 9.4 99.1 ± 5.3 
30 91.5 ± 4.2 94.0 ± 2.8 
60 94.6 ± 10.2 94.7 ± 3.3 
90 93.5 ± 7.9 96.6 ± 1.8 
120 88.4 ± 7.7 90.9 ± 1.3 
 
Insulin susceptibility to gastric and small intestinal enzymes was also shown in 
porcine GI fluids.  Incubation in porcine gastric and small intestinal fluids, 
duodenal, jejunal and ileal, resulted in an immediate and complete degradation 
of insulin, figure 3.3.  These results are in agreement with previous studies 
which reported complete insulin digestion upon addition to porcine gastric and 
small intestinal fluids within 3 minutes (Werle et al., 2008).   
Immediate and complete degradation of insulin also occurred when it was 
incubated in porcine colonic and human faecal fluids, figure 3.3.  Insulin was 
more stable in rat cecal contents with a half life of 34 minutes (Tozaki et al., 
1997, Tozaki et al., 1995).  The cecum is at the beginning of the large intestine 
whereas the porcine colonic fluids were from the descending colon and the 
human faecal fluids have been expelled from the colon.  These fluids may 
therefore contain different or a higher concentration of bacteria which can 
mediate insulin degradation. 
This investigation of intestinal stability has shown that insulin is vulnerable to 
enzymatic degradation throughout the GI tract.  Further testing in human 
intestinal fluids may give a more accurate prediction of oral insulin degradation 
in vivo. 
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Figure 3.3 Insulin recovery following incubation in simulated gastric and 
intestinal fluids with and without enzymes, porcine small intestinal and colonic 
fluids and human faecal fluids.  Error bars show mean ± SD. 
3.5.2 Eudragit L100 microparticles 
For successful oral delivery of insulin, based on the intestinal stability results, 
protection from gastric and intestinal enzymes is essential.  The first enzymatic 
barrier to overcome is pepsin in the stomach.  Enteric strategies have therefore 
been selected for many oral insulin formulations.   
Some of the commercial oral insulin formulations clinically trialled have 
displayed variability (Kalra et al., 2010, Khedkar et al., 2010, Heise et al., 2004, 
Whitelow et al., 2005) in insulin absorption and vulnerability to disruption of 
absorption by food (Khedkar et al., 2010, Blair Geho et al., 2009).  The non-
enteric formulations of Biocon and Emsiphere (Khedkar et al., 2010, Kidron et 
al., 2004, Kapitza et al., 2010) have demonstrated rapid but short lasting 
glucose control, possibly due to lack of enteric protection which may necessitate 
the use of additional basal insulin.  The enteric coated capsule and tablet 
formulations of Diabetology and Oramed exhibited a delayed and prolonged 
glucose reduction in clinical trials which may risk late post prandial 
hypoglycaemia (Kidron et al., 2008, Eldor et al., 2010a, Kidron et al., 2009, 
Whitelow et al., 2005).   
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Enteric micro/nanoparticles may provide solutions to these problems.  Due to 
their small size they offer a faster and more uniform gastric release than larger 
dosage forms (Naikwade et al., 2009, Beverley et al., 1987) potentially enabling 
insulin formulations to overcome the variability in absorption previously seen in 
clinical trials.  Their small size may also reduce the effects of food on insulin 
absorption which can affect larger dosage forms.  They could offer a better 
prandial glucose control than enteric capsules and tablets, while still providing 
gastric protection, and a more prolonged control of glucose than the non-enteric 
forms.  Their more immediate insulin release, due to increased surface area, 
should lessen the risk of late post prandial hypoglycaemia compared to larger 
enteric dosages.   
Insulin loaded, enteric, Eudragit micro and nanoparticles were able, in previous 
studies, to restrict insulin release in acid, therefore offering protection from 
pepsin digestion (Zhang et al., 2012b, Naha et al., 2008, Sonia and Sharma, 
2012, Mundargi et al., 2011a, Jain et al., 2006, Jain et al., 2005).  In vivo they 
generally caused a faster maximum glucose reduction than other enteric 
micro/nanoparticles offering a better opportunity for controlling prandial 
glycemic excursions (Naha et al., 2008, Mundargi et al., 2011a, Zhang et al., 
2012b, Jain et al., 2005).  While the glucose response was no faster than that 
produced by larger, enteric coated capsules and tablets in clinical trials these 
particles offer the best potential for reducing the delay in insulin absorption.  
They were therefore selected for formulating insulin. 
Chapter 2 showed Eudragit L100 microparticles can prevent the release of an 
encapsulated protein but are not impermeable to acid.  As the primary structure 
of insulin is stable in acid, demonstrated in the intestinal stability studies, this 
may not be a problem.  Pepsin is a large enzyme, 35kDa, and therefore is 
unlikely to be able to permeate the microparticles and destroy the encapsulated 
insulin.  Therefore they were selected as a delivery strategy to protect insulin 
from pepsin.   
The method selected to produce insulin loaded Eudragit L100 microparticles 
was based on that of Kendall et al.   
 
179 
 
This o/o emulsion solvent evaporation method was selected due to its lack of 
potentially harmful solvents, such as DCM, and high shear processes such as 
homogenisation or sonication which could damage insulin.  Other advantages of 
using an o/o  method rather than w/o/w include a reduced risk of hydrophilic 
insulin migrating to an outer aqueous phase, reducing its encapsulation and 
leaving it vulnerable on the surface of the particles to premature gastric release 
and pepsin digestion (Qi and Ping, 2004). 
The microparticles had a dv,0.5 less than 100μm and a span less than 2.5, 
table 3.6.  SEM images show that most of the microparticles are actually 
smaller than 40μm, spherical and uniformly sized, figure 3.4.  The dv,0.5 
determined by the Mastersizer is larger than this possibly due to being skewed 
by a few much larger particles, as seen in figure 3.4 (a).  The particles are much 
smaller than those  previously produced using an o/o method which were 300-
500µm, possibly due to the use of the sorbitan sesquioleate surfactant 
(Morishita et al., 1993).  The particle size of insulin loaded Eudragit L100/S100 
microparticles produced using high speed homogenisation were between 4-
70µm.  This method has managed to produce particles of a comparable size but 
without potentially damaging high shear homogenisation (Mundargi et al., 
2011a, Jain et al., 2005, Jain et al., 2006).   
Table 3.6 Size, span, insulin loading, encapsulation efficiency and yield of 
Eudragit L100 microparticles with encapsulated insulin.  Data represents  
means ± SD. 
Microparticles 
Size 
(μm) Span  
Insulin 
loading 
(µg/mg) 
Encapsulation 
efficiency (%) 
Yield 
(%) 
Insulin: 
Eudragit L100 
90.85 ± 
17.55 
2.09 ± 
0.21 11.83 ± 2.07 72.2 ± 12.6 
78.4 ± 
5.6 
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Figure 3.4 (a) & (b) SEM images of Eudragit L100 microparticles with 
encapsulated insulin 
There was a high yield, >75%, and encapsulation efficiency, >70%, table 3.6.  
Insulin encapsulation efficiency was slightly lower than with the w/o/w double 
emulsion method, 82-85% (Jain et al., 2005, Jain et al., 2006), and the 
previously used o/o method, 80% (Morishita et al., 1993).  The encapsulation 
efficiency had a high standard deviation and some of the batches actually had 
an insulin encapsulation efficiency >80%.  The small batch size may be 
responsible for this variability and higher proportional insulin losses by 
attachment to glassware and stirrers.  The yield and encapsulation efficiency 
were also lower than those produced by Kendall et al. with prednisolone, 
possibly due to scaling down the amounts of excipients. 
These results show this is a suitable method for encapsulating insulin within 
enteric microparticles.  The microparticles produced are micron sized, spherical 
and mainly uniform which should enable their rapid and uniform gastric 
emptying, small intestinal dissolution and insulin release.  There is a high yield 
which is beneficial when working with expensive and small amounts of peptide 
and protein drugs.  The encapsulation efficiency is high demonstrating insulin 
has not been degraded by the microparticle production process.   
3.5.2.1 In vitro insulin release 
The ability of the microparticles to prevent insulin release in gastric conditions 
and protect insulin from pepsin degradation was investigated.   
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The microparticles were immersed in SGF without pepsin, SGF with pepsin and 
porcine gastric fluid for two hours.  Insulin release during this period could only 
be assessed in the SGF without pepsin as in the other media any insulin 
released would be degraded and not quantifiable.  There was a burst release of 
28% of the insulin during this period, table 3.7, figure 3.5.  This may be due to 
instant release of insulin located near the surface of the microparticles.  This 
does not fulfil the USP (724) requirements for an enteric dosage form which 
state, on average, no more than 10% of the drug load should be released in 
acid.  The release of insulin from these particles in acid is also greater than from 
previously tested Eudragit nano/microparticles, which released <20% (Zhang et 
al., 2012b, Naha et al., 2008, Sonia and Sharma, 2012, Mundargi et al., 2011a, 
Jain et al., 2006, Jain et al., 2005).   This may be due to a sub-optimal ratio of 
enteric polymer to insulin therefore not preventing all insulin release at low pH.  
To increase the enteric protection the amount of Eudragit L100 could be 
increased, or a reduction in stirring speed or sorbitan sesquioleate may allow 
larger particles to form which would provide more protection. 
Table 3.7 Intact insulin release from Eudragit L100 microparticles after 2 hours 
in SGF with and without pepsin and porcine gastric fluid followed by pH rise to 
pH 6.8.  Data represent means ± SD. 
Incubation media 
Insulin release 120 
minutes (%) 
Insulin release 165 
minutes (%) 
SGF to pH 6.8 28.3 ± 3.0 114.1 ± 29.4 
SGF and pepsin to pH 6.8 - 79.7 ± 12.5 
Pig gastric fluid to pH 6.8 - 48.8 ± 9.3 
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Figure 3.5 Insulin release from Eudragit L100 microparticles after incubation for 
2 hours in SGF without pepsin followed by a pH rise to pH 6.8.  Error bars show 
mean ± SD. 
After two hours in gastric media the pH was raised to pH 6.8 to simulate 
transition into the small intestine.  After incubation in SGF without pepsin there 
was complete and rapid release of intact insulin within 45 minutes, table 3.7, 
figures 3.5 & 3.6.  This fulfils the USP (724) requirements for drug release from 
an enteric formulation during the buffer stage of dissolution testing.   
Figure 3.6 Insulin release from Eudragit L100 microparticles after incubation in 
either SGF with or without pepsin, or porcine gastric fluid for 2 hours and 45 
minutes in pH 6.8 phosphate buffer.  Error bars show mean ± SD. 
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The release of insulin from these particles at small intestinal pH was faster than 
from Eudragit L100/S100 particles prepared by dissolving the polymer in DCM 
and using an outer aqueous phase.  After 45 minutes these particles released 
less than 40% of their encapsulated insulin (Jain et al., 2006, Jain et al., 2005).  
The rapid release of insulin was comparable to other o/o produced insulin 
loaded Eudragit microparticles, 60-90% in 45 minutes (Morishita et al., 1993, 
Mundargi et al., 2011a).  The slower evaporation of ethanol may have allowed 
the formation of a more porous microparticle interior.  This would allow faster 
dissolution of the particles and insulin release at small intestinal pH.  A faster 
solvent evaporation rate forming polylactide microspheres resulted in a less 
porous microstructure (Hong et al., 2005).  This may be due to a reduced 
opportunity for solvent droplet coalescence within the particles preventing the 
formation of larger internal pores.  Further investigation of the morphology of 
microparticles produced using DCM or ethanol and an outer oil or aqueous 
phase would be useful to fully elucidate their influence on drug release. 
The faster release in small intestinal conditions in vivo may allow faster insulin 
absorption and blood glucose reduction providing better immediate post 
prandial glycemic control.  The complete release may also prevent glucose 
reduction occurring for so long that late post prandial hypoglycaemia may arise. 
After incubation in SGF with pepsin 80% of encapsulated insulin released in pH 
6.8 phosphate buffer was intact, table 3.7, figure 3.6.  The remaining 20% was 
possibly burst released in the gastric media and degraded by pepsin.  After 
incubation in porcine gastric fluid there was 49% intact insulin release upon pH 
rise, table 3.7, figure 3.6.  The remaining 51% was either burst released in the 
stomach fluid and degraded by the enzymes or insulin exposed at the particle 
surface was digested.  There was a greater loss of insulin after incubation of the 
microparticles in porcine stomach fluid than in SGF with pepsin.  Possibly the 
activity or concentration of pepsin in this fluid was greater than in the simulated 
fluid.  Some of the enzymes in the stomach sample may have remained after 
the pH change and were active at the higher pH allowing insulin degradation.  
They may also have been re-activated by the pH decrease at the end of the 
experiment. 
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Insulin released from the microparticles after incubation in SGF with pepsin or 
porcine gastric fluid had a comparable HPLC retention time to insulin alone, 
Figure 3.7.  This suggests its ionisation and tertiary structure was not altered in 
the microparticles and was successfully protected from gastric conditions. 
 
   
Figure 3.7 (a)  
 
Figure 3.7(b)  
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Figure 3.7 (c) 
Figure 3.7 HPLC chromatograms of (a) insulin (b) insulin released from 
Eudragit L100 microparticles after incubation in SGF with pepsin then pH 6.8 
phosphate buffer (c) insulin released from Eudragit L100 microparticles after 
incubation in pig gastric fluid, then pH 6.8 phosphate buffer 
These particles provided more protection from pepsin digestion than enteric 
HPMCP cross linked chitosan nanoparticles (Makhlof et al., 2011b) and 
hyaluronic acid nanoparticles (Han et al., 2012) which only protected 30% and 
45% of their encapsulated insulin respectively.  This suggests insulin may have 
been exposed at the surface of particles and digested when exposed to pepsin.  
This demonstrates the success of this method for successfully encapsulating 
insulin within the particles and leaving only a small proportion vulnerable to 
pepsin digestion.  None of the other particles were tested with actual gastric 
fluids.   
In vivo testing would be useful to determine if insulin absorption can be 
increased by encapsulation in these microparticles and if glucose lowering is 
faster than with enteric capsules/tablets.  It would also be useful to determine if 
insulin absorbance from these particles is affected by the timing of food 
ingestion post dosing and if they are less affected than enteric capsules/tablets. 
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3.5.3 Eudragit L100 microparticles with citric acid 
Insulin released from Eudragit L100 microparticles in the small intestine would 
be vulnerable to enzyme digestion.  To overcome this obstacle citric acid was 
also encapsulated within the microparticles.  The aim of this strategy was to 
reduce the pH around the released insulin inactivating any intestinal enzymes in 
the vicinity.  Citric acid has been used in oral formulations of protein and peptide 
drugs and demonstrated its ability to minimise enzymatic degradation 
(Fjellestad-Paulsen et al., 1995, Fredholt et al., 1999, Lee et al., 2000, Lee et 
al., 1999, Wu et al., 2010, Ushirogawa et al., 1992).  By encapsulating citric acid 
within the enteric microparticles it ensures it is only released in the small 
intestine simultaneously with the insulin so it has the maximum potential for 
protection and minimal disruption of digestion.  This should also minimise the 
loss of protection seen previously due to its intestinal spreading (Lee et al., 
2000). 
To test the hypothesis that citric acid can lower the pH and disable intestinal 
enzymes it was added to SIF with pancreatin and insulin.  After 30 minutes 
incubation the pH of the mixture was pH 4 showing citric acid had lowered the 
pH.  In stability studies of insulin with SIF and pancreatin insulin was instantly 
degraded, figure 3.3, with citric acid 14% of the insulin was intact after 30 
minutes incubation.  This shows lowering the pH of intestinal fluids can 
inactivate enzymes and protect insulin. 
All the microparticles with co-encapsulated citric acid had a yield of >50%, table 
3.8.  The addition of citric acid prevented the formation of discrete 
microparticles.  When 100mg of citric acid was added there were no 
microparticles formed just large aggregates, figure 3.8 (a) and (b).  Reducing 
the amount of citric acid to 30mg allowed the partial formation of microparticles 
but they were still aggregated figure 3.9 (a) and (b).  As these large aggregates 
were formed it was not possible to use the Mastersizer to measure their size 
and dispersity.  Citric acid appears to have affected the polymer preventing it 
forming microparticles.  This may be due to the plasticizing effect of citric acid 
on these polymers (Andrews et al., 2008, Schilling et al., 2007).  The increased 
pliability of the polymer may have prevented the formation of discrete particles 
and enabled the formation of large aggregates.   
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Further testing is needed to discover the influence of citric acid on the glass 
transition temperature of Eudragit L100 and this can be used to find the optimal 
ratio of citric acid to Eudragit L100. 
Table 3.8 Yields of blank and insulin loaded Eudragit L100 microparticles with 
either 100mg or 30mg of citric acid.  Data represents means ± SD. 
Microparticles Yield (%) 
Insulin with 100mg citric acid 81.5 ± 42.6 
Blank with 100mg citric acid 87.4 ± 74.8 
Insulin with 30mg citric acid 53.4 ± 28.2 
Blank with 30mg citric acid 59.0 
 
  
Figure 3.8 (a) and (b) SEM images of insulin loaded Eudragit L100 
microparticles with 100mg of co-encapsulated citric acid 
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Figure 3.9 (a) and (b) SEM images of insulin loaded Eudragit L100 
microparticles with 30mg of co-encapsulated citric acid 
The release of insulin from the aggregates of Eudragit L100, insulin and citric 
acid was tested in SIF without pancreatin.  There was no released insulin 
detected after two hours.  The average pH of the samples at the end of the 
experiment was 5.13.  Citric acid may not have been encapsulated within the 
microparticles so was free to lower the pH below the pH threshold of the 
Eudragit L100 polymer.  Therefore the aggregates did not break down and did 
not release insulin.  Large aggregates were visible at the end of the incubation 
period.   
There was also no insulin detected after incubation of the particles in SGF and 
pepsin for two hours and then 45 minutes in either SIF with pancreatin or SIF 
without pancreatin.  This may be due to pepsin and/or pancreatin degradation of 
any released insulin.  However the pH of the samples at the end of the 
experiment were all below the pH threshold of Eudragit L100, pH 6, potentially 
restricting its dissolution and insulin release.  The average pH of the samples 
after incubation in SGF with pepsin and SIF with or without pancreatin was 
5.25.  Aggregates were also visibly intact at the end of the experiment.   
The failure to form microparticles may be a cause of the failure to detect any 
insulin release.  The aggregates may be just mixtures of Eudragit L100, citric 
acid and insulin.  Therefore there would be no protection of insulin from pepsin 
and the citric acid would be released without control.   
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The insulin may also be so deeply embedded within the large aggregates that 
its release may be delayed. 
To determine if burst released citric acid is preventing insulin release by 
lowering the pH below the threshold for Eudragit L100 the pH of the samples 
should be raised above pH 6.  It can then be determined if insulin has been 
protected from pepsin and if citric acid released simultaneously with insulin can 
inactivate pancreatin and preserve insulin. 
3.6 Conclusion 
Despite numerous attempts to develop an oral formulation of insulin that is 
capable of controlling the symptoms of diabetes no such formulation is yet 
available.  The largest hurdles to oral insulin delivery are its intestinal instability 
and incompatibility with permeation from the GI tract but additional challenges 
arising during clinical trials are a need to eliminate variability in insulin 
absorption and minimise variability in insulin availability caused by food 
consumption. 
Investigations into the intestinal stability of insulin found that its primary 
structure is stable at gastric and small intestinal pH but it was rapidly degraded 
by enzymes found throughout the GI tract.  The structure of this small protein is 
stabilised at low pH by disulphide bonds, however the enzymes of the GI fluids 
can easily access susceptible peptide bonds and break them. 
Encapsulation of insulin in Eudragit L100 microparticles was selected as an oral 
delivery strategy for their ability to protect insulin from pepsin digestion and their 
potential, due to their small size, to produce faster post prandial glycemic 
control than larger enteric dosage forms.  Their small size may also be able to 
minimise variability in insulin absorption and susceptibility to absorption 
disruption by the presence of food experienced by oral insulin formulations in 
clinical trials. 
An o/o emulsion solvent evaporation method, based on that developed by 
Kendall et al. was selected to encapsulate insulin in Eudragit L100 
microparticles.  In chapter 2 this method successfully encapsulated a large 
protein, lactase, and restricted its release in acid.   
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This method was also selected for its lack of potentially damaging parameters 
which could endanger the integrity of insulin and benefits of increased 
encapsulation, reduced burst release and increased pepsin protection than 
those produced by a w/o/w method.   
The microparticles had a high insulin encapsulation efficiency, >72%, and a 
mean particle size of <100µm.  This was comparable to insulin loaded Eudragit 
microparticles produced using homogenisation but didn’t involve exposure to 
high shear forces.  The Eudragit L100 microparticles prevented 72% of insulin 
release in acid and protected 80% of encapsulated insulin from pepsin 
digestion.  This implies the vast majority of insulin was successfully fully 
encapsulated within the particles and not left exposed on their surface.  Insulin 
release from the Eudragit L100 microparticles was rapid and complete within 45 
minutes at small intestinal pH.  This rapid release makes these particles more 
suitable to promote a faster insulin absorption and control prandial glycemic 
excursions than larger dosage forms.  The complete release may also prevent 
glucose reduction occurring for so long that late post prandial hypoglycaemia 
may arise. 
To provide enzymatic protection in the small intestine citric acid was co-
encapsulated in the microparticles.  Citric acid released simultaneously with 
insulin would be able to lower local pH and inactivate enzymes reducing insulin 
degradation.  However, the plasticizing effect of citric acid on Eudragit L100 
hampered the formation of microparticles instead forming large aggregates.  
This would restrict rapid and uniform gastric emptying.  Their large size and 
release of citric acid appeared to prevent insulin release in any media in vitro.  
However, in vivo, the higher buffer capacity of the small intestinal fluids may 
prevent released citric acid lowering the pH below the threshold pH of Eudragit 
L100.  Therefore they may still offer a mode of successful oral insulin delivery. 
Insulin loaded Eudragit L100 microparticles offer a promising oral delivery 
strategy.  Their protection of insulin from pepsin digestion and rapid release at 
small intestinal pH could enable insulin absorption and glucose reduction 
sufficient and fast enough to control post prandial glycemia.  Additional 
excipients may further increase their potential to successfully deliver insulin 
orally. 
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Chapter 4 
Investigation of the intestinal stability of    
Peptide 1 and development of its oral 
formulations 
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4.1 Introduction 
The intestinal stability and oral delivery of a recently discovered small (10 amino 
acids), chemotherapeutic peptide, Peptide 1, was investigated in this chapter.  
While this peptide lacks the more complex structure of lactase and insulin it is 
still larger than commonly orally delivered low molecular weight drugs and still 
has to contend with the issues of intestinal instability and impermeability 
outlined in chapter 1.  Investigation into its intestinal stability, combined with the 
results of the previous chapters, should provide an insight into the relationship 
between the size and structure of protein and peptide drugs and their stability. 
Gonadotrophin releasing hormone (GnRH) agonists are peptides of a similar 
size to peptide 1 and are used to treat prostate and breast cancers.  They are 
available as injectable, depot formulations of polymeric particles of poly (D,L-
lactide-co-glycolide) (PLGA) which provide protection to the peptide and sustain 
their release to reduce the frequency of injections.  Therefore they have been 
used for oral delivery of peptides and increased their gastrointestinal stability 
and permeability but they have experienced problems of immediate, 
uncontrolled peptide release.  If administered orally the encapsulated peptide 
could be burst released in the stomach where it may be degraded by acid or 
pepsin.  To prevent gastric degradation of burst released peptide the 
encapsulation of peptide loaded PLGA nanoparticles in enteric Eudragit L100 
microparticles, which successfully encapsulated insulin and lactase in the 
previous chapters, has been investigated here. 
4.1.1 Peptide 1, function and structure 
Peptide 1 is a 10 amino acid peptide, 1190.4 MW, which can halt the growth of 
human mammary and prostate cancer cells (Migliaccio et al., 2007).  Peptide 1 
inhibits the interaction of androgen receptor (AR)-estradiol receptor (ER) 
complex with Src and stops its activation by mimicking the sequence that 
interacts with Src.  This prevents the progression from G1 to S (synthesis) in the 
cell cycle of cancer cells, stopping their growth.   
Peptide 1 was used to treat human prostate and mammary cancer cells (LNCaP 
and MCF-7) in vitro and inhibited androgen or estradiol induced association 
between the AR/ER and Src, Src activation, DNA synthesis and S phase entry.  
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When administered intraperitoneally to mice the peptide was taken up by and 
strongly inhibited the growth of LNCaP xenografts. 
4.1.2 Chemotherapeutic peptides 
The GnRH agonists, buserelin, goserelin, histrelin, leuprorelin and triptorelin, 
are of a similar size and structure to peptide 1 and are used to treat prostate 
and breast cancers, table 4.1.  These synthetic peptides are modelled on GnRH 
and bind to the GnRH receptor for a prolonged period reducing sex hormones 
and enabling treatment of hormonally sensitive cancers.   
All the GnRH agonists available are solely delivered by injection, except for a 
nasal spray of buserelin, and none are available orally, table 4.1.  Except for 
buserelin the injectable GnRH agonist formulations provide a sustained release 
of the drug over 1, 3, 6 or 12 months, dependent on the properties of their 
polymeric carrier.  The sustained release capacity of goserelin, leuprorelin and 
triptorelin formulations is conferred by the biocompatible and biodegradable 
polymers polylactic acid (PLA) and PLGA.  They have been used to form 
microcapsules for leuprorelin and triptorelin delivery.  The peptide is released 
initially by diffusing through pores in the spheres followed by slower, sustained 
release as the microspheres are eroded and the pores enlarged (Crotts and 
Park, 1998).  The microspheres are able to protect the encapsulated peptide 
and by providing a sustained release the inconvenience and pain of frequent 
injections is avoided (Dai et al., 2005).   
None of the protein or peptide drugs currently used in cancer treatment are 
available as oral formulations.  This is probably due to intestinal instability and 
limited absorption, due to their relatively large size and hydrophilicity, as 
described in chapter 1.  Despite these obstacles oral delivery would be 
preferable to injections because of increased convenience, patient compliance, 
ease of administration and reduced production costs. 
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Table 4.1 Molecular weight (MW) of GnRH agonists, GnRH pharmaceutical products available and their sustained release component 
GnRH 
agonist 
MW Amino 
acids 
Pharmaceutical product Sustained release polymer 
Buserelin 1299 9 Suprefact (Sanofi-Aventis) subcutaneous (sc) injection, nasal 
spray 
- 
Goserelin 1269 10 Novgos (Genus) implant , monthly sc injection 
Zoladex (Astrazeneca) implant, monthly sc injection, Zoladex 
LA implant, 3 monthly sc injection 
PLGA 
 
Histrelin 1324 9 Vantas (Orion Pharma), 12 monthly sc implant Hydrogel reservoir, acrylic 
copolymer shell 
Leuprorelin   1209 9 Prostap 3, SR (Takeda) 1 and 3 monthly microcapsule depot 
by sc injection  
PLA, PLGA 
Triptorelin 1312 10 Decapeptyl SR (Ipsen), Gonapeptyl depot (Ferring), 
intramuscular or sc injection 1, 3 or 6 monthly depots of 
sustained release microcapsules 
PLGA 
 
Subcutaneous (sc)
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4.1.3 Barriers to oral delivery of peptides for cancer treatment 
Intestinal stability studies revealed GnRH and leuprorelin are vulnerable to 
degradation by small intestinal enzymes.  GnRH was degraded by the intestinal 
enzymes chymotrypsin (Wen et al., 2002c, Walker et al., 2001) and elastase 
(Walker et al., 2001) but was not degraded by trypsin.  It was also rapidly 
degraded in small intestinal extracts from possum and rat intestines and had a 
half life of only 22 minutes in the possum jejunal extract (Wen et al., 2002c, 
Wen et al., 2002b, Wen et al., 2002a, Zheng et al., 1999a).  Rates of GnRH 
degradation in the brushtail possum corresponded to levels of proteolytic 
activity in the intestinal segments; greatest in the jejunum and ileum and least in 
the duodenum and colon (Wen et al., 2002b, Wen et al., 2002c). 
The intestinal permeability of the GnRH agonist leuprorelin has been assessed 
in vitro with rabbit intestinal segments and in vivo in rats by site directed delivery 
(Zheng et al., 1999b).  Permeability in rabbit intestinal segments was very low 
but was greater in the ileum and colon than the jejunum.  In anesthetized rats 
the bioavailability of leuprorelin was only 1.28% when administered to the 
jejunum increasing to 5.62% in the ileum and 9.59% in the colon (Zheng et al., 
1999b).  Bioavailability was reduced in conscious rats to only 0.23% when 
administered to the duodenum (Adjei et al., 1993), 0.58% in the ileum and 
0.41% in the colon (Zheng et al., 1999b).  These differences may be due to 
greater enzymatic activity and thicker mucus covering in the jejunum or the 
presence of macromolecule sampling M cells in the ileum.  Intact peptide was 
recovered from these intestinal regions at the end of the experiment 
demonstrating that even when the peptide was not degraded it was not 
absorbed due to its low permeability.   
These experiments show the vulnerability of these peptides to degradation in 
the small intestine and their low permeability demonstrating why they are not 
delivered orally.  The permeability and stability studies conducted did not take 
into account any degradation that may have occurred in the stomach so oral 
bioavailability figures may actually be lower than indicated.  As these peptides 
are used to treat cancer it is absolutely vital that the dose delivered is 
therapeutic and reliable.   
196 
 
Peptide 1 has a similar molecular weight and structure to the GnRH agonists 
and therefore may also have a low oral bioavailability due to similar intestinal 
instability and impermeability.   
4.1.4 Oral delivery strategies investigated for peptide chemotherapeutics 
To overcome the instability of GnRH agonists protease inhibitors have been 
used in oral formulations.  Protease inhibitors inhibited enzymatic degradation 
of buserelin (Kotze et al., 1997a) and leuprorelin (Zheng et al., 1999a) in vitro 
with rat intestinal homogenates and increased leuprorelin permeation in a rabbit 
intestinal sac (Guo et al., 2004).  However this strategy may not be ideal for oral 
delivery as it could disrupt the digestion of dietary proteins. 
To increase the permeability of GnRH agonists mucoadhesive polymers, 
chitosan and carbomer, have been investigated.  They increased in vitro 
transport of buserelin and leuprorelin across Caco-2 cells and rat intestinal 
mucosa (Kotze et al., 1997a, Thanou et al., 2000a, Kotze et al., 1997b, Guo et 
al., 2004, Iqbal et al., 2012).  As well as increasing intestinal residence time due 
to their adhesive properties they appeared to open tight junctions between the 
cells increasing paracellular absorption.  N-trimethyl chitosan chloride reduced 
the transepithelial electrical resistance (TEER) of Caco-2 cells and fluorescent 
markers were seen in the intercellular spaces indicating an opening of the tight 
junctions (Kotze et al., 1997b, Guo et al., 2004).  In vivo, carbomer and chitosan 
increased buserelin and leuprorelin bioavailability from less than 1% for the 
drug solutions to up to13% when administered intraduodenally and 4.52% when 
administered orally to rats (Thanou et al., 2000a, Luessen et al., 1996, Iqbal et 
al., 2012).   
Other delivery strategies for GnRH agonists include encapsulation in polymeric 
nanoparticles (Iqbal et al., 2011) , solid lipid nanoparticles (Yuan et al., 2009) 
and liposomes (Carafa et al., 2006).  These formulations can provide protection 
to the encapsulated peptide and may be able to enhance permeability.  
However, these systems suffered from an immediate burst release in vitro of up 
to 60% in 10 minutes which would leave the released drug vulnerable to 
degradation (Iqbal et al., 2011).   
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Only one of these systems was tested in vivo and produced an oral 
bioavailability of 0.55% in rats, a small improvement compared to the 0.26% 
bioavailability of an oral leuprorelin solution (Iqbal et al., 2011). 
Of the oral delivery strategies investigated for the GnRH agonists here none 
produced an oral bioavailability of more than 5% compared to an intravenous 
dose so more work is needed to enable oral delivery.   
4.1.5 PLGA nanoparticles for oral delivery of proteins/peptides 
Injectable microspheres of PLGA and PLA encapsulating GnRH agonists 
prevent the peptide being rapidly degraded and provide a prolonged release.  
Another advantage of PLGA is its lack of toxicity as it degrades to lactic and 
glycolic acids which are metabolised by the Krebs cycle (Singh et al., 2008).  
Compared to liposomes polymeric particles have greater stability in biological 
fluids and during storage (Pinto Reis et al., 2006).  Due to their proven benefits 
they have been explored for oral protein and peptide drug delivery too. 
PLGA particles have been used to encapsulate peptide and protein drugs; 
salmon calcitonin (Yoo and Park, 2004), cyclosporine A (Italia et al., 2007), 
ovalbumin (Uchida et al., 1994, Challacombe et al., 1992, Garinot et al., 2007), 
HBsAg antigen (Gupta et al., 2007), helodermin (des Rieux et al., 2007), BSA 
(Blanco and Alonso, 1998, Panyam et al., 2003), lysozyme (Blanco and Alonso, 
1998, Nam et al., 2000), leuprorelin acetate (Luan et al., 2006), thymopentin 
(Yin et al., 2007) and erythropoietin (Geng et al., 2008).  They have increased 
their oral bioavailability and induced immune responses in rodents (Yoo and 
Park, 2004, Gupta et al., 2007, Uchida et al., 1994, Challacombe et al., 1992).   
The most frequently investigated protein/peptide drug for oral delivery in PLGA 
particles is insulin (Sun et al., 2011b, Yang et al., 2012, Cui et al., 2006b, 
Carino et al., 2000, Sun et al., 2011a, Teply et al., 2008, Cheng et al., 2006, 
Pan et al., 2002, Li et al., 2004, Wu et al., 2012b).  In vivo they increased its 
oral bioavailability compared to an orally administered insulin solution.  Oral 
bioavailabilities, compared to an injected dose of insulin, ranged between 5.11 
and 15.9% in rodents (Sun et al., 2011b, Cui et al., 2006b, Carino et al., 2000, 
Sun et al., 2011a, Teply et al., 2008, Pan et al., 2002, Li et al., 2004, Wu et al., 
2012b). 
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Non-peptide cancer drugs have also been encapsulated in PLGA particles; 
doxorubicin (Wang et al., 2009), cisplatin (Dhar et al., 2008) and paclitaxel 
(Danhier et al., 2009).  They induced apoptosis of cancer cells in vitro (Wang et 
al., 2009) and produced a greater effect than an unencapsulated drug (Danhier 
et al., 2009).   
4.1.5.1 PLGA particles- stability and permeability enhancement 
PLGA particles provide a physical barrier between an encapsulated drug and 
the acidic pH of the stomach and enzymes of the gastrointestinal tract thereby 
increasing their oral bioavailability. 
PLGA particles have shown their ability to increase the in vitro permeability of a 
hydrophilic marker (Cohen-Sela et al., 2009), paclitaxel (Westedt et al., 2007), 
salmon calcitonin (Yoo and Park, 2004) and BSA (Panyam et al., 2003) 
compared to an unencapsulated drug in cell culture models (RAW 264 cells, 
rabbit vascular smooth muscle cells, Caco-2 cells, rabbit conjunctival epithelial 
cells).  After uptake the particles could be seen within the cells (Westedt et al., 
2007) 
As the PLGA particles are more lipophilic than the encapsulated hydrophilic 
protein or peptide their transport across the lipid membrane of cells can be 
increased and their transcellular transport has been observed (des Rieux et al., 
2007).  Studies with rabbit conjunctival epithelial cells and Caco-2 cells 
demonstrated the TEER was unchanged with PLGA particles indicating the 
junctions between cells were not opened and their transport was transcellular 
not paracellular (Qaddoumi et al., 2004, Yoo and Park, 2004).   
The M cells of Peyer’s patches, lymphoid nodules found in the small intestine, 
are a potential portal for PLGA particle uptake.  M cells sample and transport 
intact antigens from the GI tract to underlying lymphoid tissues and have high 
transcytosis capabilities.  This route of nanoparticle absorption appears to be 
preferred to that via the enterocytes (Kim et al., 2002).  A human M cell culture 
model increased PLGA particle uptake 600 fold compared to a Caco-2 cell 
model (des Rieux et al., 2007).  There was also greater uptake of PLGA 
particles in a rat in situ intestinal loop model in areas with Peyer’s patches than 
in areas without (Desai et al., 1996).   
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However it is not known how relevant these studies are to indicate human in 
vivo behaviour as rodents have a higher percentage of M cells, 10-50%, in their 
Peyer’s patches compared to humans, with only 5%. 
The size of the PLGA particles appears to be crucial to their permeation.  PLGA 
particle uptake was found to be size dependent in Caco-2 cells (Gaumet et al., 
2009), rat in situ intestinal loop (Desai et al., 1996) and rabbit conjunctival 
epithelial cells (Qaddoumi et al., 2004).  In all cases the smallest 100nm 
particles showed the highest uptake compared to larger particles (Gaumet et 
al., 2009, Desai et al., 1996, Qaddoumi et al., 2004).  PLGA particles of 100nm 
and 300nm were seen intracellularly in Caco-2 cells whereas those greater than 
300nm were not but were observed on the apical membrane of Caco-2 cells 
(Gaumet et al., 2009).  Particles of 100nm diffused through submucosal layers 
of a rat intestinal loop but particles of 500nm or greater were localised in the 
epithelial lining (Desai et al., 1996).  Ideally PLGA particles for oral delivery of 
proteins and peptides should be less than 300nm for successful absorption.  
Oral bioavailabilities of protein/peptide drugs encapsulated in PLGA particles 
can be further increased by chitosan coating.  Its mucoadhesive properties, 
positive charge, enhancing interaction with negatively charged GI tract cells, 
and ability to open paracellular channels have increased the in vitro absorption 
and in vivo bioavailability in rats of buserelin (Kotze et al., 1997a, Thanou et al., 
2000a, Kotze et al., 1997b), insulin (Zhang et al., 2012a), cyclosporine A 
(Malaekeh-Nikouei et al., 2008) and elcatonin (Kawashima et al., 2000).  Insulin 
oral bioavailability in rats was increased from 7.6% to 10.5% when PLGA 
particles were coated with chitosan (Zhang et al., 2012a).   
4.1.5.2 Formation of PLGA particles 
PLGA particles can be formed by many methods, a single emulsion method can 
be used for hydrophobic molecules but for hydrophilic proteins and peptides the 
most frequently used method is the water in oil in water (w/o/w) double 
emulsion solvent evaporation method.  Commercial, injectable PLGA 
microspheres of leuprorelin were produced using this method (Okada, 1997).   
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Nanoparticles encapsulating protein and peptide drugs with a mean size less 
than 300nm were produced (Yang et al., 2012, Pan et al., 2002, Wu et al., 
2012b, Garinot et al., 2007) with protein/peptide encapsulation efficiencies from 
30% to 80% (Yang et al., 2012, Teply et al., 2008, Cheng et al., 2006, Pan et 
al., 2002, Li et al., 2004, Wu et al., 2012b, Garinot et al., 2007, Gupta et al., 
2007) demonstrating the suitability of this method for their production.  Varying 
the parameters of the w/o/w method can affect the physicochemical 
characteristics of the PLGA particles and these in turn affect their behaviour in 
vitro and in vivo.   
4.1.5.3 Overcoming drug burst release from PLGA particles 
One of the common problems encountered with protein/peptide drug loaded 
PLGA particles is their uncontrolled initial burst release (Yang et al., 2012, Cui 
et al., 2006b, Carino et al., 2000, Pan et al., 2002, Wu et al., 2012b, Yoo and 
Park, 2004, Blanco and Alonso, 1998, Panyam et al., 2003, Luan et al., 2006).  
This initial burst could be detrimental to the oral bioavailability of an 
encapsulated peptide drug as it would be released and potentially destroyed in 
the GI tract before being absorbed into the bloodstream.  This initial burst could 
be due to the peptide being present at the surface of the particles or released 
from pores in the particle.  To prevent burst release in the stomach enteric 
polymers have been used in conjunction with or to coat polymeric particles.  
Encapsulation of protein/peptide loaded nanoparticles in microparticles has also 
reduced burst release.  Reduction of burst release can reduce degradation and 
increase the amount of intact drug which can be absorbed. 
Enteric coatings reduced in vitro drug release in acid and reduced pepsin 
digestion of insulin and ovalbumin loaded in PLGA particles (Naha et al., 2008, 
Cui et al., 2006a, Delgado et al., 1999, Wu et al., 2012b).  Enteric coating of 
PLGA/PLA particles also increased bioavailability and produced a sustained 
effect in vivo, compared to uncoated particles, of insulin (Naha et al., 2008, Cui 
et al., 2006a), ovalbumin (Delgado et al., 1999), leuprorelin (Iqbal et al., 2011) 
and calcitonin (Cetin et al., 2012).  Oral bioavailability of encapsulated insulin 
was increased from 3.68% to 6.27% by enteric coating (Cui et al., 2006a).  Oral 
leuprorelin bioavailability increased 4.2 fold following enteric coating of tablets 
of drug loaded polyacrylic acid nanoparticles (Cetin et al., 2012).   
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Microencapsulation of poly ε caprolactone nanoparticles in microparticles of 
ethylcellulose or Eudragit RS or a blend of these polymers reduced in vitro burst 
release of triptorelin from 71% from the nanoparticles to only 5.4% from the 
ethylcellulose/Eudragit RS blend microparticles (Hasan et al., 2007).  
4.2 Aims 
 To assess the stability of peptide 1 throughout the GI tract using 
simulated and porcine gastrointestinal fluids and human faecal fluids 
o To use this knowledge for optimal targeting and rational design of 
oral peptide 1 delivery vehicles  
o To gain an insight into the oral stability of small peptides 
 To produce oral peptide 1 formulations based on the intestinal stability 
study, previous studies of peptide intestinal permeability, existing delivery 
strategies for chemotherapeutic peptides and research into peptide oral 
delivery strategies 
o To characterise their physical characteristics (size, polydispersity, 
morphology, charge), loading and encapsulation efficiency 
o To assess their in vitro peptide 1 release  
o To assess the impact of varying method parameters  
o To select method parameters which produce formulations with the 
highest probability for successful oral delivery 
 To improve the permeability and peptide release profile by additional 
coatings/enteric encapsulation 
4.3 Materials 
Peptide 1 was supplied by Thermo Scientific.  Pepsin from porcine gastric 
mucosa, 469 units/mg solid, 924 units/mg protein, pancreatin from porcine 
pancreas, activity at least 3x USP specifications and trifluoroacetic acid were 
from Sigma Aldrich.  Hydrochloric acid 37%, specific gravity 1.18, and glacial 
acetic acid (100%) were from BDH.  Acetonitrile HPLC grade was from Fisher 
Scientific.  Pig gastric and intestinal fluids were from freshly slaughtered pigs 
and immediately frozen and store at -80⁰C.  Human faecal fluids were from 
healthy individuals not taking antibiotics. 
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Faecal basal media materials:  Bacteriological peptone and yeast extract were 
from Oxoid.  Sodium chloride, L-cysteine hydrochloride, vitamin K, resazurin 
sodium salt and sodium hydroxide were from Fisher Scientific.  Dipotassium 
hydrogen orthophosphate and magnesium sulphate 7-hydrate were from BDH.  
Calcium chloride dihydrate was from VWR.  NaHCO3 and haemin were from 
Sigma Aldrich.   Bile salts were from Fluka Analytical.  Tween 80 was from 
Fluka Chemika. 
Poly (lactic-co-glycolic acid) (PLGA), 5050 DLG 2A was from Lakeshore 
Biomaterials (USA).  Polyvinyl alcohol (PVA), 87-89% hydrolysed, and 
monobasic potassium phosphate were from Sigma Aldrich.  Dichloromethane 
(DCM) was from VWR.   Ethanol, 96% v/v, was from BDH. Chitooligosaccharide 
(1-4) 2-amino-2-deoxy-β-D-glucose, (chitosan) average molecular weight 5K 
was from KittoLife.   
MDA-MB-231 breast cancer cells were from the American type culture 
collection (ATCC), Manassas, USA.  Crystal violet ACS reagent, anhydrous dye 
>=90% was from Sigma Aldrich.  PrestoBlueTM cell viability reagent, Gibco 
0.25% trypsin-EDTA, Gibco Leibovitz’s L15 medium, Penicillin-Streptomycin 
liquid, and fetal bovine serum were from Invitrogen 
Eudragit L100 was a gift from Degussa/ Evonik (Darmstadt, Germany), sorbitan 
sesquioleate (Alacel 83) and phosphate buffered saline tablets (PBS) were from 
Sigma Aldrich.  Liquid paraffin BP was supplied by JM Loveridge Plc.  Sodium 
phosphate, tribasic, anhydrous was from Alfa Aesar.  n-hexane was from Fisher 
Scientific.   
4.4 Methods 
4.4.1 Peptide 1 intestinal stability 
100µl of a 10mg/ml peptide 1 solution was added to 1.9ml of simulated gastric 
fluid (SGF) with and without pepsin and simulated intestinal fluid (SIF) with and 
without pancreatin (final peptide 1 concentration of 0.5mg/ml).  These were 
placed in a Gallenkamp shaking incubator at 37±0.5°C and agitated at 100rpm.   
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Samples (0.15ml) were removed after 0, 15, 30, 60, 90 and 120 minutes and 
added to either 0.45ml 0.002M NaOH to raise the pH of acidic fluids or 50% 
acetic acid to lower the pH of SIF to halt the reaction (final peptide 1 
concentration 0.125mg/ml).  These samples were analysed for peptide 1 
content using HPLC.  SGF and SIF were prepared as described in chapter 2, 
section 2.4.2.   
100μl of a 10mg/ml peptide 1 solution was added to 1.9ml of gastric (pH 2.31), 
duodenal (pH 6.55), jejunal (pH 6.79), ileal (pH 6.86) and descending colonic 
fluids (pH 7.06) from a pig, giving a final peptide 1 concentration of 0.5mg/ml.  
The pig intestinal fluids were prepared by centrifuging at 10,000rpm for 10 
minutes and using the supernatant for testing.  These mixtures were placed in a 
Gallenkamp shaking incubator at the parameters used for the simulated fluids.  
Samples (0.15ml) were removed after 0, 15, 30, 60, 90 and 120 minutes and 
added to either 0.45ml of 0.002M NaOH to raise the pH of acidic fluids or 50% 
acetic acid to lower the pH of small and large intestinal fluids and halt the 
reaction (final peptide 1 concentration 0.125mg/ml).  These samples were 
filtered using 0.45µm filters (Millex GP, Millipore, Ireland) and analysed for 
peptide 1 content using HPLC.  
0.05ml of a 10mg/ml peptide 1 solution was added to 0.95ml of human faecal 
slurry and placed in a Gallenkamp shaking incubator at the parameters used in 
the previous tests (final peptide 1 concentration 0.5mg/ml). Samples (0.15ml) 
were removed after 0, 15, 30, 60, 90 and 120 minutes and added to 0.45ml 
50% acetic acid to halt the reaction (final peptide 1 concentration 0.125mg/ml).  
These samples were centrifuged at 10,000rpm for 10 minutes and the 
supernatants analysed for peptide 1 content using HPLC.  The human faecal 
slurry was prepared as described in chapter 2, section 2.4.2.1. 
Peptide 1 recovery in the withdrawn samples was calculated using the equation 
below.  The theoretical concentration of the sample is the concentration of 
peptide 1 assuming 100% recovery.: 
Peptide 1 recovered (%)=
                                        
                                           
x100 
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4.4.1.1 Statistics 
The peptide 1 degradation data from gastric and small intestinal fluids were 
analysed using a simple regression model using least squares.   Assuming a 
zero order degradation rate, the concentration of peptide 1 in the samples was 
plotted against time.  The slope of this line is defined as –k, the rate constant is 
k.  This is used to determine the half life (t ½) of the peptide in the intestinal 
fluids using this equation where C[0] is the concentration of peptide 1 (µg/ml) at 
time 0: 
t ½=         
The data from peptide 1 degradation in porcine colonic and human faecal fluids 
were analysed as a first order reaction.  The natural log (ln) of the concentration 
of peptide 1 was plotted against time.  The slope of this line is defined is –k, the 
rate constant is k.   
Half life of the peptide is calculated using this equation: 
t½=          
The slope of the regression line was assessed for significance by one way 
ANOVA.  Comparisons between the rate constants and half lives of peptide 1 in 
different intestinal fluids were performed by one way ANOVA.  Values of p≤0.05 
were considered significant.  All statistical analyses were determined using 
Minitab 15. 
4.4.2 HPLC method 
Samples were run in a mobile phase of 0.1% (v/v) trifluoroacetic acid in water 
and 0.1% trifluoroacetic acid in acetonitrile (5-45%) at 25°C.  Samples were 
separated with a C18 column and detected at 220nm. 
4.4.3 Formation of PLGA nanoparticles 
The method used to produce PLGA nanoparticles was a double emulsion 
solvent evaporation process based on those previously used to encapsulate 
protein and peptide drugs (Garinot et al., 2007, Yang et al., 2012, Pan et al., 
2002, Wu et al., 2012b).  The process is outlined in figure 4.1.   
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Figure 4.1 Double emulsion solvent evaporation method used to produce PLGA nanoparticles encapsulating peptide 1 
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PLGA (200mg) samples were dissolved in DCM (5ml).  An inner aqueous phase 
(1ml) of 5% PVA, a stabiliser, was added to the PLGA solutions to form blank 
nanoparticles.  For peptide 1 nanoparticles, peptide 1 (10 or 20mg) was 
dissolved in the inner aqueous phase and left for 20 minutes prior to primary 
emulsification giving ratios of PLGA to peptide of 10:1 and 20:1.  These were 
emulsified with an Ultra Turrax T25 homogeniser at 24000rpm for one minute 
and sonicated at 17 microns amplitude with a Sanyo Soniprep 150 probe 
sonicator for five minutes to form a primary water in oil emulsion.  The 
emulsions were added dropwise to an outer aqueous phase (40ml) and 
emulsified at 10000rpm with a Silverson L4RT mixer for 5 minutes.  The outer 
aqueous phase varied in PVA concentration; either 1.25% PVA, 2.5% PVA. 
All emulsification and sonication steps were carried out with the samples on ice 
to protect the peptide from thermal denaturation (Zambaux et al., 1998).  The 
double emulsions were magnetically stirred for either 2 or 4 hours during 
solvent evaporation.  The nanoparticles were separated by centrifuging at 
21000 rpm, RCF 41415 at 15°C for 20 minutes in a Sigma 3K30 centrifuge.  
Supernatants were poured off and retained for analysis of peptide 1 content by 
HPLC.  The nanoparticles were resuspended and washed in water and 
centrifuged again using the same parameters.  The supernatants were retained 
and analysed for peptide 1 content by HPLC.  Pellets were finally re-suspended 
in DI water (5ml).   
The supernatants from the centrifugation of the double emulsions and from 
washing the nanoparticles were analysed for peptide 1 content using HPLC and 
this was subtracted from the initial amount of peptide 1 added.  Encapsulation 
efficiency (EE) and drug loading were calculated using these equations: 
EE (%) = 
                                                           
                              
 x100 
Drug loading= 
                                                           
                                         
 x1000 
(Drug loading =μg peptide 1/mg nanoparticles) 
Each nanoparticle sample was dispersed in DI water for size, polydispersity and 
zeta potential measurements using a Malvern Zetasizer nano Z-S.   
207 
 
The nanoparticle suspensions were freeze dried using a VirTis Advantage 
freeze dryer using the parameters described in chapter 2, section 2.4.8.  The 
resulting powder was weighed and the yield determined using the equation 
below. 
Yield (%)= 
                                         
                               
x100 
The morphology and size of the freeze dried nanoparticles were examined by 
scanning electron microscopy (SEM) (Philips XL30, Eindhoven, Holland).  
Nanoparticles were fastened on a SEM stub using carbon adhesive pads and 
then coated with gold using an Emitech K550 sputter coater.  Routine, high 
vacuum imaging at 10/5kV was used. 
4.4.3.1 In vitro peptide 1 release  
Nanoparticles (10mg) with encapsulated peptide 1 were placed in a glass vial 
with 1ml PBS, pH 7.4, in triplicate.  Samples were placed in a Gallenkamp 
shaking incubator at 100rpm, 37°C.  After 30 minutes, 2, 4, 8 and 24 hours 
samples were centrifuged at 10,000rpm for 10 minutes and 0.5ml of the 
supernatant analysed for peptide 1 content by HPLC.  0.5ml of fresh PBS was 
added to replace the 0.5ml removed, the nanoparticles were resuspended and 
the samples returned to the shaking incubator.  Those nanoparticles prepared 
after a solvent evaporation period of 2 hours were also sampled after 1 and 2 
weeks. 
Peptide 1 release (%)=
                                            
                    
 
4.4.4 Chitosan coated PLGA nanoparticles 
Chitosan coated PLGA nanoparticles were prepared as described above with a 
1:20 ratio of peptide 1 to PLGA but with a 1% 5K chitosan/1.25% PVA external 
aqueous phase.  Size and morphology of the nanoparticles were assessed as 
described previously.  The yield was calculated in the same way but the weight 
of excipients also included the chitosan added.  The peptide 1 loading and 
encapsulation efficiency were determined as before.  In vitro peptide 1 release 
from the chitosan coated nanoparticles (20mg) was performed in PBS as 
described for the uncoated particles and monitored over 2 weeks. 
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4.4.5 Peptide 1 efficacy 
MDA-MB-231 (ATCC HTB-26) breast cancer cells were cultured in Leibovitz’s 
L-15 medium with 15% fetal bovine serum and 1% penicillin-streptomycin 
solution in an incubator without CO2 at 37°C.  2 x 10
5 cells per well were plated 
in 24 well plates in 100µl culture medium, to these either 1µM of peptide 1 
alone, peptide 1 encapsulated in PLGA nanoparticles, peptide 1 encapsulated 
in chitosan coated PLGA nanoparticles, blank or blank chitosan coated PLGA 
nanoparticles were added in 100µl culture medium.  Some of the cells were left 
without peptide or formulation.  After 24 hours incubation the cells were 
trypsinised and transferred to 12 well plates.  After 6 days further incubation the 
cells were tested for viability.  This was to determine the effect of peptide 1 on 
breast cancer cell proliferation and the effects on peptide 1 efficacy caused by 
its encapsulation in PLGA nanoparticles. 
After removing and refreshing the culture media PrestoBlueTM cell viability 
reagent was added to the cells and incubated for 2 hours at 37°C.  This reagent 
is a resazurin based solution that is reduced by metabolically active cells 
changing colour to red to give a measure of cell viability.  100µl samples were 
plated in a 96 well plate and their absorbance at 550nm measured using a Bio-
Tek Powerwave XS plate reader. 
The medium with the viability reagent was removed and the cells washed twice 
with PBS.  The cells were fixed with methanol for 5 minutes.  This was removed 
and 0.05% w/v crystal violet solution added to the cells to stain remaining cells.  
After 30 minutes the stain was removed and the cells washed twice with PBS.  
After drying, methanol was added to solubilise the dye, transferred to a 96 well 
plate and absorption measured at 550nm using a plate reader as before. 
4.4.6 Enteric microparticles 
To overcome any immediate burst release of peptide 1 from the PLGA 
nanoparticles in the stomach the strategies of enteric coating and 
microencapsulation of nanoparticles were combined.   
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Due to the ability of Eudragit L100 microparticles prepared using the Kendall et 
al. method to encapsulate lactase and insulin without damaging them, elicit a 
pH dependent release and provide protection from pepsin they were selected to 
encapsulate peptide 1 loaded PLGA nanoparticles.  As this method uses 
ethanol to dissolve Eudragit L100, rather than DCM, it will be suitable to 
encapsulate intact nanoparticles as PLGA is not soluble in ethanol. 
Enteric microparticles encapsulating peptide 1 alone and PLGA nanoparticles 
with peptide 1 were prepared with the substitution of peptide 1 or peptide 1 
loaded PLGA nanoparticles for prednisolone (Kendall et al., 2009).  The 
amounts of excipients used were scaled down for the reduced amounts of 
peptide 1 and peptide 1 loaded nanoparticles available.  Eudragit L100 (300mg) 
was dissolved in ethanol (3ml).  Peptide 1 (20mg) was suspended in the ethanol 
to prepare microparticles with a drug to polymer weight ratio of 1:15.   PLGA 
nanoparticles (30mg), with a 1:20 peptide 1:PLGA initial ratio prepared with 
1.25% PVA outer aqueous phase after a solvent evaporation of 2 hours, were 
added to the polymeric solution to prepare microparticles with a nanoparticle to 
microparticle weight ratio of 1:10.   
The polymeric suspensions with either peptide 1 or peptide 1 PLGA 
nanoparticles were emulsified into liquid paraffin (20ml), containing 1% (w/w) of 
sorbitan sesquioleate (Arlacel 83) as an emulsifying agent, using a Heidolph 
RZR1 stirrer at 1500rpm.  Stirring proceeded for 18 hours at room temperature 
to allow solvent evaporation and particle solidification.  The microparticles 
formed were recovered by vacuum filtration through a Pyrex sintered glass filter 
(pore size 4; 5-15μm) and washed three times with n-hexane (50ml).  The 
microparticle formulations were prepared in triplicate.  Blank microparticles 
containing no peptide 1 and microparticles with blank nanoparticles (30mg) 
were also prepared using the same parameters 
The yield and size of the microparticles, measured using a Malvern Mastersizer, 
were determined as described in chapter 2, section 2.4.6.1.  The morphology 
and size of the microparticles were examined by scanning electron microscopy 
(SEM) (Philips XL30, Eindhoven, Holland), with routine, high vacuum imaging at 
5kV as described in chapter 2, section 2.4.6.2. 
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4.4.6.1 Loading and encapsulation efficiency 
Microparticles (5/10mg) with encapsulated peptide 1 were placed in pH 
6.8±0.05 phosphate buffer for 2 hours in a Gallenkamp shaking incubator to 
break down the microparticles and determine the peptide 1 loading per mg of 
microparticles and the efficiency of its encapsulation in the microparticles.  The 
amount of peptide 1 released was determined by HPLC and the equations 
below were used to calculate peptide 1 loading and encapsulation efficiency.   
Peptide 1 loading per mg microparticles (μg/mg)=
                            
                            
 
Encapsulation efficiency (%)=
                                  
                                     
x100 
The theoretical peptide 1 loading is the loading of peptide 1 if all the peptide 
loaded nanoparticles were encapsulated in the microparticles. 
These tests were not performed with the microparticles containing nanoparticles 
as only the microparticles would be broken down using this method.  Instead 
the peptide 1 loading in the microparticles encapsulating nanoparticles was 
theoretically determined assuming complete encapsulation of the peptide 
loaded nanoparticles in the microparticles 
Obviously it would be better to experimentally and accurately determine the 
actual peptide 1 content in the microencapsulated PLGA nanoparticles.  
However, attempts to do this by extracting the polymer into an organic phase 
and peptide into an aqueous phase led to the formation of a white precipitate at 
the interface of these phases which seemed to prevent peptide extraction.  The 
most important aspect of this work was to demonstrate if the enteric 
microencapsulation was able to prevent peptide 1 release in acid.  Once this 
had been achieved other methods for determining peptide 1 content could be 
explored. 
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4.4.6.2 In vitro release  
Peptide 1 PLGA nanoparticles, peptide 1 Eudragit L100 microparticles and 
peptide 1 PLGA nanoparticles encapsulated in Eudragit L100 microparticles 
were placed in 0.75 ml 0.1N HCl, pH 1.2 ± 0.05, for 2 hours to simulate gastric 
conditions.  The pH was then raised to pH 6.8 ± 0.05 by the addition of 0.25ml 
0.2M tribasic sodium phosphate to simulate the small intestine.  Samples were 
placed in a Gallenkamp shaking incubator at 100rpm, 37±0.5°C.  After 30 
minutes, 2, 4, 8 and 24 hours samples were taken from the nanoparticle 
mixture, centrifuged at 10,000rpm for 10 minutes and 0.5ml of the supernatant 
analysed for peptide 1 release by HPLC.  After 30 minutes, 2 hours and 2 hours 
and 45 minutes samples were taken from the microparticle mixtures, 
centrifuged and analysed in the same way.  0.5ml of 0.1N HCl/pH 6.8 
phosphate buffer were added to replace that removed, the particles 
resuspended and the samples returned to the shaking incubator after each 
sampling time point.  Cumulative peptide 1 release was calculated as in section 
4.4.4. 
4.4.7 Statistics 
Differences in particle characteristics caused by altering the method 
parameters, chitosan coating or enteric microencapsulation were assessed for 
significance by one-way ANOVA using the Minitab 15 program.  Results were 
considered to be significant for p values ≤0.05. 
4.5 Results and Discussion 
4.5.1 Peptide 1 intestinal stability 
The stability of peptide 1 was assessed in simulated and pig intestinal fluids and 
in human faecal fluids.  This was used to design oral formulations of peptide 1. 
4.5.1.1 Gastric fluids 
More than 70% of intact peptide 1 was recovered from SGF, with and without 
pepsin, and porcine gastric fluid after 2 hours incubation, table 4.2.  In SGF 
without pepsin there was more than 90% intact peptide 1 recovered suggesting 
it has high stability at gastric pH possibly due to its small size and lack of higher 
structure which can be disrupted at this pH.   
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Intact peptide 1 gradually reduced during incubation in SGF with pepsin from 
96% to 75% in a significant zero order degradation (p≤0.05).  This suggests 
there is some pepsin digestion of peptide 1.  Pepsin cleaves between 
hydrophobic, preferably aromatic amino acids.  Peptide 1 doesn’t contain these 
amino acids adjacently but it appears pepsin was still able to digest some of the 
bonds slowly.  Despite the lack of preferred theoretical pepsin digestion sites in 
teriparatide it was completely degraded within 5 minutes with pepsin suggesting 
it has a broad substrate spectrum (Werle et al., 2006).   
Table 4.2 Peptide 1 recovery after incubation in SGF and porcine gastric fluids.  
Data represents means ± SD. 
Sample 
(minutes) 
Peptide 1 
recovered (%) SGF 
Peptide 1 
recovered (%)  
SGF + pepsin 
Peptide 1 recovered 
(%) pig gastric fluid 
0 98.6 ± 22.4 95.8 ± 8.5 79.3 ± 3.6 
15 96.1 ± 20.0 92.8 ± 7.5 82.9 ± 18.1 
30 92.6 ± 21.5 86.3 ± 7.5 71.2 ± 9.2 
60 92.1 ± 23.0 77.0 ± 12.6 90.9 ± 77.2 
90 94.4 ± 30.9 77.4 ± 9.0 82.0 ± 9.9 
120 96.8 ± 28.2 74.5 ± 6.1 86.1 ± 7.1 
 
There was an immediate 20% loss of peptide 1 when placed in porcine gastric 
fluid.  Recovery values of the peptide then fluctuated around 80%.  Fluctuation 
may be due to differences in sampling caused by the viscous gastric fluid 
preventing homogenous peptide 1 distribution.  To develop a delivery system 
which allows as high a concentration of intact peptide 1 to reach the absorbing 
membranes of the small intestine as possible protection from gastric enzymes 
would be beneficial. 
The degradation rate constant (k) of peptide 1 was significantly greater (p≤0.05) 
in SGF with pepsin than in SGF or porcine gastric fluid, table 4.3.  Active pepsin 
concentration may be lower in the porcine gastric fluid than in SGF with pepsin.  
Possibly it was denatured during storage reducing its activity or may be present 
in porcine gastric fluids at a lower concentration than in the simulated fluid.   
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The presence of pepsin in the porcine gastric fluids is dependent on which part 
of the stomach it is taken from.  Possibly the fluids were removed from a part 
with little pepsin content and fluids from another segment may have been more 
proteolytic.  The negative degradation rate constant and half life of peptide 1 in 
porcine gastric fluid actually indicate an accumulation of peptide 1 rather than 
degradation, table 4.3.  This may be due to sampling problems with the viscous 
fluids or an interaction of the peptide with constituents of the gastric fluids 
preventing its complete extraction. 
Table 4.3 Degradation rate constants (k) and half lives of peptide 1 in SGF and 
porcine gastric fluids.  Data represents means ± SD. 
Sample Slope (k) Half life (minutes) 
SGF 0.01 ± 0.34 963.18 ± 1726.45 
SGF + pepsin 0.68 ± 0.13 359.36 ± 42.09 
Gastric fluid -0.46 ± 0.21 -519.89 ± 305.24 
 
4.5.1.2 Small intestinal fluids 
There was a gradual, significant zero order decline in peptide 1 concentration 
over 2 hours to 76% in SIF without pancreatin, table 4.4.  This indicates the pH 
or composition of this fluid may cause a gradual loss of peptide 1 structure.  
With pancreatin there was no intact peptide 1 recovered at any time point, only 
four degradants; the products of peptide 1 digestion.   
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Table 4.4 Peptide 1 recovery in SIF and porcine small intestinal fluid.  Data 
represents means ± SD. 
Sample 
(min) 
Peptide 1 
recovered 
(%) SIF 
Peptide 1 
recovered (%) 
duodenal fluid 
Peptide 1 
recovered (%) 
jejunal fluid 
Peptide 1 
recovered (%) 
ileal fluid 
0 92.5 ± 5.7 78.1 ± 1.5 21.8 ± 5.7 45.0 ± 5.3 
15 95.1 ± 7.3 71.1 ± 7.5 18.3 ± 9.1 37.0 ± 0.4 
30 90.7 ± 3.7 70.2 ± 2.9 36.7 ± 7.5 27.1 ± 3.0 
60 80.7 ± 5.5 66.4 ± 2.5 29.3 ± 4.0 19.8 ± 1.9 
90 77.9 ± 3.8 63.7 ± 1.1 22.9 ± 1.3 13.6 ± 2.6 
120 76.2 ± 5.1 56.6 ± 5.0 17.3 ± 2.0 8.6 ± 2.8 
 
The stability of peptide 1 in the porcine small intestinal fluids tended to decline 
along the small intestine, table 4.4.  There was a gradual decline in peptide 1 
recovery to 57% after 2 hours in the duodenal fluids.  There was an immediate 
loss of peptide 1 upon mixing with jejunal and ileal fluids, to 22% and 45% 
respectively, and then a decline to 17% and 9% respectively.  This loss in 
activity could be due to the increasing pH along the small intestine as peptide 1 
was shown to be more unstable at pH 6.8 than at pH 1.2.  Increasing peptide 1 
degradation in the jejunal and ileal fluids compared to the duodenal fluids could 
be due to increasing amounts of degradative enzymes.  This pattern of 
degradation is similar to that of GnRH in brushtail possum intestinal extracts 
where it was degraded more in the jejunal and ileal extracts than duodenal 
samples (Wen et al., 2002b).  Analysis of the proteolytic activity of these 
samples revealed there was more enzymatic activity in the jejunal and ileal 
samples than the duodenal samples (Wen et al., 2002c).   
Analysis of the peptide 1 sequence indicated multiple bonds were vulnerable to 
digestion by the small intestinal enzymes trypsin, chymotrypsin and elastase so 
it is unsurprising it was degraded in these samples, figure 4.2.  These results 
indicate peptide 1 could be more successfully orally delivered if it is targeted for 
absorption from the proximal small intestine where there is reduced proteolytic 
activity. 
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Ac- Pro –Pro –Pro –His –Pro –His –Ala –Arg –Ile –Lys -NH2 
 
Figure 4.2 Peptide bonds of peptide 1 susceptible to chymotrypsin, trypsin and 
elastase cleavage 
Peptide 1 degradation followed a significant zero order degradation in porcine 
duodenal and ileal fluids.  Degradation of peptide 1 in jejunal fluids after 30 
minutes incubation until completion of the experiment also followed a significant 
zero order degradation.  Only these significant results were used for 
comparison of degradation in the intestinal fluids. 
There was significantly faster degradation of peptide 1 in all three small 
intestinal fluids than porcine gastric fluids and the half life of peptide 1 was 
significantly reduced in the jejunal and ileal fluids, tables 4.3 and 4.5.  This 
suggests peptide 1 is more vulnerable to degradation in the small intestine than 
in the stomach possibly due to the nature or concentration of the enzymes 
there.  The degradation rate of peptide 1 was faster in the jejunal and ileal fluids 
than SIF due to the presence of enzymes, table 4.5.  The duodenal fluids have 
a lower peptide 1 directed proteolytic activity than the other small intestinal 
fluids and also, surprisingly, than SIF without any enzymes.  Possibly the 
constituents of SIF or its slightly higher pH destabilise the peptide.  The enzyme 
activity of the duodenal fluids may also have declined during storage. 
Table 4.5 Degradation rate constants (k) and half lives of peptide 1 in simulated 
and porcine small intestinal fluids Data represents means ± SD. 
Sample Slope (k) Half life (minutes) 
SIF 0.63 ± 0.20 386.90 ± 103.36 
Duodenal fluid 0.36 ± 0.32 631.35 ± 1277.72 
Jejunal fluid 0.95 ± 0.37 105.80 ± 27.88 
Ileal fluid 1.32 ± 0.29 86.45 ± 11.89 
 
Elastase 
Chymotrypsin Trypsin 
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Peptide 1 degradation in SIF with pancreatin was faster than in the porcine 
small intestinal fluids.  The simulated fluids seem to have a greater proteolytic 
activity and therefore may not be representative of what would happen in vivo.  
However the degradation results from the porcine intestinal fluids may be an 
underestimate of the stability of the peptide in these intestinal segments.  The 
fluids were removed from the lumen of the intestinal segments so any intestinal 
wall associated enzymes would not be present.  As the samples are then 
centrifuged and only the supernatants used for testing any enzymes associated 
or entangled with the solid matter would not be present to digest peptide 1. 
4.5.1.3 Colonic fluids 
There was an immediate loss of peptide 1 upon addition to the porcine colonic 
fluid and human faecal slurry; 44% and 24% respectively, table 4.6.  After 15 
minutes incubation there was only 16% and 27% intact peptide 1 left in the pig 
colonic fluid and human faecal slurry respectively.  For the remainder of the 
experiment there was a gradual loss of peptide 1 in the porcine colonic fluids, 
only 2% remained intact after 2 hours.  Loss of peptide 1 followed a significant 
first order degradation.  Unlike the zero order degradation of peptide 1 in the 
gastric and small intestinal fluids degradation in the colonic fluids is dependent 
on its concentration and slowed as it was depleted over time.   
Table 4.6 Peptide 1 recovery in porcine colonic and human faecal fluids.  Data 
represents means ± SD. 
Sample 
(min) 
Peptide 1 recovered (%) 
pig colonic fluid 
Peptide 1 recovered (%) 
human faecal slurry 
0 66.4 ± 5.1 76.2 ± 9.2 
15 15.7 ± 7.8 26.8 ± 0.7 
30 15.7 ± 4.7 32.3 ± 0.4 
60 9.7 ± 0.7 41.2 ± 1.6 
90 2.5 ± 2.0 38.2 ± 2.5 
120 2.0 ± 0.5 30.9 ± 2.2 
 
The loss of peptide 1 could be due to the higher pH of the colonic fluid and/or 
the presence of microbial enzymes and fermenting bacteria.   
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GnRH was less degraded in the colonic fluids of a brushtail possum and these 
fluids were less proteolytic than the small intestinal fluids (Wen et al., 2002b, 
Wen et al., 2002c).  Possibly peptide 1 is more susceptible to bacterial 
mediated fermentation in the colon than GnRH despite their similar size.  The 
colonic fluids from a pig may contain more fermenting bacteria or microbial 
proteases than those from the brushtail possum.   
Degradation of peptide 1 in the human faecal slurry did not produce a significant 
zero or first order reaction rate.  Peptide 1 was rapidly degraded during the first 
15 minutes but stabilised with 30% remaining, producing a very low reaction 
rate constant, table 4.7.  Possibly the enzymes or bacteria responsible for its 
degradation were inactivated and so peptide 1 depletion stopped.  This may not 
reflect what would happen in vivo where conditions for enzyme and bacterial 
activity would be optimal.  Peptide 1 was also rapidly degraded initially in the 
porcine colonic fluids but was then continuously degraded until only 2% 
remained.  Peptide 1 had a significantly different (p≤0.05) calculated half life in 
these fluids, table 4.7.  Possibly the enzymes and bacteria of the pig colonic 
fluids are more stable or concentrated and therefore active for longer in vitro 
than those in the human faecal fluids.  As the colonic fluids are taken directly 
from the colon whereas the human faecal fluids are prepared from the faeces 
expelled from the colon they may have differing bacterial and enzyme activities. 
Table 4.7 Degradation rate constants (k) and half lives of peptide 1 in porcine 
colonic and human faecal fluids calculated by regression of a first order reaction 
Data represents means ± SD. 
Sample Slope (k) Half life (minutes) 
Porcine colonic fluid 0.03 ± 0.00 27.11 ± 3.55 
Human faecal slurry 0.00 ± 0.00 224.02 ± 48.50 
 
The degradation rate of peptide 1 was significantly slower in the colonic fluids 
than in the gastric and small intestinal fluids, this is due to a slowing of the 
reaction rate as peptide 1 is degraded, tables 4.3, 4.5 and 4.7.  The half life of 
peptide 1 was significantly reduced in the colonic fluids compared to the porcine 
gastric and small intestinal fluids due to initial rapid degradation of peptide 1.   
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The different peptide 1 degradation pattern in colonic fluids may be due to both 
bacterial mediated fermentation and enzymatic degradation occurring rather 
than just enzymatic digestion.  The rapid initial degradation of peptide 1 in the 
porcine colonic and human faecal fluids may make the large intestine an 
unsuitable target for peptide 1 delivery. 
4.5.1.4 Overall intestinal stability 
Figure 4.3 shows the recovery of intact peptide 1after incubation in the various 
intestinal fluids.  Peptide 1 is more stable in the proximal than distal regions of 
the intestinal tract suggesting the peptide should be targeted for absorption from 
the upper regions of the small intestine.  Of the small/large intestinal fluids 
peptide 1 degradation rate was slowest and half life longest in the duodenal 
fluids.  The further it travels down the GI tract the more likely it is to be rapidly 
degraded and have reduced time for intact peptide absorption.  Assessment of 
peptide 1 stability in human intestinal fluids would provide a better prediction of 
its in vivo behaviour.  While peptide 1 had a similar stability profile to GnRH in 
small intestinal fluids it was more unstable in colonic fluids than GnRH.  This 
may be due to differences in the animal from which the fluids were extracted.  It 
may also show that despite similarities in size and number of amino acids 
stability is also dependent on individual amino acid sequences. 
 
Figure 4.3 Peptide 1 recovered after incubation in simulated, porcine and 
human intestinal fluids.  Error bars show mean ± SD. 
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4.5.2 PLGA nanoparticles 
The intestinal stability studies demonstrated a huge obstacle to the oral delivery 
of peptide 1 is its susceptibility to digestion by intestinal enzymes.  An oral 
delivery system may need to provide protection from pepsin in the stomach to 
ensure as high a concentration of intact peptide as possible is present when it 
reaches the small intestine.  Protection from small intestinal enzymes would 
also be beneficial to allow peptide 1 absorption for as long as possible. Peptide 
intestinal permeability studies have demonstrated their low absorption (Adjei et 
al., 1993, Zheng et al., 1999b).   
Peptide 1 was encapsulated in PLGA nanoparticles for its oral delivery for their 
ability to protect and enhance the permeability of an encapsulated peptide (Yoo 
and Park, 2004, Panyam et al., 2003, Cohen-Sela et al., 2009, Westedt et al., 
2007).  PLGA particles have demonstrated their suitability and compatibility for 
delivering other chemotherapeutic peptides as sustained release, injectable 
depot formulations (Crotts and Park, 1998, Dai et al., 2005).  They have also 
been used to encapsulate a variety of protein and peptide drugs increasing their 
oral bioavailability (Yoo and Park, 2004, Uchida et al., 1994, Challacombe et al., 
1992, Gupta et al., 2007, Italia et al., 2007, Sun et al., 2011b, Cui et al., 2006b, 
Carino et al., 2000, Sun et al., 2011a, Teply et al., 2008, Pan et al., 2002, Li et 
al., 2004, Wu et al., 2012b) 
4.5.2.1 Method development 
PLGA nanoparticles encapsulating peptide 1 were produced using a double 
emulsion solvent evaporation method which has frequently been used to 
encapsulate therapeutic proteins and peptides (Okada, 1997, Garinot et al., 
2007, Yang et al., 2012, Pan et al., 2002, Wu et al., 2012b, Gupta et al., 2007, 
Teply et al., 2008, Cheng et al., 2006, Li et al., 2004).  Varying parameters of 
this method affected the characteristics of the PLGA particles produced and 
these in turn had a profound impact on their in vivo success. 
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The size of PLGA particles was critical to their permeability (Gaumet et al., 
2009, Desai et al., 1996, Qaddoumi et al., 2004).  In vitro studies revealed that 
particles >300nm remained outside cells so to maximise uptake ideally particles 
should be smaller than 300nm (Gaumet et al., 2009).  A high peptide 1 
encapsulation efficiency and low initial burst release were also aimed for. 
DCM was selected to dissolve PLGA in the oil phase of the double emulsion as 
it produced smaller particles with a higher encapsulation efficiency than ethyl 
acetate (Cui et al., 2006b).  When forming the emulsions an increased 
homogenisation speed was shown to produce smaller particles (Luan et al., 
2006, Guo and Gemeinhart, 2008).   Therefore the highest possible speeds of 
the homogenisers and greatest amplitude of the sonicator were used.  PVA was 
included in the inner aqueous phase of the double emulsion to stabilise small 
aqueous phase droplets containing peptide 1, which would be more easily 
encapsulated within the oily polymer droplets.  This increased encapsulation 
efficiency and reduced initial burst release of BSA (Yang et al., 2001). 
The duration of solvent evaporation from the double emulsion was varied as it 
was shown to affect the encapsulation efficiency and drug release from PLGA 
particles (Luan et al., 2006).  Increasing the solvent evaporation time from 30 
minutes to 24 hours increased the initial drug release from the PLGA particles.   
The effect of varying the concentration of PVA in the outer aqueous phase of 
the double emulsion has been researched.  Generally an increased 
concentration produced smaller PLGA particles (Nam et al., 2000, Sun et al., 
2011b, Zambaux et al., 1998, Lamprecht et al., 1999, Yang et al., 2001), 
however there are some conflicting results concluding the opposite (Shi et al., 
2009).  An increased PVA concentration has also been shown to decrease the 
encapsulation efficiency so the benefits and disadvantages of an increased 
concentration need to be balanced (Nam et al., 2000).  Two different PVA 
concentrations were trialled to discover the optimal conditions for producing 
small (<300nm) nanoparticles with a high encapsulation efficiency. 
The amount of peptide 1 added to the inner aqueous phase was also varied.  
An increased peptide concentration in the inner aqueous phase was previously 
shown to increase encapsulation efficiency but also increased initial burst 
release (Luan et al., 2006, Sun et al., 2011b). 
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4.5.2.2 Solvent evaporation duration 
Neither the size nor the polydispersity of the particles was significantly affected 
by varying the solvent evaporation duration from 2 to 4 hours, table 4.8.  The 
particles produced using both evaporation durations were approximately 
300nm.  Previous research has found that particle absorption is size dependent 
and those larger than 300nm were not internalised by cells (Gaumet et al., 
2009, Desai et al., 1996, Qaddoumi et al., 2004).  Other method parameters 
may need to be adjusted to ensure the particles produced are smaller than 
300nm. 
All the nanoparticles were negatively charged as PLGA is an anionic polymer, 
table 4.8.  The particles with positively charged peptide 1 did have a more 
positive charge indicating its presence.  Zeta potentials became more negative 
with an increase in stirring time, significantly (p≤0.05) more for particles loaded 
with 20mg of peptide 1.  This could indicate positively charged peptide held on 
the surface of the particles was lost due to the increased stirring time or that the 
peptide is more deeply embedded within the particles formed during the longer 
evaporation period.  This could be the result of the oily, polymeric droplets 
coalescing during the extended evaporation period enabling the formation of a 
thicker polymeric layer between the peptide and the surface of the particle.  
However the particles were not significantly larger which might be expected if 
this were the case. 
Encapsulation efficiency was decreased by an increased evaporation time, 
significantly (p≤0.05) so for those formed with 20mg peptide 1, table 4.8.  This 
may be due to the increased time available for the hydrophilic peptide to 
migrate into the outer aqueous phase and avoid encapsulation.  The prolonged 
period of stirring may have detached some of the surface adsorbed peptide 
decreasing the apparent encapsulation efficiency.  This hypothesis is also 
indicated by the more negative charge of the nanoparticles, due to loss of 
positive, surface adsorbed peptide 1.  Despite reduction of encapsulation 
efficiency caused by the increased solvent evaporation duration the peptide 1 
loading of these particles increased.  This was because the yield of the particles 
was reduced so there was more peptide per mg of nanoparticles.   
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Table 4.8 Size, polydispersity, yield, zeta potential, encapsulation efficiency and peptide 1 loading of blank and peptide 1 loaded PLGA 
nanoparticles prepared with a solvent evaporation duration of 2 or 4 hours.  Data represents means ± SD. 
Nanoparticles,  
evaporation duration Size (nm) PDI  Yield (%) 
Zeta potential 
(mV) 
Peptide 1 
loading (ug/mg) 
Encapsulation 
Efficiency (%) 
Blank 2 hrs 271.34 ± 40.54 0.38 ± 0.08 54.0 ± 4.1 -24.87 ± 4.67   
Blank 4 hrs  289.66 ± 24.89 0.36 ± 0.04 69.3 ± 3.8 -26.48 ± 1.95   
           
Peptide 1 10mg 2hrs  293.02 ± 46.46 0.40 ± 0.11  48.5 ± 2.8 -19.93 ± 3.71 60.13 ± 4.38 62.1 ± 6.7 
Peptide 1 10mg 4 hrs 313.10 ± 51.22 0.48 ± 0.09 43.8 ± 1.2 -22.09 ± 1.78 53.92 ± 8.19 54.6 ± 7.6 
  
     
Peptide 1 20mg 2 hrs 304.79 ± 58.65 0.43 ± 0.08 47.8 ± 9.2 -17.53 ± 1.57 100.18 ± 13.42 57.5 ± 5.0 
Peptide 1 20mg 4hrs 265.98 ± 50.03 0.36 ± 0.09 34.9± 9.4 -22.86 ± 2.25 131.93 ± 27.16 48.6 ± 3.9 
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Encapsulation efficiency and peptide 1 loading were calculated by subtracting 
the amount of peptide in supernatants from centrifugation of the emulsions from 
the total peptide 1 added initially.  This won’t account for any peptide losses or 
degradation during formation caused by its exposure to solvent and shear 
stresses so may give an over estimated loading and encapsulation efficiency.  It 
would be better to break down the particles and determine how much intact 
peptide 1 is associated with them.  However, attempts to do this by extracting 
PLGA into DCM and peptide 1 into an aqueous phase resulted in the formation 
of a white precipitate between the phases from which the peptide could not be 
extracted.  Degradation of peptide 1 may also have occurred at the 
solvent/aqueous interface.  Problems with extracting peptides from PLGA 
particles using this method have been encountered before (Blanco and Alonso, 
1997). 
The nanoparticles formed after 4 hours solvent evaporation appear to be larger 
and more spherical than those formed after 2 hours, figures 4.4-4.6.  The 
prolonged evaporation period may have allowed coalescence and larger particle 
formation.  The longer stirring duration may have caused more spherical 
particles to form.  However size analysis revealed there were no significant 
differences in the size of the particles.  This may be due to aggregation of the 
particles formed after 2 hours solvent evaporation. 
 
4.4 (a)                                                        4.4 (b) 
Figure 4.4 SEM images of blank PLGA nanoparticles prepared after (a) 2 hours 
solvent evaporation, (b) 4 hours solvent evaporation 
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4.5 (a)                                                        4.5 (b) 
Figure 4.5 SEM images of 10mg peptide 1 loaded PLGA nanoparticles 
prepared after: (a) 2 hours solvent evaporation, (b) 4 hours solvent evaporation 
 
4.6 (a)                                                       4.6 (b) 
Figure 4.6 SEM images of 20mg peptide 1 loaded PLGA nanoparticles after: 
(a) 2 hours solvent evaporation (b) 4 hours solvent evaporation 
Some of the images show the presence of visible pores in the nanoparticle’s 
surface figures 4.4 (b), 4.5 (a) & (b) and 4.6 (b).  There appear to be more in 
nanoparticles initially loaded with 10mg of peptide 1.  Peptide 1 in the inner 
aqueous phase may have increased the osmotic pressure between the 
aqueous phases causing the solvent to burst from the particles rupturing them.  
This has previously occurred when the drug concentration of the inner aqueous 
phase was increased (Lamprecht et al., 1999).   
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Pores appeared in the particles formed after both evaporation durations but 
there seem to be more in those prepared by the longer evaporation period 
possibly as there is greater opportunity for pore formation. 
4.5.2.3 In vitro release 
There was a slight decrease in the proportion of peptide released from the 
particles formed by a longer solvent evaporation period, but not significantly so, 
figure 4.7.  This may have been due to the loss of surface adsorbed peptide by 
the increased stirring duration which would have reduced, comparatively, initial 
release. 
Figure 4.7 Cumulative release of peptide 1 from PLGA nanoparticles prepared 
after 2 or 4 hours solvent evaporation.  Error bars show mean ± SD. 
Previous investigations found an increased evaporation time of 24 hours 
produced particles with a higher initial release compared to those prepared with 
a 30 minute solvent evaporation time (Luan et al., 2006).  During the longer 
evaporation period the peptide may have partitioned from the interior of the 
particles to the surface providing a greater burst release.  The 4 hour 
evaporation period may not have been long enough for this to occur to an 
extent to significantly increase initial release. 
There was an immediate release of peptide 1 from the nanoparticles upon 
addition to PBS.  This may be the detachment of surface adsorbed peptide 
which may be present due to an electrostatic interaction between the positively 
charged peptide and negatively charged particle.   
0 
2 
4 
6 
8 
10 
12 
14 
16 
0 200 400 600 800 1000 1200 1400 
C
u
m
u
la
ti
ve
 r
e
le
as
e
 (
%
) 
Time (mins) 
10mg 2 hrs 
10mg 4hrs 
20mg 2 hrs 
20mg 4 hrs 
226 
 
It may also be the result of transit of hydrophilic peptide 1 from the inner 
aqueous phase to the external aqueous phase of the double emulsion, 
localising it to the particle surface. 
Peptide 1 release from the nanoparticles prepared after 2 hours solvent 
evaporation was also measured after one and two weeks.  There was no further 
peptide 1 release from these particles.  The peptide may still be within the 
particles and may be released after this period as PLGA particles can provide a 
sustained GnRH agonist release over 1 and 3 months, table 4.1.  The peptide 
released may have been degraded before it could be measured.  It would be 
useful to test if peptide 1 is stable in PBS over prolonged periods or is degraded 
following its release.  This apparent large incomplete release may also be due 
to an overestimate of peptide 1 loading calculated by the subtraction method.  A 
better method for determining encapsulation efficiency and peptide loading is 
needed to determine exactly how much peptide has been encapsulated. 
Incomplete peptide release from PLGA particles has previously been reported 
(Wu et al., 2012b, Blanco and Alonso, 1998).  The positively charged 
encapsulated protein in these cases was thought to interact with the degrading 
microspheres of negatively charged PLGA preventing its release.  This may be 
occurring here as peptide 1 is positively charged.  It would be useful to place 
peptide 1 and PLGA in PBS to see if there is an interaction between them which 
could restrict peptide 1 extraction.  To prevent this interaction and enable 
complete release additional excipients could be included in the formulation.   
For future work the shorter evaporation time, 2 hours, was selected due to the 
higher encapsulation efficiency.  It would be useful to further reduce the solvent 
evaporation period to see if encapsulation efficiency could be increased.  
However, there is a risk that solvent evaporation may not be complete after 
shorter evaporation periods resulting in incomplete polymer precipitation and 
nanoparticle formation. 
4.5.2.4 External aqueous phase PVA concentration 
Reduction of PVA concentration from 2.5% to 1.25% significantly (p≤0.05) 
reduced particle size and polydispersity of blank and peptide 1 loaded 
nanoparticles, table 4.9.   
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Table 4.9 Size, polydispersity, yield, zeta potential, encapsulation efficiency and peptide 1 loading of blank and peptide 1 loaded PLGA 
nanoparticles prepared in a 1.25% or 2.5% PVA outer aqueous phase.  Data represents means ± SD. 
Nanoparticles, outer 
aqueous phase PVA 
concentration Size (nm) PDI Yield (%) 
Zeta potential 
(mV) 
Peptide 1 
loading (ug/mg) 
Encapsulation 
Efficiency (%) 
Blank 1.25% PVA  174.19 ± 7.69 0.18 ± 0.04 41.3 ± 7.0 -26.71 ± 3.35   
Blank 2.5% PVA  271.34 ± 40.54 0.38 ± 0.08 54.0 ± 4.1 -24.87 ± 4.67   
              
Peptide 1 10mg 1.25% PVA  175.28 ± 11.95 0.18 ± 0.07 45.4 ± 5.8 -21.29 ± 4.36 60.76 ± 3.24 62.6 ± 1.6 
Peptide 1 10mg 2.5% PVA  293.02 ± 46.46 0.40 ± 0.11 48.5 ± 2.8 -19.93 ± 3.71 60.13 ± 4.38 62.1 ± 6.7 
              
Peptide 1 20mg 1.25% PVA 170.56 ± 10.09 0.15 ± 0.07 42.5 ± 9.8 -16.19 ± 2.81 96.14 ± 15.47 54.8 ± 0.9 
Peptide 1 20mg 2.5% PVA  304.79 ± 58.65 0.43 ± 0.08 47.8 ± 9.2 -17.53 ± 1.57 100.18 ± 13.42 57.5 ± 5.0 
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In previous studies an increased PVA concentration generally decreased 
particle size, possibly due to increased stabilisation of the emulsion droplets, 
which is the opposite of what has been found here (Nam et al., 2000, Sun et al., 
2011b, Zambaux et al., 1998, Lamprecht et al., 1999, Yang et al., 2001).  
However, another study also found a lower PVA concentration decreased PLGA 
particle size (Shi et al., 2009).  It was concluded here a reduced PVA 
concentration reduced the viscosity of the outer aqueous phase allowing faster 
solvent evaporation and more rapid particle formation.  This may prevent the 
formation of larger particles or coalescence of polymer droplets.   
Charge, yield, encapsulation efficiency and loading were not significantly 
affected by the change in outer aqueous phase PVA concentration, table 4.9.  
Another study found that a reduction of PLGA particle size and interfacial 
tension caused by an increased PVA concentration reduced the encapsulation 
efficiency (Nam et al., 2000).  Fortunately here neither an increased PVA 
concentration nor decreased particle size significantly reduced peptide 1 
loading or encapsulation efficiency. 
A reduction in outer aqueous phase PVA concentration clearly produced 
smaller and more uniform blank and peptide loaded nanoparticles, figures 4.8-
10.  There were some visible pores in the nanoparticles formed in an outer 
aqueous phase of 2.5% PVA (figures 4.9 (b), 4.10 (b)) but these were not 
visible in particles produced with 1.25% PVA.  The increased viscosity of the 
2.5% PVA outer aqueous phase may have slowed solvent evaporation and 
allowed pores to form.   The presence of pores may allow immediate peptide 
release upon oral administration which could be degraded before it can be 
absorbed. 
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4.8 (a)                                                       4.8 (b) 
Figure 4.8 SEM images of blank PLGA nanoparticles prepared in (a) 1.25% 
PVA and (b) 2.5% PVA 
 
4.9 (a)                                                     4.9 (b) 
Figure 4.9 SEM images of 10mg peptide 1 loaded PLGA nanoparticles 
prepared in (a) 1.25% PVA and (b) 2.5% PVA 
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4.10 (a)                                                      4.10 (b) 
Figure 4.10 SEM images of 20mg peptide 1 loaded PLGA nanoparticles 
prepared in (a)1.25% PVA and (b) 2.5% PVA 
4.5.2.5 In vitro release 
There was no significant difference in release of peptide 1 from particles formed 
with different outer aqueous phase PVA concentrations, figure 4.11.  
Figure 4.11 Cumulative peptide 1 release in pH 7.4 phosphate buffer from 
PLGA nanoparticles prepared in an outer aqueous phase of 1.25% or 2.5% 
PVA.  Error bars show mean ± SD. 
There was an immediate release of approximately 10% of the loaded peptide 
from the nanoparticles as was reported in section 4.5.4.1.   
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This again may be due to the detachment of peptide 1 weakly associated with 
the particle surface and could be vulnerable to enzymatic digestion when orally 
delivered.  There was no further peptide 1 release after one or two weeks.  The 
reasons for this incomplete peptide release were described in section 4.5.2.3. 
The lower PVA concentration, 1.25%, was selected for future use as it produced 
significantly smaller nanoparticles which would have an increased probability for 
absorption into the bloodstream.  It would be useful to further decrease PVA 
concentration to investigate if particle size could be further reduced and 
minimise any residual PVA in the nanoparticles. 
4.5.2.6 Inner aqueous phase peptide 1 concentration 
Peptide 1 concentrations in the inner aqueous phase of the nanoparticles 
produced in the studies above were 10mg/ml and 20mg/ml.  The size of the 
nanoparticles was not significantly affected by changes in the peptide 
concentration, tables 4.8 and 4.9. 
The charge of peptide 1 loaded nanoparticles was significantly (p≤0.05) more 
positive than for the blank nanoparticles, tables 4.8 and 4.9.  This indicates the 
presence of positively charged peptide 1.  An increase in peptide 1 
concentration from 10 to 20mg/ml, in particles produced with an outer aqueous 
phase of 1.25% PVA, also produced significantly more positive particles. 
An increased peptide 1 concentration produced nanoparticles with a 
significantly (p≤0.05) greater peptide 1 loading, tables 4.8 and 4.9.  However 
the encapsulation efficiency was not significantly increased, as it had been in 
previous studies (Luan et al., 2006, Sun et al., 2011b).  In fact encapsulation 
efficiency of peptide 1 was significantly (p≤0.05) reduced by increasing the 
peptide concentration of particles produced with a 1.25% PVA outer aqueous 
phase.  Possibly there is a finite amount of peptide that can be encapsulated 
with a certain amount of polymer and any more added will not be encapsulated, 
reducing the encapsulation efficiency. 
The presence of peptide 1 appeared to increase the pores visible on the surface 
of the nanoparticles and has been observed previously (Lamprecht et al., 1999), 
figures 4.5, 4.6, 4.9 and 4.10.   
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This may be caused by an increased osmotic pressure between the inner and 
external aqueous phases causing the particles to rupture and pores to form.  
The presence of pores might be expected to increase immediate peptide 
release, however this was not seen, figures 4.7 and 4.11.  In fact an increased 
peptide 1 concentration significantly reduced the percentage of peptide 1 
released from particles prepared in an outer aqueous phase of 2.5% after 2 
hours solvent evaporation.  The amount of peptide 1 released from both sets of 
particles was similar but due to the increased loading of the particles prepared 
with 20mg of peptide 1 the proportion of its load released was reduced.  The 
amount of peptide 1 released may represent the amount of peptide 1 
associated with the surface of the nanoparticles which was the same for both as 
they are similar sizes. 
In further tests it would be useful to assess if PLGA encapsulation can increase 
peptide 1 stability with gastrointestinal enzymes, in vitro permeability and in vivo 
peptide 1 oral bioavailability. 
4.5.3 Chitosan coated PLGA nanoparticles 
To enhance the permeation of peptide 1 loaded PLGA nanoparticles they were 
coated with chitosan.  Coating the PLGA nanoparticles with chitosan 
significantly (p≤0.05) increased their size and polydispersity, table 4.10.  The 
increased size indicates that chitosan has coated the particles.  It may also be 
due to increased viscosity of the external aqueous phase decreasing shear 
stress on the PLGA organic phase, therefore producing larger emulsion droplets 
(Guo and Gemeinhart, 2008).  The greater polydispersity of the particles 
suggest the particles may be coated to varying extents with chitosan.  The 
mucoadhesivity of the chitosan may also have caused the formation of some 
larger aggregates of particles.  The particles loaded with peptide 1 had a mean 
size greater than 300nm which may prevent their cellular uptake and therefore 
reduce their absorption into the systemic circulation (Gaumet et al., 2009, Desai 
et al., 1996, Qaddoumi et al., 2004).  This may be negated by the ability of 
chitosan to adhere to the intestinal membranes and open paracellular channels 
between cells. 
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Table 4.10 Size, polydispersity, yield and charge of blank and peptide 1 loaded 
PLGA nanoparticles with a chitosan coating.  Data represents means ± SD. 
Chitosan coated 
nanoparticles Size (nm) PDI Yield (%) 
Zeta potential 
(mV) 
Blank  291.91 ± 49.76 0.49 ± 0.11 17.6 ± 1.6 26.56 ± 9.05 
Peptide 1  350.13 ± 44.70 0.58 ± 0.13 21.6 ± 1.8 31.42 ± 1.12 
 
The positive zeta potential is another indication of successful chitosan coating, 
table 4.10.  This should promote interaction with the negatively charged cell 
membranes of the intestinal tract and may increase oral bioavailability of the 
peptide.  The increased positive charge of the peptide 1 loaded particles 
compared to the blank particles indicates the presence of the positively charged 
peptide.  The yield of the coated particles is significantly (p≤0.05) lower than for 
the uncoated particles but this may be misleading as the yield calculation 
includes all the chitosan added.  Not all the chitosan would have coated the 
nanoparticles and would have been lost accounting for the lower yields. 
The chitosan coated nanoparticles in figure 4.12 are slightly larger and less 
spherical than the uncoated nanoparticles, figure 4.8 (a).  This may indicate 
chitosan coating of the nanoparticles. 
Chitosan coated nanoparticles had a significantly (p<0.05) lower peptide 1 
loading and encapsulation efficiency than the uncoated nanoparticles, table 
4.11.  This may be due to electrostatic repulsion between the positively charged 
peptide and chitosan.   
Table 4.11 Peptide 1 loading and encapsulation efficiency in PLGA 
nanoparticles with a chitosan coating.  Data represents means ± SD. 
Chitosan coated 
nanoparticles 
Peptide 1 loading 
(ug/mg) 
Encapsulation Efficiency 
(%) 
Peptide 1 35.09 ± 1.28 46.3 ± 4.9 
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4.12 (a)                                                      4.12 (b) 
Figure 4.12 SEM images of chitosan coated PLGA nanoparticles (a) blank     
(b) 10mg peptide 1 loaded 
4.5.3.1 In vitro release 
Chitosan coated particles released a very small proportion (≤1%) of their 
encapsulated peptide, significantly (p≤0.05) less than the uncoated particles in 
PBS, table 4.12.  This could be due to a slower erosion rate of the chitosan 
coated particles and longer diffusion pathway of the peptide out of the 
nanoparticles.  Lower peptide release may also be due to less peptide on the 
surface of the nanoparticles due to electrostatic repulsion between chitosan and 
peptide 1.   
Table 4.12 Peptide 1 release from chitosan coated PLGA nanoparticles in PBS.  
Data represents means ± SD. 
 Chitosan 
coated 
nanoparticles 
30 mins 
release  
(%) 
120 mins 
release  
(%) 
240 mins 
release  
(%) 
480 mins 
release 
 (%) 
Peptide 1 1.0 ± 0.7 0.6 ± 0.3 0.8 ± 0.5 0.5 ± 0.1 
 
There was no further measurable peptide release after 8 hours.  Samples were 
taken after 1 and 2 weeks but there was no peptide detected.  This incomplete 
release may be due to the reasons previously described in section 4.5.2.3. 
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It would be useful to investigate if the chitosan coating can increase the in vitro 
absorption and in vivo oral bioavailability of peptide 1 compared to uncoated 
PLGA nanoparticles and the peptide alone. 
4.5.4 Peptide 1 efficacy 
The efficacy of the chemotherapeutic peptide, peptide 1, was assessed with 
breast cancer cells.  Peptide 1 loaded PLGA nanoparticles and chitosan coated 
nanoparticles were added to the cells to assess if their production had impaired 
the therapeutic action of peptide 1.  The viability of the cells was measured to 
assess if the peptide was able to successfully limit their growth compared to 
controls with no formulation added.  Blank nanoparticles were also added to 
cells to determine their toxicity alone. 
Two different tests were carried out to assess cell viability.  The viability reagent 
PrestoBlueTM is reduced by metabolically active cells to a red colour.  However, 
this did not occur in any of the samples and the absorbance values for the cells 
with or without formulation were not significantly different, table 4.13.  This 
indicates none of the cells were active.  Crystal violet was used to stain viable 
cells which were fixed by methanol.  Again there were no significant differences 
in the absorbance values for the cells incubated alone or with a formulation.  
The absorbance values were also very low suggesting there were very few 
viable cells left.   
Table 4.13 Absorbance values from PrestoBlueTM and crystal violet cell viability 
assays performed on MDA-MB-231, breast cancer cells, alone and with peptide 
1 formulations.  Data represents means ± SD. 
 Formulation added to cells 
PrestoBlue- 
Absorbance 
Crystal violet- 
Absorbance 
No formulation 0.44 ± 0.02 0.07 ± 0.00 
Blank PLGA nanoparticles 0.45 ± 0.02 0.09 ± 0.01 
Blank chitosan coated nanoparticles 0.45 ± 0.02 0.08 ± 0.01 
Peptide 1 0.46 ± 0.01 0.09 ± 0.02 
PLGA nanoparticles with peptide 1 0.46 ± 0.02 0.09 ± 0.02 
Chitosan coated peptide 1 nanoparticles 0.44 ± 0.02 0.08 ± 0.01 
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It appears the cells may have died during testing and therefore the effect of 
peptide 1 either alone or released from the nanoparticles on the proliferation of 
the breast cancer cells could not be assessed.  Possibly the cells should have 
been tested for viability within a few days rather than a week.  Further work to 
determine the efficacy of peptide 1 released from the PLGA nanoparticles 
should be conducted with prostate and breast cancer cell lines to determine if 
their formulation hindered its efficacy. 
4.5.5 Enteric microencapsulation 
The in vitro release studies showed encapsulated peptide 1 was immediately 
burst released from the nanoparticles.  To minimise degradation of prematurely 
released peptide 1 enteric coating and microencapsulation of nanoparticles 
were combined. 
In chapters 2 and 3 the proteins lactase and insulin were successfully 
encapsulated in enteric Eudragit L100 microparticles using a method developed 
for the encapsulation of low molecular weight drugs (Kendall et al., 2009).  
While these particles were not impermeable to acid they provided protection 
from pepsin and a pH dependent release.  Peptide 1 is not hydrolysed at gastric 
pH, possibly due to its small size and simple structure.  It is slowly degraded by 
pepsin so encapsulation in these microparticles should ensure a greater amount 
reaches the small intestine intact.  However, here peptide 1 would be vulnerable 
to enzymatic digestion.  Enteric microencapsulation of peptide 1 loaded PLGA 
nanoparticles would ensure the peptide is protected from small intestinal 
enzymes when released there and would benefit from the permeation 
enhancing effects of encapsulation in PLGA particles and chitosan. 
The novel use of the Kendall et al method to encapsulate peptide 1 loaded 
PLGA nanoparticles in enteric Eudragit L100 microparticles should provide 
pepsin protection to any peptide exposed on the nanoparticle surface or any 
peptide that would have been burst released in the stomach.  The acid stability 
of peptide 1 also means any acid permeating the microparticles would not 
degrade its primary structure.  The rapid pH dependent release upon entry in 
the small intestine will also provide a high local concentration of the 
nanoparticles which could promote uptake by an increased concentration 
gradient.   
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This method is compatible with PLGA nanoparticle encapsulation as Eudragit 
L100 is dissolved in ethanol, which PLGA is not soluble in, so they will remain 
intact in the polymeric suspension. 
4.5.5.1 Microparticle size, span, yield and morphology 
The microparticles formed were micron sized and all had a dv, 0.5 less than 
100μm, except those produced with peptide 1 alone, table 4.14.  The smaller 
particles produced with the peptide 1 nanoparticles may be the result of residual 
PVA acting as an emulsifier.   The span of the microparticles is quite large and 
may indicate the presence of some aggregates (>1).  None of the particle yields 
are greater than 80%, this may be a result of reducing the amounts of 
excipients relative to that used by Kendall et al. in their optimised method. 
Table 4.14 Size, span and yield of blank, peptide 1, peptide 1 PLGA 
nanoparticles and blank nanoparticles loaded in Eudragit L100 microparticles.  
Data represents means ± SD. 
Microparticles Size (μm) Span Yield (%) 
Peptide 1 352.11±82.27 1.43±0.35 42.64±4.66 
Blank  54.41 ± 2.13 3.84 ± 0.11 73.10 
Peptide 1 nanoparticles  41.05 ± 6.67 5.38±2.55 65.3 ±13.1 
Blank nanoparticles  86.17 ± 19.42 3.54±1.99 70.2 
 
Blank Eudragit L100 microparticles were spherical but some were very large, 
figure 4.13 (a).  Eudragit L100 microparticles with encapsulated peptide 1 were 
aggregated together to form chains of smaller, individual microparticles, figure 
4.13 (b).  Due to the larger size of these aggregates they may not empty as 
rapidly from the stomach as smaller particles.  Possibly additional surfactant is 
required to ensure this aggregation doesn’t occur. 
The nanoparticle loaded microparticles were fairly spherical, uniform and less 
than 100µm, figures 4.13 (c) and (d).  They should empty rapidly and uniformly 
from the stomach immediately releasing the nanoparticles in the small intestine, 
creating a high local concentration.  There were no visible nanoparticles 
indicating that they have been encapsulated in the microparticles.   
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4.13 (a)                                                      4.13 (b) 
 
4.13 (c)                                                      4.13 (d) 
Figure 4.13 SEM images of Eudragit L100 microparticles (a) blank, with 
encapsulated (b) peptide 1 (c) blank PLGA nanoparticles (d) peptide 1 PLGA 
nanoparticles 
Split microparticles with encapsulated peptide 1 or peptide 1 nanoparticles 
revealed a porous interior, figure 4.14 (a), (b) and (c).  No nanoparticles could 
be discerned in the microparticles, figure 4.14 (a) and (b). 
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4.14 (a)                                                       4.14 (b) 
 
4.14 (c) 
Figure 4.14 SEM images of split Eudragit L100 microparticles (a) & (b) with 
encapsulated peptide 1 PLGA nanoparticles, (c) with encapsulated peptide 1 
The microparticles with encapsulated nanoparticles do not appear to be 
different to the microparticles without nanoparticles.  Possibly it would be 
difficult to identify any nanoparticles within the polymer matrix of the 
microparticles and at this magnification. 
4.5.5.2 Peptide 1 loading and encapsulation efficiency 
Encapsulation efficiency of peptide 1 alone was less than 50%, table 4.15.  This 
may be due to; peptide 1 partitioning to the liquid paraffin phase, reducing the 
amounts of excipients to that of the Kendall et al. method and the possible 
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incomplete formation of discrete particles.  Peptide 1 loading of the 
microparticles containing peptide 1 nanoparticles was not experimentally 
determined but calculated assuming 100% encapsulation of the nanoparticles.  
Encapsulation efficiency of peptide 1 was much less than for lactase and insulin 
in chapters 2 and 3.  Possibly its smaller size enables it to escape 
encapsulation. 
Table 4.15 Peptide 1 loading and encapsulation efficiency in Eudragit L100 
microparticles.  Data represents means ± SD. 
Microparticles 
Peptide 1 loading 
(μg/mg) 
Encapsulation efficiency 
(%) 
Peptide 1 25.70±2.01 41.12±3.21 
Peptide 1 nanoparticles 5.31 ± 0.19 - 
 
4.5.5.3 In vitro release  
There was an immediate burst release of peptide 1 from the PLGA 
nanoparticles in 0.1N HCl, figure 4.15.  There was a significantly (p<0.05) 
higher proportion of peptide 1 immediately released than in PBS, pH 7.4.  
Faster erosion of PLGA particles in acid has been observed previously and 
attributed to acid hydrolysis of the PLGA polymer (des Rieux et al., 2007).  This 
may be detrimental to the bioavailability of orally administered peptide 1 as it 
would first encounter the acidic pH of the stomach and may leave it vulnerable 
to pepsin digestion.   
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Figure 4.15 Peptide 1 release from PLGA nanoparticles initially loaded with 
10mg peptide 1 in 0.1N HCl for 2 hours followed by pH rise to pH 6.8.  Error 
bars show mean ± SD. 
Enteric microparticles encapsulating peptide 1 alone released <10% of peptide 
1 in acid, figure 4.16.  At pH 6.8 there was almost complete release, 97%.  This 
demonstrates the ability of these microparticles to prevent release of peptide 1 
in the stomach avoiding pepsin digestion.  However, when released in the small 
intestine it would be vulnerable to enzymatic digestion and the formulation lacks 
permeation enhancers. 
Figure 4.16 Peptide 1 release from Eudragit L100 microparticles in 0.1N HCl for 
2 hours and 45 minutes in pH 6.8 phosphate buffer.  Error bars show mean ± 
SD. 
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Enteric microparticles with encapsulated peptide 1 nanoparticles released <2% 
of peptide 1 in acid, figure 4.17.  At pH 6.8 there was a 7% release of peptide 1.  
The enteric microparticles restricted peptide 1 burst release in acid so should 
protect it from pepsin digestion when orally administered.  It would be useful to 
test the particles with pepsin and determine if they can increase in vivo oral 
bioavailability compared to peptide 1 alone or when encapsulated in PLGA 
nanoparticles only.  The peptide release upon pH rise mirrors its burst release 
in PBS.  Peptide 1 burst released in the duodenum would be more stable than if 
released further along the small intestine due to its lower proteolytic activity.  
Enteric microparticles are preferable to larger enteric dosage forms for their 
rapid release of encapsulated entities in the small intestine.  Release from 
larger enteric dosage forms may be delayed until further along the small 
intestine due to their smaller surface area.  This would release nanoparticles 
into a more proteolytic environment and increase the likelihood of peptide 
degradation. 
 
Figure 4.17 Peptide 1 release from PLGA nanoparticles encapsulated in 
Eudragit L100 microparticles in 0.1N HCl for 2 hours and 45 minutes in pH 6.8 
phosphate buffer.  Error bars show mean ± SD. 
The release pattern of peptide 1, if not the percentages released, from Eudragit 
L100 microparticles and from PLGA nanoparticles encapsulated within 
microparticles were very similar.  This could mean the peptide and 
nanoparticles have been encapsulated as separate entities and not together.   
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It could be argued that as the profiles are so similar there is little benefit in first 
encapsulating the peptide in nanoparticles.  However, some of the peptide 
should remain within the nanoparticles and be protected in the small intestine 
and absorbed associated with the PLGA particles unlike peptide 1 alone.   
Peptide 1 release from PLGA nanoparticles encapsulated in enteric 
microparticles in acid was significantly (p≤0.05) reduced compared to its release 
from unencapsulated nanoparticles, figure 4.18.  Upon pH rise peptide 1 was 
burst released from the nanoparticles released from the microparticles.  By 
delaying the peptide burst release until the upper small intestine pepsin 
digestion in the stomach will be avoided.  The duodenum has been shown to be 
more favourable for peptide stability so release here is better than in the distal 
small intestine.  Peptide 1 release from the nanoparticles was again very low 
over 24 hours, this incomplete release may be due to reasons outlined in 
section 4.5.4.1. 
Figure 4.18 Peptide 1 release from PLGA nanoparticles and from PLGA 
nanoparticles encapsulated within Eudragit L100 microparticles after 2 hours in 
0.1N HCl and 45 minutes in pH 6.8 phosphate buffer.  Error bars show mean ± 
SD. 
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4.6 Conclusion  
The feasibility of delivering peptide 1 orally was investigated by incubation with 
simulated and porcine intestinal fluids and human faecal fluids.  These studies 
revealed that the primary structure of peptide 1 was stable at gastric pH but was 
susceptible to digestion by GI enzymes.  This instability was not uniform along 
the GI tract.  Peptide 1 was most stable in gastric and duodenal fluids and was 
increasingly digested along the small intestine and in the porcine colonic and 
human faecal fluids. 
To provide protection from intestinal degradation and increase its absorption 
into the systemic circulation peptide 1 was encapsulated in PLGA nanoparticles.  
The parameters of the double emulsion solvent evaporation method used to 
form the particles were varied to produce nanoparticles with optimal 
characteristics for oral delivery. 
The longer solvent evaporation duration of 4 hours significantly reduced the 
encapsulation efficiency of peptide 1 in the nanoparticles, initially loaded with 
20mg peptide 1, from 57.5 to 48.6%.  The increased evaporation time may have 
allowed hydrophilic peptide 1 to partition into the external aqueous phase 
evading encapsulation.  The extended stirring time may have caused loss of 
surface associated peptide so for these reasons the shorter evaporation time of 
2 hours was selected for further PLGA nanoparticle production.   
The lower PVA concentration, 1.25%, in the outer aqueous phase significantly 
reduced nanoparticle size to less than 200nm and, as a small particle size is 
critical for absorption, this concentration was selected for use.  Formation of 
smaller particles might be due to faster solvent evaporation and particle 
formation due to the decreased viscosity of an external aqueous phase.  
Successful peptide loading was indicated by the charge of the nanoparticles 
becoming increasingly positive when positively charge peptide 1 was included 
in the formulations.   
Chitosan coating of the PLGA nanoparticles was conducted to enhance 
intestinal permeation.  Chitosan coating significantly increased nanoparticle 
size, to more than 300nm, which may hamper its permeation.  However, its 
other permeation enhancing effects may counteract this.   
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Chitosan coating significantly reduced peptide 1 loading, from 61 to 35µg/mg, 
and encapsulation efficiency, from 63% to 46%, compared to the uncoated 
particles.  This may be due to electrostatic repulsion between positively charged 
chitosan and peptide 1.  Peptide 1 release in vitro was significantly reduced 
from 11% in 30 minutes from the uncoated particles to only 1% from the 
chitosan coated nanoparticles.  This may be due to an increased diffusion 
pathway.   
In vitro the PLGA nanoparticles immediately released approximately 10% of the 
peptide 1 load in 30 minutes, followed by very little further release up to 2 
weeks later.  This pattern of in vitro release does not bode well for oral peptide 
1 bioavailability.   Any peptide 1 immediately released upon oral administration 
may be subject to pepsin digestion in the stomach and further enzymatic 
digestion in the small intestine.  The peptide not released but remaining within 
the nanoparticles may, based on these results, not ever be released and so 
would be unable to halt tumour growth.  The lack of any further detectable 
peptide release could be a result of the peptide degrading when it is released.  
Incomplete release may also be caused by the positively charged peptide 
interacting with negatively charged PLGA.   
The novel use of the Kendall et al method to encapsulate peptide 1 loaded 
PLGA nanoparticles in enteric Eudragit L100 microparticles significantly 
reduced peptide 1 burst release in acid compared to peptide 1 nanoparticles, 
from 15% to 1%, which should prevent its digestion in the stomach.  The rapid 
pH dependent release in the small intestine should provide a high concentration 
of the nanoparticles which could promote uptake by an increased concentration 
gradient.  There was still a burst release of peptide 1 from the released 
nanoparticles which in vivo may be vulnerable to digestion in the small intestine 
but at least this would occur in the duodenum where peptide 1 was shown to be 
more stable than the other small intestinal segments. 
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Chapter 5 
Final conclusions and future work 
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5.1 Conclusion 
Very few protein/peptide drugs are currently orally available due to acidic and 
enzymatic instability in the GI tract and their large size and hydrophilicity limiting 
their absorption from the intestinal tract into the bloodstream.  Oral delivery 
strategies are being actively pursued by academic and industrial research 
groups to increase oral bioavailabilities from less than 1% to 30-50% (Shaji and 
Patole, 2008). 
One of the aims of this project was to compare the intestinal stability of protein 
and peptide drugs of varying size using simulated and porcine gastrointestinal 
fluids and a human faecal slurry. Those studied in this project were a large 
protein, lactase, 464 kDa, a small protein, insulin, 5.8 kDa, and a small peptide, 
peptide 1, 1.2 kDa.  Lactase was immediately denatured at fasting stomach pH 
whereas the primary structures of insulin and peptide 1 were not unstable.  This 
may be due to disruption of the weak interactions holding together the more 
complex structure of lactase by ionisation changes caused by the low pH.  The 
2 polypeptide chains of insulin are primarily held together by stronger disulphide 
bonds which may not be affected at low pH.  The simpler structure of peptide 1 
may make it more stable at low pH. 
Lactase was stable with intestinal enzymes possibly due to inaccessibility of its 
peptide bonds to the digestive enzymes.  The smaller protein insulin was 
immediately digested by gastric, small intestinal and large intestinal enzymes.  
This may be due to greater accessibility of its peptide bonds to digestive 
enzymes and possible loss of the disulphide bonds holding its polypeptide 
chains together by the presence of glutathione.  Peptide 1 was degraded by 
enzymes in all GI fluids but more gradually than insulin over a two hour period.  
This may be due to there being less bonds susceptible to digestion as it simply 
has less amino acids.   
To overcome acid instability of lactase and pepsin digestion of insulin they were 
encapsulated in enteric Eudragit L100 microparticles.  Oral delivery of both 
these drugs must be carefully coordinated with food consumption as they must 
be available to digest it or control the effects of its digestion.  Delayed drug 
release at small intestinal pH and delayed efficacy caused by food has 
previously been observed with enteric tablets or capsules.   
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By reducing dosage form size this delayed release can be avoided as the 
greater surface area can provide a faster and more uniform drug release in the 
small intestine and their ability to mix with the contents of the stomach and 
rapidly empty avoids delays caused by food.  This should also help to minimise 
variability in absorption and bioavailability and allow effective and rapid control 
of symptoms. 
The preparation of enteric micro and nanoparticulates can pose a threat to the 
integrity of protein and peptide drugs.  An oil in oil emulsion solvent evaporation 
method previously used for encapsulation of small molecular weight drugs in 
enteric Eudragit microparticles was used due to its use of the less toxic ethanol 
to dissolve the polymer and its lack of any high shear homogenisation steps.  It 
also required no control of temperature making it a far simpler method and 
possibly more attractive for future commercial use.  Lactase and insulin were 
both successfully encapsulated in Eudragit L100 microparticles by this method 
with a high yield and encapsulation efficiency, >70%, and uniformly sized 
particles less than 100µm were produced which should allow rapid and uniform 
gastric emptying and drug release. 
Eudragit L100 microparticles were able to control the release of lactase and 
insulin in a pH dependent manner, once lactase particle size had been reduced 
by spray drying allowing a deeper encapsulation.  Below pH 6 there was <30% 
release of encapsulated drug, this release was probably protein drug held at the 
surface of the particles.  The particles were able to protect insulin from pepsin 
digestion, 80% remaining intact after 2 hours with the enzyme in SGF and 49% 
after 2 hours in porcine gastric fluid, however encapsulated lactase was 
completely inactivated after incubation of the microparticles in 0.1N HCl.   
As it was established that most of the encapsulated lactase remained within the 
particles it was hypothesised acid may be able to enter the particles.  An 
investigation into the porosity and morphology of the particles revealed a porous 
interior and by using an SEM with a new back scatter detector, crystal-like 
structures were observed on the surface of the particles.  It was concluded 
these are most likely to be residual surfactant and they disappeared when 
incubated in acid.  This may provide a means for acid to enter the particles as 
they appear not to be solely composed of the acid resistant polymer.   
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To overcome acid permeability antacids were co-encapsulated to protect 
lactase.  Co-encapsulated magnesium hydroxide provided the greatest 
protection of lactase, 9.2% remaining intact after 2 hours in acid, superior to any 
of the oral lactase supplements tested during this study. 
Insulin release at pH 6.8 was rapid and complete within 45 minutes.  This 
should enable fast insulin absorption in vivo and rapid control of post prandial 
glycemia.  Release of insulin from Eudragit L100 particles was faster than from 
particles of the same polymer prepared with an outer aqueous phase and DCM 
as the solvent to dissolve the polymer.  Possibly the faster evaporation of DCM 
than ethanol did not allow as many or as large pore formation so their 
breakdown was slower.  It would be useful to explore further the effects of 
solvents and outer aqueous phase on the morphology of the particles. 
As insulin is also very unstable with small intestinal enzymes a protease 
inhibitor, citric acid, was included in the microparticles.  Its release in the small 
intestine should provide intestinal protection.  Citric acid reduced insulin 
degradation with pancreatin but caused large aggregates of microparticles to 
form.  The inclusion of magnesium hydroxide with lactase in the microparticles 
also caused aggregation of the particles.  This may have been due to a 
plasticising effect on the Eudragit L100 polymer.  More work is needed to find 
an optimal ratio to form microparticles. 
The recently discovered chemotherapeutic peptide 1 was the most stable of the 
proteins/peptide tested, possibly due to its smaller size.  However, it is still large 
compared to commonly orally delivered low molecular weight drugs so will still 
encounter permeability limitations and is gradually degraded by enzymes 
throughout the GI tract.  PLGA particles are currently used for the injectable, 
prolonged release of chemotherapeutic peptides of a similar size and structure 
to peptide 1.  Due to this compatibility and ability of PLGA nanoparticles to 
provide enzyme protection, without causing digestive disruption, and increased 
permeability, without disrupting intestinal cell membranes, they were selected 
for formulation of peptide 1.   
All the PLGA nanoparticles produced a rapid peptide 1 burst release in PBS 
followed by very little further release over 24 hours and up to 2 weeks in some 
cases, overall less than 20% was released.  
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Incomplete release may be caused by destruction of the peptide when released 
or possibly interaction of cationic peptide 1 with anionic, degrading PLGA .  To 
limit burst release of peptide 1 in the stomach, where it would be gradually 
degraded by pepsin, the peptide 1 loaded PLGA nanoparticles were 
encapsulated in Eudragit L100 microparticles using the method previously used 
for lactase and insulin.  The microparticles produced were <100µm and reduced 
peptide 1 release in acid from ~16% to <2%.  Peptide 1 burst release would be 
delayed until the small intestine where it would have an increased chance of 
being absorbed than from the stomach.  The rapid and uniform release of the 
nanoparticles may also create a high local concentration promoting their 
absorption into the bloodstream. 
The commercial oral protein/peptide drug delivery system which has progressed 
furthest so far is Tarsa Therapeutics’ salmon calcitonin formulation which has 
successfully completed phase III clinical trials.  This is an enteric coated tablet 
with an enzyme inhibitor, citric acid, and permeation enhancer, acylcarnitine.  
Enteric coated tablets/capsules have previously suffered from delayed release 
at small intestinal pH and may be more affected by the presence of food in the 
stomach than smaller dosages.  This may create variability in drug absorption, 
for calcitonin this may not be too detrimental as it has a large therapeutic 
window.  However for those drugs with a narrow therapeutic window or whose 
availability must be carefully coordinated with food this may not be acceptable.   
This work has demonstrated that the method of Kendall et al can successfully 
encapsulate protein and peptide drugs of widely varying size without impairing 
the activity of these notoriously fragile macromolecules in Eudragit L100 
microparticles.  They provided pH dependent release, pepsin protection, rapid 
release at small intestinal pH, may be less delayed by the presence of food than 
larger enteric tablets/capsules and may reduce variability in drug absorption 
seen with larger dosages.  They were also able to encapsulate nanoparticles 
with encapsulated peptide and co-encapsulate citric acid and antacids.  This 
may allow formulation of a modular delivery system incorporating enteric 
protection with permeation enhancement and enzyme inhibitors.   
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5.2 Future work 
It would be useful to test the stability of the protein/peptide drugs in human 
intestinal fluids to gain a better insight into their in vivo behaviour.  Testing more 
protein/peptide drugs of varying sizes and structure complexities would provide 
more information about where they are stable and unstable in the GI tract and 
may enable more tailored oral formulation development based on size. 
Further studies to increase the protection of acid labile protein/peptide drugs in 
Eudragit L100 microparticles by co-encapsulation of antacids could be 
conducted.  It would also be useful to optimise the ratio of co-encapsulated 
enzyme inhibitors to Eudragit L100 and investigate their ability to increase 
protection in vitro in enzyme solutions and with animal intestinal fluids. 
It would be beneficial to explore the permeability of protein/peptide drugs with 
Caco-2 cells and attempt incorporation of permeability enhancers within the 
microparticles to explore their potential to increase absorption.  Increased 
permeation caused by encapsulation in PLGA nanoparticles should also be 
studied and the effects of chitosan coating of these particles should be 
investigated. 
It would be useful to conduct in vivo, oral bioavailability studies in animals to 
investigate if enteric microencapsulation can increase the bioavailability of 
protein/peptide drugs encapsulated alone or loaded in polymeric nanoparticles.  
The bioavailability, inter/intra subject variability in absorption and delay between 
administration and onset of action should be compared to enteric 
tablets/capsules to investigate the effects of dosage form size reduction.  The 
effects of food on the action of enteric capsules/tablets and microparticles 
should also be compared. 
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